


The background is a vibrant green. On the left side, there is a faint, translucent silhouette of a human figure from the neck down to the waist. Inside this silhouette, there are intricate, white, plant-like or cellular structures that resemble a cross-section of a plant or a microscopic organism. The overall aesthetic is clean, modern, and nature-inspired.

Responsibility Report

2024

Evolving our ESG leadership

As a recognised leader in environmental, social, and governance (ESG) matters, we continue to proactively pursue best-in-class corporate sustainability practices. This publication marks the next chapter in our ESG journey. The report is based on¹ the European Sustainability Reporting Standards (ESRS), prepared and audited voluntarily and well ahead of legal requirements. Our transition from the Global Reporting Initiative (GRI) to ESRS introduces changes in structure, terminology, and methodology – enhancing transparency and improving comparability with our peers.



¹ For exact scope see section [BP-1 'General basis for preparation of sustainability statements'](#)

**2 Letter from
the CEO**

**5 General
disclosures**

- 6 About this report
- 8 Sustainability organisation
- 14 Sustainability strategy

27 Environment

- 28 Climate change
- 42 Environmental pollution
including the supply chain

49 Social

- 50 Own workforce
- 76 Patient


101 Governance

- 102 Business conduct

115 ESRS Index

These colours are
used as a content
index for better orientation
within the report:

- General disclosures
- Environment
- Social
- Governance
- ESRS Index



Letter from the CEO

Dear Friends and Partners,

At Grünenthal, everything we do is guided by a bold and meaningful vision: **A World Free of Pain**. With one in five people worldwide suffering from chronic pain¹, our ambition to transform the way pain is managed has never felt more urgent – or more personal.

2024 was a successful year of progress for Grünenthal. We advanced our pipeline of innovative, non-opioid treatments, delivered strong business performance, and reinforced our commitment to sustainability and responsible business. All business areas collaborated to make a positive impact on our focus areas of Patient, People and Planet.

Patient, People, Planet

From harnessing artificial intelligence to designing next-generation molecules, to cutting our environmental footprint and fostering inclusive, healthy workplaces, we believe sustainability continues to be a driver of innovation and impact.

This report offers an honest account of where we have made progress, where we are challenged, and where we are heading as we work towards a fair, healthy, and sustainable future.



Pioneering ESG reporting

As an industry leader in ESG, we have long believed that companies should set the pace, not wait to be told what to do. That is why we proactively aligned our reporting with the new European Sustainability Reporting Standards (ESRS) under the Corporate Sustainability Reporting Directive (CSRD) – even before it is mandatory for us.

This early move reflects our belief in transparency, accountability, and leadership. By shifting from the Global Reporting Initiative (GRI) to ESRS, we have refined our framework, terminology, and data analysis to raise the bar on how we measure and report what truly matters.

Sharpening focus on what counts

In 2024, we conducted a double materiality assessment in line with the upcoming legal requirements. This analysis sharpened our focus on seven material topics which reflect both the impact of our business and the risks and opportunities that shape our future:

- Climate change
- Pollution
- Own workforce
- Personal safety of consumers and/or end-users
- Access to healthcare
- Research and development
- Business conduct

We actively engage stakeholders to challenge ourselves and evolve our goals.

¹ Treede RD, et al. Pain. 2015 Jun;156(6):1003-1007

Recognised ESG industry leader

Our efforts have not gone unnoticed. Leading independent ESG rating agencies consistently position Grünenthal as an industry leader in managing ESG risks and opportunities. We have received a (p) AA rating from MSCI, placing us among the leaders in our industry, a low ESG risk status from Sustainalytics, recognising our strong risk management and a gold medal status from EcoVadis, reflecting our high performance in environmental, social, ethics, and procurement criteria.


These acknowledgements reaffirm that responsibility and performance can – and must – go hand in hand.

Thank you for joining us on this journey

On behalf of the Executive Board Team, I extend heartfelt thanks to everyone who contributes to this journey – especially our employees and partners, whose commitment and ideas fuel our progress. Together, we are not just building a more sustainable Grünenthal but striving for a healthier world.

We look forward to what we can achieve together in the years ahead.

Warm regards,



Gabriel Baertschi
Chief Executive Officer


May 2025

As one of the world's leading specialists in the therapeutic area of pain, we continue pushing boundaries to make a positive impact – with and beyond our core business.

Gabriel Baertschi
Chief Executive Officer







GENERAL DISCLOSURES

- About this report
- Sustainability organisation
- Sustainability strategy

About this report

BP-1 General basis for preparation of sustainability statements

Consolidated basis of reporting

This sustainability statement has been prepared on a consolidated basis, in alignment with the consolidated financial statements of Grünenthal Pharma GmbH & Co. Kommanditgesellschaft. Unless explicitly noted otherwise, the scope of consolidation reflects the framework applied in the company's financial reporting. This approach aligns with prior reporting periods, ensuring comparability across reporting cycles.

Subsidiary undertakings and exemptions

As of August 2023, Grünenthal has a 51% majority stake in Grünenthal Meds, a joint venture with Kyowa Kirin Co., Ltd., a global specialty pharmaceutical company based in Japan. Grünenthal plans to acquire the remaining 49% share at the beginning of 2026. While this report does not comprehensively cover Grünenthal Meds, the selected topics compliance, climate change and Human Resources have been included as follows: The report covers Healthcare Interactions (HCI) training, see section [👁 'G1-4 Ethical business culture, corruption and bribery, metrics and targets'](#), and opioid-related training for employees and business partners, see section [👁 'S4-5 Responsible use of opioids, metrics and targets'](#). HR-related data for Grünenthal Meds is collected separately, as it is not integrated into the general HR system, see section [👁 'S1-6 Characteristics of Grünenthal's workforce'](#). Scope 1 and 2 greenhouse gas (GHG) emissions of Grünenthal Meds are included while Scope 3 emissions are not yet included in the report (see section [👁 'E1-6 Gross Scopes 1, 2, 3 and Total GHG emissions'](#)).

As of July 2024, Grünenthal holds 100% ownership of US-based pharmaceutical company Valinor Pharma. While Valinor is now a wholly owned subsidiary, it is not yet fully integrated into Grünenthal's organisational and reporting structures. As a result, HR data for Valinor is collected

separately and is not yet incorporated into Grünenthal's central HR systems. For HR-related data, see section [👁 'S1-6 Characteristics of Grünenthal's workforce'](#).

Coverage of value chain

The sustainability statement encompasses the entire Grünenthal value chain, covering its own operations, upstream and downstream. Material topics have been systematically mapped to reflect their relevance within this value chain, enabling a comprehensive understanding of Grünenthal's sustainability impacts.

Application of the ESRS

Grünenthal provides comprehensive information on the ESRS requirements relevant to general disclosures and material topics. ESRS S1-16 constitutes an exception, as only pilot findings on the gender pay gap are available, with no consolidated Group-level data yet in place. No specific information is omitted in this report. Sections of this report that contain unaudited data or information not covered by the ESRS are visually distinguished either by a grey background or by French quotation marks (»...«) surrounding the relevant text, tables, and graphs.

BP-2 Disclosures in relation to specific circumstances

Disclosure of data using indirect sources, estimations or approximations

Certain Scope 3 emissions (see section [👁 'E1-6 Gross Scopes 1, 2, 3 and Total GHG emissions'](#)), particularly employee commuting, the end-of-life treatment of sold products, and upstream transportation were quantified using data from the ecoinvent database, which converts spending and weight information into emissions figures.

For Grünenthal Meds, emissions from transportation in vehicles owned or controlled by the company were calculated based on the total number of vehicles in use.

Employee commuting emissions were quantified based on a dedicated internal survey conducted in 2023, capturing commuting patterns across Grünenthal operations globally. The survey collected information on commuting frequency, distance, and transport modes. For employees not covered by the survey, commuting profiles were estimated using national statistical averages on transport behaviour. The commuting data was split by transport type and converted to emissions using the UK Government GHG Reporting Factors 2023. Each data stream used the relevant emission factor for either passenger.km or vehicle.km as appropriate. All emission estimates were classified as having 'Fair' accuracy ($\pm 25\%$ to $+30\%$) due to uncertainty in self-reported distances and extrapolations.

For leased office spaces, including for Grünenthal Meds, where no electricity meter data was available and electricity costs were bundled into rental agreements, consumption was estimated using floor area (m^2) and country-specific average electricity consumption per square metre, sourced from the [🔗 Odyssee-Mure energy efficiency database](#). These averages reflect standard office energy usage per country, and were applied to each relevant building's floor area. The estimated electricity consumption was then converted into GHG emissions using IEA 2022 country-specific electricity emission factors for location-based reporting.

'End-of-life treatment of sold products' was quantified using packaging material data from Germany and Italy, covering approximately 81.5% of total packaging spend. Where weight data was missing, packaging emissions were estimated using a spend-to-weight ratio, applying average material emission factors from Ecoinvent 3.9.1 and Exiobase 3.8.2. For remaining countries, regional averages and proportional assumptions based on spend share (e.g., Latin America, Switzerland) were used. These estimations were based on a blended mix of packaging material types, including plastics, glass, aluminium, and paper.

Emissions from upstream transportation and distribution were calculated using a hybrid methodology combining supplier-provided GHG figures and modelled emissions using tonne.km-based UK.gov emission factors.

The 2024 Scope 3 greenhouse gas (GHG) emissions have been estimated using a spend-based scaling method. In 2023, the following three categories 3.1 (Purchased Goods and Services), 3.4 (Upstream Transportation and Distribution), and 3.6 (Business Travel) have contributed more than 94% of the total Scope 3 GHG emissions. The total Scope 3 emissions for 2024 have been estimated by applying a combined scaling factor based on aggregate spend across these three categories. The underlying assumption is that these three categories drive the majority of Scope 3 emissions also in 2024 and that overall emissions can be reasonably approximated by tracking changes in total spend across them.

This methodology assumes a proportional relationship between financial spend and GHG emissions and provides a simplified, consolidated estimate to reflect directional change in total emissions where a full category-level update is not yet feasible. While this is not the preferred method, the GHG Protocol endorses spend-based estimation for Scope 3 categories where direct emissions data is not available.

Changes in the preparation and presentation of sustainability information

In the current reporting period, we have revised the preparation and presentation of sustainability information to align with the CSRD and the ESRS. This transition from the Global Reporting Initiative (GRI) standards to ESRS involves updates in terminology, methodology, and reporting structures, ensuring compliance with the latest regulatory frameworks. Due to the transition from the GRI standards to ESRS, certain methodological differences may result in variances in reported figures. Consequently, adjustments to comparative information for previous periods may be impracticable. Where relevant, we have provided explanations for significant deviations to maintain clarity and enable stakeholders to follow changes in our sustainability performance metrics.

Sustainability standards and reporting frameworks

Grünenthal does not disclose data points that result from other EU legislation listed under ESRS2 Annex B. We do though take generally accepted sustainability standards and frameworks into account: As a United Nations Global Compact (UNGC) participant, Grünenthal is committed to the ten universal principles of the UNGC on human rights, labour standards, environmental and climate, and corruption prevention (see section [👁 'United Nations Global Compact'](#)). Our Statement of Compliance with Human Rights and Environmental Standards reflects this formal commitment. In addition, we support the achievement of the United Nations Sustainable Development Goals (SDGs) in line with our business strategy. We particularly contribute to SDG 3, which aims at ensuring healthy lives and promoting wellbeing for all, see section [👁 'Grünenthal's contribution to the SDGs'](#).

We are committed to the Science Based Targets initiative (SBTi), guiding our decarbonisation and emissions reduction efforts. We report according to the Global Logistics Emissions Council (GLEC) Framework, which enables both distance-based and fuel-based GHG emissions calculations.

For specific data points, we reference internationally recognised standards, including:

- ISO 14001 – Environmental Management Systems (Environment, Health & Safety).
- ISO 45001 – Occupational Health & Safety Management Systems.

We continue to implement a comprehensive environmental management system based on ISO 14001:2015, aligned with regulatory requirements, corporate sustainability standards, and the Greenhouse Gas Protocol. Our approach integrates best

practices from across industries and geographies to optimise efficiency, reduce emissions, and minimise environmental impact.

To uphold occupational health and safety and achieve our VISION ZERO (zero accidents and zero lost working days to accidents) commitment, all manufacturing sites maintain ISO 45001-certified safety management systems.

External assurance and verification

To ensure the accuracy and reliability of our sustainability disclosures, our data and processes undergo external verification, including:

- SWOT (Strengths – Weaknesses – Opportunities – Threats) analyses conducted in compliance with ISO 45001 and ISO 14001.
- Third-party ISO audits to validate conformance to industry-leading standards.
- Certification processes aligned with ISO 45001 and ISO 14001 to uphold global best practices in health, safety, and sustainability for manufacturing sites.

The individual performance metrics disclosed in this report are not subject to external validation.

Corporate Hub Lisbon



Sustainability organisation

GOV-1 The role of the administrative, management and supervisory bodies

Grünenthal's administrative, management and supervisory bodies play a pivotal role in guiding the organisation's operations, ensuring alignment with regulatory frameworks, ethical standards, and sustainability objectives.

Corporate structure and dual governance system

The ultimate parent company, Grünenthal Pharma GmbH & Co. KG, is a limited partnership (Kommanditgesellschaft) incorporated in Germany with corporate seat in Aachen, and with a limited liability company (Gesellschaft mit beschränkter Haftung) as general partner incorporated under the laws of the Principality of Liechtenstein. It wholly owns Grünenthal GmbH (the 'GmbH'), which is the active pharmaceutical entity. This is a limited liability company incorporated under German law with its corporate seat in Aachen, managing Grünenthal's pharmaceutical business since its establishment under the name Chemie Grünenthal GmbH in 1946. Both the Ultimate Parent Company and the GmbH have a dual management system characterised by a separation of personnel between the management and supervisory bodies, as further explained below.

Advisory Board (Beirat)

The advisory board members are elected by the limited partners ('Principal Shareholders') of the parent company respectively the shareholder of Grünenthal GmbH. Pursuant to the partnership agreement of the parent company, the members of the advisory board of the parent company and the advisory board of Grünenthal GmbH have to be identical (the 'Advisory Board'). The

Advisory Board appoints the managing directors (Geschäftsführer) of Grünenthal GmbH, who form the 'Corporate Executive Board'. The Advisory Board supervises Grünenthal's management. For significant actions, such as acquisitions, license deals, and major strategic decisions, the Corporate Executive Board requires the approval of the Advisory Board (Beirat).

The Advisory Board comprises five external, independent voting members with significant expertise in relevant industries (e.g., pharmaceuticals, legal, finance) and four internal members who represent the Principal Shareholders' family of the parent company. The four internal members do not have voting rights, meaning that 100% of the voting members and 56% of all members are independent. One of the five external voting members (20%) and three of the four non-voting members (75%) are female. The five voting members are:

- Dr. Pär Johansson, chairman of the Advisory Board and of the Supervisory Board, a lawyer specialising in corporate law and M&A, providing legal, financial, and governance oversight for Grünenthal.
- Dr. Petra Danielsohn-Weil, a pharmaceutical industry leader with expertise in strategy, operations, and commercialisation.
- Dr. Gotthard Kleine, a strategic consultant supporting organisational development, ethical business practices, and patient advocacy.
- Franz Wynands, a tax consultant and accountant ensuring financial oversight, risk management, and regulatory compliance.

- Dr. Martin Zügel, a healthcare executive offering expertise in business development, private equity, and pharmaceutical strategy.

The Advisory Board also has an Audit Committee and a Personnel Committee to manage specific governance tasks.

Corporate Executive Board

The Corporate Executive Board (CEB) is Grünenthal's senior leadership decision-making body, responsible for the day-to-day management of the company. Its ESG-related duties include reporting on economic, environmental, and social performance, business conduct, as well as on ESG risk management, and aligning business operations with Grünenthal's strategic objectives and corporate responsibility initiatives. As environmental, social and governance impacts by Grünenthal, as well as related risks and opportunities for Grünenthal (IROs) concern nearly all business areas, ESG falls under the overall responsibility of the CEB as such. Nevertheless, the CEB has delegated specific areas to experts e.g. Human Rights Officer or Occupational Safety Officer (Arbeitsschutzbeauftragter). Since 2009, no member of the Principal Shareholders' family is part of the CEB anymore.

The Corporate Executive Board comprises four executive members, the Chief Executive Officer (CEO), Chief Financial Officer (CFO), Chief Scientific Officer (CSO) and Chief Commercial Officer (CCO), who collectively have experience in relevant roles and sectors across the globe:

- Gabriel Baertschi, Chairman and CEO, with over 20 years of pharmaceutical experience and expertise in transformation leadership.
- Jan Adams, M.D., CCO and former CSO (until September 2024), with extensive experience in R&D and corporate strategy. For the period up to September 2024, the CCO was Janneke van der Kamp, a pharmaceutical industry commercial specialist.
- Prof. Dr. med. Uli Brödl, CSO (as of February 2025), with more than 15 years of industry experience.
- Fabian Raschke, CFO, with a strong background in corporate controlling and financial leadership.

Corporate Executive Board members receive comprehensive training, for example on anti-corruption, corporate responsibility, and ethical conduct, ensuring informed decision-making at the highest level.

The Executive Board Team (EBT) comprises the CEB members plus Victor Barbosa, Head Global Operations, Leen Hofkens, Head Global Human Resources, Sebastian Köhler, General Counsel, and Quentin Le Masne de Chermont, Head Corporate Strategy and Portfolio Management. This team defines the mid-term and long-term corporate strategy to make Grünenthal's vision of a World Free of Pain a reality. While the CEB members are all male, one of the EBT members is female.

Supervisory Board (Aufsichtsrat)

Grünenthal GmbH has an additional third co-determined supervisory board (Aufsichtsrat), with powers limited to the extent as legally permitted. This board supports the governance structure by providing additional oversight and approving actions of the CEB in case these are subject to approval by corporate bylaws. The three members of the Supervisory Board are Dr. Pär Johansson (chairman), Christina Plath and Sabine Hees (employee representative). Two of the three Supervisory Board members are female.



From left to right, top to bottom: Gabriel Baertschi, CEO; Jan Adams, MD, CCO; Uli Brödl, MD, CSO; Fabian Raschke, CFO

Embedding sustainability into governance

Grünenthal's Corporate Responsibility Board serves as the central body for sustainability governance. In the reporting period, it was chaired by the Compliance & Responsibility Officer Headquarters (from 2025, the position holder's title changed to Head of Responsibility) and comprises leaders responsible for material topics and selected strategic business functions.

The Board serves as a decision-making body and sounding board for all Corporate Responsibility matters. Its key duty is to implement, continuously develop and drive Grünenthal's Corporate Responsibility Programme. The Programme aims to create a net-positive impact for society in our focus areas of Patient, People and Planet. It sets

ambitious sustainability targets for our material topics and contributes to transparent reporting. Progress is monitored via metrics that are tracked continuously as part of the Group Scorecard. The Board works towards a company-wide, consistent and yet localised implementation of the Programme and gives guidance to employees working on it. Apart from internal stakeholders, the Corporate Responsibility Board engages in a continuous dialogue with external interest groups.

The Corporate Responsibility Board meets quarterly to review sustainability performance. It reports regularly to the Corporate Executive Board and the Advisory Board (Beirat) via the Global Compliance & Responsibility Officer.

Employee representation and governance framework

Grünenthal has established works councils in Chile, France, Germany, Italy and Spain, complying with local legislation to ensure employee representation. In Germany, the Works Constitution Act defines the functions, rights, and responsibilities of the works councils, enabling structured negotiations on social, occupational health and safety, and environmental matters. At the European level, the European Works Council (EWC) represents employees across EU member states and the European Economic Area (EEA), ensuring cross-border employee consultation. National organisations with at least 150 employees – currently Italy, Spain, and Germany – are entitled to appoint members to the EWC, which convenes annually.

GOV-2 Information provided to and sustainability matters addressed by the undertaking's administrative, management and supervisory bodies

Reporting structures and information flow

Grünenthal has established a robust governance framework to ensure that its administrative, management, and supervisory bodies are consistently informed about sustainability matters. The Corporate Responsibility Board (CRB) reports directly to the Corporate Executive Board (CEB) through annual reporting cycles and ad hoc updates when necessary. This structure ensures timely communication on material impacts, risks, and opportunities, as well as updates on the implementation of due diligence processes and the effectiveness of sustainability policies, targets, metrics, and actions.



Sebastian Köhler, General Counsel and Leen Hofkens, Head Global Human Resources

The Global Compliance & Responsibility Officer plays a vital role in reporting to the Corporate Executive-, the Supervisory- and the Advisory Boards respectively. These reports include critical updates on training initiatives, healthcare interactions, audit outcomes, emerging compliance concerns, and significant developments. Both the CRB and the CEB serve as active decision-making bodies, ensuring alignment of sustainability strategies with Grünenthal's corporate objectives, particularly regarding the Compliance Management System.

Consideration of sustainability-related impacts, risks, and opportunities

Grünenthal's Corporate Responsibility Programme integrates sustainability into the core of its business operations. It is designed to manage ESG on a global scale and address material impacts through targeted initiatives. The responsibility for overseeing this programme has been delegated by the CEB to the CRB, ensuring consistent oversight.

Strategic oversight

The CRB conducts periodic reviews to assess key ESG risks and opportunities, ensuring alignment with Grünenthal's long-term corporate strategy and objectives. This includes evaluating both the potential positive and negative impacts of strategic decisions on stakeholders and the environment.

Major transaction decisions

Before approving significant business transactions, Grünenthal conducts a thorough due diligence involving all relevant business areas on a global level, including Quality Assurance, Manufacturing and Supply Chain Management, Legal and Compliance, Drug Safety, Medical and Medical Information, Commercial, Finance, HR and others. Once a recommendation is reached, it is discussed in detail by the Corporate Executive Board, involving also all key functional stakeholders. This includes detailed discussion of the risks and opportunities as well as business

impacts associated with the respective transaction. Amongst others, Grünenthal verifies that all patient-related safety measures and processes meet company standards, examines sustainability and efficiency of the entire production and supply chain, and ensures that the acquisition target has been carefully reviewed in relation to all business relationships with third parties. The company ensures that legal, ethical and sustainable considerations are thoroughly evaluated and prioritised alongside commercial benefits. Upon approval of the CEB, the final decision is taken by the Supervisory Board.

Material impacts, risks, and opportunities

While Grünenthal has identified a range of material ESG impacts across its operations, it has not identified any material ESG-related risks or opportunities. The material impacts, that can be mapped to Grünenthal's material topics, are the result of multiple workshops by the Corporate Responsibility Board and CEB as part of the double materiality analysis process (details in section [👁️ 'IRO-1 Description of the processes to identify and assess material impacts, risks and opportunities'](#)). All IROs were integrated into the corporate strategy.

Monitoring and performance mechanisms

Grünenthal ensures the continuous monitoring of its sustainability performance through key governance mechanisms. Targets for material topics are reviewed and approved annually by the Executive Board Team and formulated in a Group Scorecard. Progress is tracked throughout the year using metrics embedded in the internal Group Scorecard. This tracking provides transparent and actionable insights to the Executive Board Team, reinforcing Grünenthal's commitment to continuous improvement in sustainability practices.

This comprehensive approach ensures that Grünenthal's administrative, management, and supervisory bodies are not only well-informed but also actively engaged in driving sustainability performance across the organisation.

GOV-3 Integration of sustainability-related performance in incentive schemes

Characteristics of Grünenthal's incentive schemes

Grünenthal has implemented remuneration policies and incentive schemes designed to align individual performance with the company's strategic goals, including sustainability objectives. The remuneration principles, implemented into our remuneration policy, aim to attract and retain top talent by offering competitive, market-aligned compensation.

A key component of Grünenthal's incentive schemes is the Short-Term Incentive (STI) programme, which provides a variable compensation component and rewards employees for achieving agreed-upon priorities within a financial year. These priorities are defined through a global, uniform target-setting process, ensuring that corporate goals are cascaded down to the individual level.

The STI programme applies to most employees, including members of the administrative and management bodies, starting with the Corporate Executive Board. Supervisory Board members are excluded from the STI programme. Sales employees and certain tariff employees, who operate under separate incentive programmes, are excluded from the global STI programme.

The STI bonus payout is determined by two factors:

- 1. Employee performance:** Assessed through an annual performance rating.
- 2. Corporate performance:** Measured via the Corporate Factor, which is derived from the Group Scorecard. This scorecard assesses the company's performance across key priorities, including financial

results, innovation, growth, cultural transformation, and sustainability advancements. The evaluation of these priorities, including sustainability-related metrics which account for 5% of the Corporate Factor calculation, takes place annually and directly influences the Corporate Factor, thereby impacting STI payouts for employees, including senior executives.

By linking personal contributions to overall business goals, the STI programme promotes transparency and employee involvement. It encourages exceptional performance by offering financial rewards tied to both personal achievements and the company's success.

Sustainability is explicitly integrated into Grünenthal's Short-Term Incentive programme. In the Culture area of the Group Scorecard, a key priority is the progress made in implementing the company's responsibility programme, which is shaped by our material topics. We have defined annual operational targets for each of our material topics to reach our mid- and long-term ambitions. Target achievement is transparently measured. For example, for the topic of Patient Safety, we regularly track the target to achieve 97% 'on-time' submissions to authorities for Individual Case Safety Reports. Climate-related performance is included through annual operational targets that contribute to our near-term objectives published under ESRS E1 – Climate Change. These targets are part of the Group Scorecard and influence the Corporate Factor. Climate goals are not reflected in any other remuneration components than the STI. The achievement level for all targets defines target achievement for the overall sustainability priority and thus influences the Corporate Factor by a defined percentage. By linking the Corporate Factor directly to sustainability targets feeding into the Group Scorecard, both individual contribution and corporate achievements for sustainability are being incentivised.

Approval and update processes for incentive schemes

The Corporate Executive Board plays a central role in overseeing and approving the terms of Grünenthal’s incentive schemes in alignment with Grünenthal’s Global Remuneration Policy and Remuneration Framework. The Group Scorecard

serves as the foundation for the calculation of the Corporate Factor. It is reviewed, validated, and approved by the Corporate Executive Board annually at the end of the financial year to ensure alignment with the company’s strategic vision and evolving objectives.

In addition to this, over the course of 2025, the Risk Management programme itself will be subject to evolution and update. While the development of these proposals is still underway, collaborations with the ESG team have already begun to identify areas in which additional assurances could be offered as to the integrity of our sustainability reporting mechanisms.

GOV-4 Statement on due diligence

Core elements of due diligence	Paragraphs in the sustainability statement
a) embedding due diligence in governance, strategy and business model	SBM-1, SBM-3, S1.SBM-3, GOV-2
b) engaging with affected stakeholders in all key steps of the due diligence	SBM-2, S1-2, S1-3, S4-2, S4-3, G1-1
c) identifying and assessing adverse impacts	IRO-1, G1.IRO-1
d) taking actions to address those adverse impacts	S1-3, S4-3, G1.MDR-A, G1-3
e) tracking the effectiveness of these efforts and communicating	S1-3, S1-4, S4-3, S4-4, G1.MDR-A, G1-3

Sustainability reporting risks and mitigation measures

Looking ahead, the main challenge regarding sustainability reporting is the transition to the European Sustainability Reporting Standards (ESRS), respective data availability, and the need to completely re-draft reporting content in alignment with the new framework. These factors introduce complexities in ensuring data completeness, accuracy, and consistency. To mitigate these risks, Grünenthal is conducting a voluntary trial run of ESRS reporting for the reporting year 2024 to proactively identify gaps and potential challenges. The company is conducting multiple validation rounds for both data and content to enhance reporting reliability and compliance. Additionally, Grünenthal plans to further strengthen internal controls throughout 2025.

GOV-5 Risk management and internal controls over sustainability reporting

At Grünenthal, robust risk management and internal control processes are integral to ensuring the accuracy, reliability, and transparency of our sustainability reporting.

Key features of our risk management and internal control framework for sustainability reporting

Risk management

Our risk management approach is centred on evaluating potential risks based on their likelihood and potential impact on Grünenthal. Regarding our sustainability objectives, we prioritise risks that could significantly affect these objectives and take proactive steps to mitigate them. This includes a quarterly review and update to the risks identified, followed by escalation to the Risk Board to ensure ongoing management where

appropriate. Grünenthal’s Risk Board convenes four times a year, with two full-member meetings and two smaller monitoring sessions in between. Sustainability reporting is not explicitly included in our risk management yet but will be in the future. The risk assessment framework is periodically reviewed and updated to address emerging challenges and maintain its effectiveness.

Ongoing improvements to risk management

A structured approach to fully integrate ESG risks, as well as sustainability reporting risks into the regular risk management system, as well as to monitor opportunities, is under development. As an evolving area of corporate governance and responsibility for Grünenthal, further work is needed to ensure that our risk evaluation and management systems are adequately calibrated to ESG topics. For example, current risk assessment methods are more closely mapped to the evaluation of financial impact. Looking forward, proposals will be made to revise this framework to include a broader range of risk drivers.

We conduct an annual review of our sustainability reporting processes to identify and address any potential gaps. This evaluation involves a systematic analysis of reporting accuracy, completeness, and alignment with regulatory requirements. Any identified gaps are discussed with the relevant business areas, ensuring that corrective actions are effectively implemented within the respective data systems. To maintain transparency and consistency, all internal control and process improvements are integrated into our central data control matrix. This matrix serves as the single source of truth for all reported data, consolidating information on data sources, methodologies, and responsible persons.

Findings of our annual analysis are shared with the Corporate Responsibility Board and may lead to strategic and/or operational adaptations. An example of such an operational adaptation might be the installation of additional meters to measure consumption of energy, water etc.

Master data document as a single source of truth

We maintain a centrally governed master data document, which serves as the definitive source for all sustainability-related data and disclosures. This document is updated regularly to incorporate the latest metrics, performance indicators, and disclosures, ensuring consistency and accuracy across our reporting.

Internal approval steps


Our internal control system includes a multi-tier review process to validate the accuracy and completeness of sustainability data. Department heads and senior management actively participate in the review and approval stages prior to finalisation.

External verification with specialised consultants

To ensure alignment with applicable sustainability reporting standards and continuous improvement, we engage independent sustainability consultants. These experts conduct external checks, providing an additional layer of assurance and offering recommendations to enhance the quality and reliability of our disclosures.

Pre-audits and implementation of recommendations

As part of our commitment to transparency, pre-audit assessments are performed to identify any gaps or areas requiring improvement. Recommendations from these assessments are systematically reviewed and implemented, strengthening our data quality and reporting processes ahead of final audits.



German Sales Division

Sustainability strategy

SBM-1 Strategy, business model and value chain

Significant groups of products and services offered

Grünenthal is a leading pharmaceutical company focused on pain therapies with over 75 years of experience in developing, manufacturing and commercialising innovative treatments, over 50 of those specialised on pain. Its integrated capabilities span the entire value chain, from research and development (R&D) to its vertically integrated manufacturing, regulatory, and commercialisation expertise, generating commercial and production synergies across the company's portfolio and acquired brands.

The company's core therapeutic area, pain, represents a significant burden for people and society, which remains a major unmet medical need. Grünenthal offers patients a range of treatment options, including opioids, and is committed to transforming the future of pain management. The company acknowledges the benefits and risks associated with opioid treatment and has a track record of distributing opioids in Europe with the highest ethical standards.

Products sold in around


100

countries

Production capacities

5

manufacturing sites in Europe and Latin America





Key products

Grünenthal’s product portfolio comprises a complementary mix of innovative, patent protected brands and a portfolio of mature, largely off patent established brands with continued high brand awareness. In the reporting year, Grünenthal acquired the pharmaceutical company Valinor Pharma and its product Movantik, further strengthening Grünenthal’s footprint in the United States.

Our products are sold in approximately 100 countries in the world, either directly or indirectly through partners, and are promoted and/or sold to a diverse customer base, including physicians, pharmacies, hospitals, buying groups, wholesalers, and institutions.

Grünenthal’s revenue from product sales is diversified by geography, product type, and therapeutic area, which helps to limit dependence on any single country or geographic region, product type or therapeutic area.

Key brands include Crestor™, Nebido™, Nexium™, Norspan™, Palexia™, Qutenza™, Tramal™, Transtec™, Vimovo™, Versatis™, Zaldiar™, Zomig™ and the Grünenthal Meds Portfolio (13 brands, including Abstral™, PecFent™, Oramorph™, Movantik™, Rectogesic™).

Key services

We aim to pursue our vision of a World Free of Pain and address critical, unmet medical needs, with a focus on developing highly innovative, non-opioid pain treatments.

Grünenthal’s research and development capabilities span the entire product life cycle, from early research, including target identification and validation, to clinical and technical development, regulatory expertise and lifecycle management. This enables the company to pursue projects across all development phases.

With deep expertise in pain treatment, Grünenthal integrates R&D, manufacturing, regulatory and commercial capabilities, allowing it to compete



Victor Barbosa, Head Global Operations, with manufacturing team members at Aachen headquarters

successfully with both larger diversified and smaller specialist players. Over the years, the company has demonstrated its ability to drive the commercial success of innovative drugs, such as Tramal™, Palexia™, Versatis™ and Qutenza™, and achieved multiple successful product launches underscoring its commercial capabilities and the continued high unmet medical need in pain treatments.

Headquartered in Aachen, Germany, Grünenthal operates five specialised production facilities, ensuring vertical integration from active pharmaceutical ingredient (‘API’) production to packaging. These facilities are located in Germany, Switzerland, Italy, Chile and Ecuador. In addition to manufacturing Grünenthal’s own products, the production facilities also operate as full-service contract manufacturing organisations (‘CMOs’) for external customers. Grünenthal’s Contract Manufacturing Business, Grünenthal PRO, offers high-quality manufacturing solutions to global customers, including:

- Biopharma assembly and packaging.
- Unit-dose nasal spray filling and packaging.
- Bulk production of solids, semi-solids, and liquids.
- Packaging of patches, blisters, wallets, sachets, or sticks.
- Hormone and controlled drug production.
- Production of selected Active Pharmaceutical Ingredients (APIs).

Significant markets and customer groups served

Grünenthal operates in the pharmaceuticals sector of the global healthcare industry and has a total of 4,358 employees (2,803 in Europe, 1,358 in Latin America, 196 in the USA and 2 in Asia). Based on the product portfolio, the company continues to be primarily active in the growing pain and analgesic market, one of the largest

therapeutic areas globally. Demand for innovative and effective therapies continues to drive growth in the global chronic pain therapy market and the broader pharmaceutical and prescription drug markets. Grünenthal has a strong presence in Europe, the United States, and Latin America.

Customers include healthcare organisations, such as hospitals, pharmacies and pharma wholesalers as well as healthcare professionals, who in turn can provide patients in need with our products.

Grünenthal has no products and services that are banned in certain markets.

Sustainability-related goals

Given the prevalence and debilitating effects of pain, Grünenthal is committed to transforming the future of pain management. We believe that the often chronic nature of pain makes patient education and adherence to the highest ethical standards imperative and that our clear commitment in this area sets us apart from other competitors. This is supported by our [‘ESG rating results’](#).

Grünenthal integrates sustainability into its core strategy, with patient safety and product quality forming the foundation of its approach. As a global leader in pain management, Grünenthal is committed to addressing unmet medical needs by developing innovative treatments that improve patient outcomes and quality of life. Beyond patient wellbeing, Grünenthal's sustainability goals focus on workforce development, environmental responsibility, and ethical business conduct.

1. **Workforce development:** Grünenthal prioritises safety, fair working conditions, and an inclusive work environment, fostering a culture of equity, belonging, and professional growth among employees.
2. **Environmental responsibility:** Efforts are concentrated on reducing environmental impact, implementing innovative solutions

for sustainability in operations, and embracing environmentally friendly practices in packaging and production.

3. **Ethical business conduct:** Acting with integrity and adhering to high ethical standards form the foundation of Grünenthal's corporate responsibility.

Grünenthal actively collaborates with stakeholders, ensuring that sustainability strategies reflect the needs and expectations of diverse groups. This engagement fosters long-term, sustainable relationships, which are further detailed in the [‘SBM-2 Interests and views of stakeholders’](#) section.

Grünenthal's strategic alignment with material sustainability matters

At Grünenthal, our vision of a World Free of Pain aligns seamlessly with our commitment to sustainability, especially the social aspect. We regularly evaluate our products, services, and markets to ensure alignment with our sustainability objectives:

- **Patient-centric approach:** Grünenthal's quality management and pharmacovigilance systems are designed to ensure the highest levels of product safety throughout manufacturing processes and improve health outcomes for patients worldwide.
- **People-focused initiatives:** Grünenthal is proactive in fostering an inclusive and supportive work environment for all employees. This entails robust governance structures including a dedicated Diversity & Engagement Council, assessing working conditions and gathering feedback through initiatives like Great Place to Work® surveys to track progress against strategic objectives. We empower passionate employees who act as ambassadors and allies, to drive diversity awareness activities which further strengthen our inclusive culture.

- **Planet-focused efforts:** Grünenthal's Planet-focused efforts encompass climate action as well as pollution prevention and control programmes within the company's own operations and its supply chain. Grünenthal's sustainable packaging strategy for example has made significant strides toward reducing environmental impact, with tangible successes like the integration of recycled materials at its Aachen site. The company continues to innovate by exploring global opportunities for scaling recyclable packaging systems. Grünenthal's supplier engagement processes prioritise collaboration with partners who share its commitment to environmental stewardship.

The wellbeing of consumers and end-users serves as the foundation for our operations and innovations. This patient-centric approach inherently intersects with key sustainability matters, as it prioritises access to effective treatments, promotes ethical practices in patient care, and underscores the importance of long-term societal health. Our strategy also embraces sustainable development. It does so by integrating environmental, social, and governance (ESG) considerations into decision-making processes which ensures that the advancement of pain management is achieved responsibly and inclusively. This alignment shows that Grünenthal's strategic priorities are also supportive of global sustainability goals – e.g., SDG 3: Good health and wellbeing, see section [‘Grünenthal's contribution to the SDGs’](#).

Grünenthal manufactures and commercialises pharmaceuticals and is active on the global healthcare market. Based on our product portfolio, we continue to be primarily active in the pain and analgesics market, one of the largest therapeutic areas globally.

Business model, value chain and sourcing of inputs


Grünenthal's business model integrates patient-centric research, manufacturing, and distribution to deliver high-quality treatments addressing unmet medical needs. We cover increasing areas of pain research and

» Grünenthal Insight

A recognised industry leader in ESG

MSCI: Industry leader with (p) AA rating

Morgan Stanley Capital International (MSCI) recognised Grünenthal as an industry leader for managing the most significant ESG risks and opportunities by awarding a Provisional AA rating. Scores range from CCC (laggard) to AAA (leader), depending on exposure to industry-specific ESG risks and the ability to manage those risks relative to peers. Our rating puts us ahead of several high-profile competitors in the pharmaceutical industry.



Sustainalytics: Low risk and ahead of peers

Sustainalytics, another leading ESG risk rating provider, certified our company a 'low ESG risk'. This rating recognises us as one of the top performing companies in our industry, based on our ESG risk rating score. Sustainalytics rated our ESG risk management approach as 'strong', which is the highest possible assessment level.

EcoVadis: Gold medal for sustainability

EcoVadis is a provider of business sustainability ratings, with a global network of more than 150,000 rated companies. Our Gold Medal rating puts Grünenthal among the top performers assessed worldwide. EcoVadis assesses companies across various sustainability criteria including environmental impact, labour practices, ethical business conduct and sustainable procurement.

Top ratings affirm our ESG leadership position.

Sebastian Köhler
General Counsel



pharmaceutical products through organic growth and our own R&D as well as strategic acquisitions. Grünenthal also places particular importance on the engagement with patients, patient-representation groups and healthcare professionals.

Our value chain begins with research and development, where we collaborate with academic institutions and healthcare experts to design innovative pain therapies. Raw materials such as APIs (Active Pharmaceutical Ingredients), chemicals and finished or semi-finished goods are sourced from verified suppliers, prioritising quality and ethical practices to ensure safe, efficient and reliable product supply to patients. Manufacturing takes place in our advanced facilities, ensuring compliance with rigorous quality, safety, and environmental standards. Finished products are distributed through a global network, supported by logistics partners to ensure timely and equitable access for patients. The company has a strong focus to ensure safe, efficient and reliable product supply to patients. Grünenthal also works closely with healthcare professionals to enhance the safe and effective use of our therapies, integrating stakeholder feedback to continuously improve outcomes across the value chain.

Grünenthal's upstream value chain involves approximately 7,000 global suppliers. Grünenthal's largest categories of procurement include semi- and finished goods coming from external suppliers accountable for ca. 36% of spend in 2024. Suppliers are concentrated in Europe and North America with approximately 68% of suppliers accounting for ca. 88% of spend generated in 2024. Approximately 6% of Grünenthal suppliers are defined as ESG sensitive due to the risk attached to the supplier location and the industry type (e.g., country regulations around working conditions, pollution, etc.). For more information see section [👁 'G1.MDR-A Ethical business culture actions'](#). Regular risk assessments and dialogue activities focus on upholding high standards for ethics, environmental management, and social impact. The downstream value chain encompasses distributors and customers, ensuring the uninterrupted delivery of high-quality treatments.

Outputs and outcomes for stakeholders

Grünenthal measures its impact across a spectrum of stakeholder groups, ensuring that its operations deliver tangible benefits for customers, investors, R&D and industry business partners, employees, healthcare professionals and organisations, as well as communities, which are further detailed in the [👁 'SBM-2 Interests and views of stakeholders'](#) section.

SBM-2 Interests and views of stakeholders

Grünenthal operates in a dynamic environment characterised by diverse stakeholder groups with varying demands and expectations. Acting as a reliable and trustworthy partner supports Grünenthal's ability to attract talented employees, fulfil the expectations of investors and shareholders, and overall maintain strong relationships with all key stakeholders.

Overview of key stakeholder groups

Grünenthal has identified the following key stakeholder groups, that either have a strong influence on the company or are significantly impacted by its operations: Patients, patient experts, caregivers, and patient organisations; employees; healthcare professionals and healthcare organisations; payers and budget holders; governments, policymakers, and regulators; investors; R&D partners; industry business partners; suppliers and communities. The stakeholder groups are annually validated and refined as necessary.

Engagement with key stakeholder groups

Grünenthal actively engages with its stakeholders through open dialogue and conducts an analysis of the information gathered from Grünenthal counterparts and main contact partners for each stakeholder group. Engagement activities include feedback platforms, regular meetings, conferences, and formal consultations to understand the specific needs and expectations of each group. Two groups of affected stakeholders are especially to be highlighted as crucial for Grünenthal and under SBM-2: The company's own workforce (S1.SBM-2) as well as

Consumers and/or end-users (S4.SBM-2), which for Grünenthal are patients, patient experts, caregivers, and patient organisations:

- 1. Employees (S1.SBM-2):** We want all employees to feel valued, respected, included and empowered to do their best, bring great ideas to the table and develop their full potential. Our Values & Behaviours are the foundation of our culture. They guide our decision-making and provide clarity to our teams around the world about how we want to work together to achieve successful outcomes for our company and our patients.

Grünenthal cultivates an inclusive and performance-driven culture by actively engaging with its workforce and seeking feedback through for example employee feedback platforms, regular Town Hall meetings, biennial Great Place to Work® surveys and internal 360-degree leadership feedback. The latter provides targeted leadership feedback for line and project managers on how they drive team performance and development and bring the company's Values & Behaviours to life. Employees are encouraged to regularly discuss their development goals with their people manager to create Personal Development Plans that drive growth in current roles and future opportunities. These efforts ensure employees are informed, aligning them with the company's mission and priorities, and create a work environment where they feel valued and motivated to contribute to Grünenthal's success.

Grünenthal has established works councils in Chile, France, Germany, Italy and Spain, complying with local legislation to ensure employee representation. The company ensures representation for employees across Europe through its European Works Council (EWC).

For more information, see the section [👁 'S1-2 Processes for engaging with own workforce and workers' representatives about impacts'](#).

2. Patients, patient experts, caregivers, and patient organisations (S4.SBM-2):

Patients are the focus of our company's mission and vision. Grünenthal's innovative therapies deliver significant therapeutic value to patients worldwide, addressing critical needs in pain management and enhancing quality of life. We collaborate closely with patients, caregivers and patient organisations to understand their needs and expectations. By integrating their insights into our work, we ensure that our healthcare solutions have the greatest positive impact on their lives. Our patient-centric approach extends beyond product development, encompassing education programmes that promote the responsible use of medications. Grünenthal collaborates closely with patients, patient experts, caregivers, and patient organisations to ensure its healthcare solutions have the greatest positive impact. This includes co-creating solutions with patient organisations to better understand and address patients' needs. These collaborations have also supported advances in pain management and the implementation of the World Health Organisation's International Classification of Diseases (ICD)-11 codes for pain.

For more information, see the section  'S4-2 Processes for engaging with consumers and end-users about impacts'.

3. Healthcare professionals and healthcare organisations (HCOs):

We aim to equip healthcare professionals with the latest medical knowledge related to Grünenthal's products – to enhance patient care and treatment outcomes. We focus on providing healthcare professionals with education, including Continuing Medical Education (CME), that supports their efforts

to ensure the best possible care to patients. Our educational initiatives give healthcare professionals information about advances in pain management to support them in making well-informed treatment decisions. We also interact with healthcare professionals via roundtables, webinars, symposia and partnerships to gain a deep understanding of unmet medical needs, as well as to optimise disease management strategies together and contribute to scientific exchange.

4. Payers and budget holders:

Grünenthal engages in constructive dialogue with governments and medical insurance systems to ensure sustainable access to medicines. Discussions focus on addressing unmet medical needs, ensuring fair reimbursement, and improving healthcare outcomes. In 2024, the company supported a meeting of Spanish regional budget holders to facilitate knowledge exchange and enhance holistic pain treatment across regions.

5. Governments, policymakers, and regulators:

Grünenthal maintains regular dialogue with regulatory bodies, aligning its development programmes and compliance activities with regulatory requirements. The company also contributes to policy discussions on new regulations through national and international trade associations.

6. Investors:

Grünenthal engages with investors through quarterly results calls, meetings, and conferences, providing transparency about its strategy, R&D efforts, and ESG activities. The company's strong financial performance, strategic execution, and low-risk ESG rating have supported access to international capital markets, reinforcing shareholder confidence in its long-term vision and strategy.

7. R&D partners:

Grünenthal collaborates with clinics, academic institutions, Contract Research Organisations, and biotech companies to accelerate the development of life-changing medicines. By adopting green pharmaceutical development processes, Grünenthal reduces its environmental footprint while optimising outcomes for patients.

8. Industry business partners:

Grünenthal works closely with partners to expand its product portfolio, ensure uninterrupted supply, and drive global business growth. In 2024, the company focused on strengthening its network of partners to support newly acquired products and enhance patient access worldwide.


9. Suppliers:

Grünenthal maintains mutually beneficial relationships with its suppliers, engaging in dialogue to uphold standards for quality, ethics, and environmental management across the supply chain.

10. Communities:

Grünenthal's commitment to social responsibility extends to local and global communities and reflects our dedication to making a positive impact beyond the pharmaceutical sector. These activities prioritise communities affected by crises and natural disasters and mainly support organisations and initiatives that promoted or restored people's physical or mental wellbeing, as well as public welfare and the protection of vulnerable groups. Initiatives such as the Grünenthal Foundation and the Dialogforum Contergan exemplify the company's commitment to responsible corporate citizenship. In 2024, the company continued its efforts to promote access to palliative care in Europe and Latin America.

Incorporating stakeholder views along our entire value chain



Hannah Engels, Global Compliance & Responsibility Officer, with Tobias Schäfers, Head of Responsibility

» Grünenthal Insight

Resources for patient engagement

We regularly share our experiences regarding patient partnerships with colleagues worldwide via the intranet platform PEER – Patient Engagement Excellence Resources. In 2024, we have further developed our PEER community.



Key metrics in 2024

Intranet page visits

21,174

Engagement rate¹

27%

¹ Ratio of interactions with a post to users reached.

Selection of Grünenthal's association memberships

- International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
- International Society for Pharmaceutical Engineering, Inc. (ISPE)
- International Trademark Association (INTA)
- Interpat – The biopharmaceutical Intellectual Property think tank
- Pharmaceutical Supply Chain Initiative (PSCI)
- United Nations Global Compact
- European Federation of Pharmaceutical Industries and Associations (EFPIA)

Integration of stakeholder interests into strategy and business model

Grünenthal's ongoing stakeholder dialogue provides valuable insights that enable the company to refine strategies and deliver targeted, impactful solutions. As a result of the stakeholder dialogue, Grünenthal's strategy and business model seems well aligned with stakeholder interests and no changes were made during the reporting period. Patient needs for example shape our focus on innovative pain management solutions and patient-centric initiatives, such as education programmes and co-created therapies. Feedback from investors drives our emphasis on transparency, sustainable growth, and ESG priorities, while employee input informs workplace improvements, professional development programmes, and diversity initiatives. Structured engagement mechanisms, including feedback platforms and board meetings, ensure continuous alignment with evolving stakeholder expectations. Grünenthal's Executive Board Team stays informed about key stakeholder interests and feedback through regular updates via various channels and formats, e.g. Great Place to Work®, Global Town Halls for all employees, Investor Call updates and Compliance and Responsibility updates.



Quentin Le Masne De Chermont, Head Corporate Strategy and Portfolio Management

SBM-3 Material impacts, risks and opportunities and their interaction with strategy and business model

#	ESG category	Material topic	Type of impact	Impact	Value chain	Affected stakeholders
1	Environmental	Climate change	Actual negative impact	Emissions from production-related processes	● — ● — ●	Environment
2	Environmental	Pollution	Potentially negative impact	Environmental pollution (land, air, water) including the supply chain	● — ● — ●	Local communities
3	Social	Own workforce	Actual positive impact	Workplace safety and health protection	● — ● — ●	Employees, on-site contractors
4	Social	Own workforce	Actual positive impact	Fair working conditions and remuneration (own workforce)	● — ● — ●	Employees, potential employees, suppliers
5	Social	Own workforce	Actual positive impact	Diversity, inclusion and equal opportunities	● — ● — ●	Employees, potential employees
6	Social	Own workforce	Actual positive impact	Training and development (HR)	● — ● — ●	Employees, potential employees
7	Social	Personal safety of consumers and/or end-users	Potentially negative impact	Patient safety	● — ● — ●	Patients
8	Social	Personal safety of consumers and/or end-users	Potentially negative impact	Safe pain management through responsible use of opioids	● — ● — ●	Employees, healthcare professionals, patients. Partner companies and their employees
9	Social	Personal safety of consumers and/or end-users	Potentially negative impact	Product quality	● — ● — ●	Patients, healthcare professionals, regulators, employees, suppliers, distributors
10	Social	Access to healthcare	Actual positive impact	Access to healthcare	● — ● — ●	Patients, society
11	Social	Research and development	Actual positive impact	Improving patients' quality of life through innovative medicines	● — ● — ●	Patients
12	Governance	Business conduct	Actual positive impact	Ethical business culture	● — ● — ●	Investors, suppliers, authorities
13	Governance	Business conduct	Potentially positive impact	Responsible use of AI	● — ● — ●	Patients, society
14	Governance	Business conduct	Potentially negative impact	Corruption/bribery	● — ● — ●	Investors, employees, patients, regulatory bodies

● — ● — ● Upstream ● — ● — ● Own operations ● — ● — ● Downstream ● — ● — ● Entire value chain

Climate change

The impact of GHG emissions from production-related processes highlights the company's significant environmental footprint, due to the energy-intensive nature of pharmaceutical manufacturing, emphasising the need for effective mitigation strategies from producing companies such as Grünenthal to address climate change.

Pollution

The impact of environmental pollution of air, land and water including the supply chain arises from emissions, waste, and chemical residues across Grünenthal's operations and supply chain, emphasising the need for effective mitigation strategies to identify and address pollution.

Own workforce

The impacts related to workplace safety, fair working conditions, diversity, inclusion, and equal opportunities and training highlight critical areas of Grünenthal's social responsibility towards its own workforce, emphasising the company's role in fostering a safe, equitable, and inclusive work environment while promoting employee growth.

Personal safety of consumers and/or end-users

The impacts related to personal safety of consumers and end-users emphasise the critical importance of ensuring the safety, efficacy, availability and quality of Grünenthal's pharmaceutical products through rigorous patient safety and quality control measures and of addressing safe treatment of pain through the responsible use of opioids. This topic, applied to Grünenthal, is particular to Grünenthal's business model, which is why we have made company-specific disclosures for these topics.

Access to healthcare

The IROs related to access to healthcare emphasise the importance of facilitating access to pain treatment, including through expanded access programmes or compassionate use, providing patients with the potential benefit of treatment not yet widely available. Ensuring the availability and affordability of these treatments can have a significant positive impact on public health, especially in underserved regions.

Research and Development

The impact related to research and development emphasises the creation of innovative medicines, enhancing treatment effectiveness and patient outcomes and improving the quality of life for patients experiencing chronic or acute pain.

The two topics Access to Healthcare and Research and development are distinctive to Grünenthal's business model and not provided for in the ESRS standards, which is why we have made company-specific disclosures for these topics.

Business conduct

The IROs related to business conduct focus on ensuring ethical business culture including adherence to legal requirements and industry standards, the responsible use of AI, and addressing industry specific risks such as corruption and bribery.

These material topics are all of heightened relevance to Grünenthal. It takes Responsibility to address and manage the related IROs and Grünenthal is already integrating these into its strategy and operations. While no resilience analysis was conducted, we currently believe that our strategic approach and operating model enable us to effectively manage material risks and impacts, while also leveraging opportunities to create long-term value.

IRO-1 Description of the processes to identify and assess material impacts, risks and opportunities

Overview of the double materiality analysis process

Grünenthal's approach to identifying and assessing material impacts, risks, and opportunities (IROs) follows a structured methodology that complies with ESRS requirements for the first time. It follows the prescribed steps of identifying and assessing relevant IROs and reviewing both a list of prescribed sustainability topics as well as company-specific topics for the materiality for Grünenthal at various levels of the organisation. The result of this process is validated by the

Corporate Executive Board and also presented to the Advisory Board. Leveraging comprehensive data from multiple sources, the company ensures that all relevant ESG aspects are thoroughly evaluated in alignment with its corporate strategy, governance framework, value chain, products, workforce, and environmental considerations.

IRO assessment

First, a stakeholder and value chain analysis formed the basis for identifying relevant IROs. To this end, Grünenthal's evaluation process encompassed the entire value chain, spanning all business divisions and regions, as well as upstream activities such as input materials, sourced services and downstream activities including product distribution and customer use. The process paid specific attention to stakeholder relevance and input and involved creating a structured overview of key stakeholder groups, their relevance, and existing engagement channels. Additionally, Grünenthal consulted internal proxies responsible for engaging with the respective stakeholder groups to validate stakeholder feedback and integrate it into the IRO assessment.

Further sources of information used to identify relevant IROs in all relevant categories of ESG (environment, social and governance) include the company's internal activities such as insights from Grünenthal's due diligence procedures and risk management system, competitive benchmarking and external expertise. Moreover, the identification of IROs incorporated publicly available information, including legal and regulatory frameworks, media reports, sector benchmarks, peer analyses, and other relevant sources.

As initial assessment, topic experts at Grünenthal rated the IROs individually. During this step, the **impact assessment** considered both the severity of the impact and likelihood of occurrence for potential impacts on a five-point scale with 'one' being the lowest score and 'five' being the highest score per assessment category. This process integrated time horizons by evaluating how the scale, scope, and irremediability of impacts, as well as probability of occurrence for potential impacts, evolve over time.

While short-, medium-, and long-term horizons were all taken into account – defined in accordance with ESRS as up to one year, one to five years, and more than five years, respectively – the evaluation was conducted on a consolidated basis. This dynamic approach considered both current and potential future effects, ensuring a comprehensive evaluation. The resulting score was compared against a materiality threshold, which was set at ‘three’.

During the **financial assessment**, Grünenthal’s regular risk management served as foundation as topic experts first rated known sustainability-related risks and opportunities, later on also those related to identified impacts. This was done based on the risks’ and opportunities’ maximum expected gross magnitude based on pre-defined internal financial thresholds used in Grünenthal’s risk management across short-, medium-, and long-term time horizons as well as regarding their probability of occurrence. A consistent ten-point scale guided these assessments. The scores for magnitude and probability of occurrence were multiplied and the materiality threshold set at a score of 50/100. While in Grünenthal’s regular risk management sustainability risks are not prioritised over non-sustainability risks, only those related to sustainability were considered in the double materiality analysis. No sustainability-related risks or opportunities were identified as material in this process.

Grünenthal’s risk management process and the IRO assessment process in the context of the double materiality analysis are not yet formally integrated, but they are aligned in content and ratings.

For the IROs initially rated as material, as well as those assessed with a medium outcome (i.e., impacts with a score of 2 – 2.99; risks and opportunities with a score between 20 and 49), the ESRS topic list was used to determine which topics and sub-topics were likely or less likely to be material. This informed the ensuing step, the workshops described in the next section.

Finalisation and validation of material topics

In the final process steps, Grünenthal conducted workshops at multiple organisational levels including the Corporate Responsibility Board level to determine the final list of material topics. These workshops were all based on the results of the IRO assessment and included reviewing the status quo of pre-defined ESRS (sub-)topics as well as company-specific topics, connected IROs and their materiality, performing case-by-case evaluations of topics assessed just below the materiality threshold, and reassessing excluded topics to verify accuracy and identify potential gaps.

This iterative multi-step approach was implemented by design to ensure consideration from all relevant perspectives and serve as an internal control system. The final validation of the results occurred through the Corporate Responsibility Board.

E1.IRO-1 Description of the processes to identify and assess material climate-related impacts, risks and opportunities

Climate-related impacts were already being tracked and reported in the form of GHG emissions in the past. The IROs’ assessment by Grünenthal topic experts and discussion of IROs on management level mirrors the process described above (see section [E ‘IRO-1 Description of the processes to identify and assess material impacts, risks and opportunities’](#)). As a result, emissions from production-related processes were identified as actual negative material impact.

Regarding climate-related risks and opportunities in particular, Grünenthal is preparing a comprehensive evaluation across its operations and value chain, scheduled for completion at each site during 2025. This process will address physical and transition risks over short-, medium-, and long-term horizons. It includes screening assets and activities for exposure and sensitivity to risks, applying climate scenarios, and using scenario analysis to ensure alignment with financial assumptions.

E2.IRO-1 Description of the processes to identify and assess material pollution-related impacts, risks and opportunities


Grünenthal has not yet screened for pollution-related impacts, risks and opportunities at local site-level or consulted possibly affected communities. However, during the double materiality analysis, pollution of water, air, and land, including the supply chain was assessed as a material negative impact of Grünenthal’s business activities. The assessment incorporated input from topic experts at the Group level and management-level workshops with participation from various stakeholders or their proxies.


G1.IRO-1 Description of the processes to identify and assess material business-conduct-related impacts, risks and opportunities

The process for identifying and assessing material business-conduct-related impacts, risks and opportunities mirrors the description in section [E ‘IRO-1 Description of the processes to identify and assess material impacts, risks and opportunities’](#).

IRO-2 Disclosure requirements in ESRS covered by the undertaking’s sustainability statement

An overview of the ESRS disclosure requirements addressed in this report is provided in the chapter titled [E ‘ESRS Index’](#). Information is classified as material or non-material based on our double materiality assessment (see section [E ‘IRO-1 Description of the processes to identify and assess material impacts, risks and opportunities’](#)), conducted in accordance with the criteria outlined in ESRS 1, section 3.2. Data points are deemed material if they relate to our identified material impacts and provide relevant insights to support users of this report.





ENVIRONMENT

- **Climate change (ESRS E1)**
 - Managing climate change
 - Relevant topic clusters
- **Environmental pollution (land, air, water) including the supply chain (ESRS E2)**
 - Managing pollution at Grünenthal and in the supply chain
 - Relevant topic clusters

E1 – Climate change

Managing climate change

E1.SBM-3 Material impacts, risks and opportunities and their interaction with strategy and business model

Type of impact	Impact
Actual negative impact	Emissions from production-related processes

At this point, only impacts on climate-related topics as opposed to related risks and opportunities for Grünenthal were identified during the double materiality analysis. Grünenthal recognises the importance of evaluating climate-related risks and is currently in the process of assessing physical and transitional risks as preparation for a climate resilience analysis. This evaluation forms a critical component of the company’s approach to understanding and mitigating the potential impacts of climate change on its operations.

Grünenthal’s annual greenhouse gas inventory shows what categories of emissions are most prominent and could be targets for emission reduction initiatives.

Scope and methodology

The resilience analysis will focus on Grünenthal’s own operations, providing a targeted framework to identify and address vulnerabilities. Grünenthal will apply the Task Force on Climate-related Financial Disclosures (TCFD) methodology to ensure the analysis adheres to established best practices and delivers meaningful insights.

The CO₂ footprint is being calculated according to the GHG protocol, an initiative which supplies global standardised frameworks to measure and manage greenhouse gas emissions, therefore helping to track progress towards climate goals. For more details regarding scope and methodology, see chapter [E1-6 Gross Scopes 1, 2, 3 and Total GHG emissions](#).

Time horizon and progress

Grünenthal will set the resilience analysis within a 2050-time horizon, aligning with long-term climate action goals. However, the company has not conducted any resilience analysis to date, and results are not yet available. Results are anticipated for 2026 and will be included in sustainability reporting once available.

Grünenthal’s greenhouse gas inventory is being calculated annually with more information available in chapter [E1-6 Gross Scopes 1, 2, 3 and Total GHG emissions](#).

Adaptation and strategic alignment

Grünenthal’s strategy and business model have not been adapted in response to climate-related risks at this stage. The findings from the ongoing evaluations will be important when considering future strategy or operational adjustments and help to ensure that the company’s operations remain resilient to the challenges posed by climate change.

E1-1 Transition plan for climate change mitigation

Grünenthal has developed a transition plan to support its climate change mitigation efforts, with the overarching goal of achieving its validated SBTi targets by 2030. The plan outlines the

company’s decarbonisation strategy, focusing on reducing greenhouse gas emissions across Scope 1 and Scope 2 by 50% by 2030. For Scope 1, Grünenthal is prioritising gas reduction projects, such as the installation of heat pumps at the Aachen headquarters and the Mitlödi manufacturing site to substitute gas consumption. For Scope 2, the company has already achieved a significant milestone by transitioning to 100% renewable electricity across all manufacturing sites in 2024. Regarding its Scope 3 emissions, Grünenthal has set a supplier engagement target aiming for suppliers accountable for 67% of its Scope 3 emissions to have science-based targets validated by SBTi or a similar organisation by 2028. Grünenthal plans to set a Scope 3 emissions reduction target by 2027.

While Grünenthal has largely established the mitigation aspects of the transition plan relating to emissions reductions in Scope 1 and Scope 2, the company still needs to define specific actions to meet the targets. These actions will ensure that the plan’s implementation is both effective and aligned with Grünenthal’s decarbonisation objectives.

Grünenthal has no economic activities covered by delegated regulations on climate adaptation or mitigation under the Taxonomy Regulation.

Grünenthal has not identified any risks related to locked-in greenhouse gas emissions¹, but is maintaining the flexibility to achieve targets by selecting projects aligned with business requirements. The company has not invested significant CapEx amounts during the reporting period regarding coal, oil and gas-related economic activities.

¹ Locked-in emissions are estimates of future GHG emissions that are likely to be caused by the undertaking’s key assets or products sold within their operating lifetime.

The transition plan and related activities are integrated into Grünenthal's broader business strategy and financial planning, ensuring they support the company's ambitions and commitments. The Global Operations Board (GOB) and the CEO have approved the transition plan, underscoring its strategic importance. Progress is monitored and reviewed biannually, with updates provided to the GOB as part of the company's Planet Roadmap.

Grünenthal is not excluded from the EU Paris-aligned benchmarks aimed at limiting global warming to 1.5 degrees Celsius. Although the company's transition plan for climate change mitigation follows these benchmarks, Grünenthal intends to define further measures to ensure the specific actions are fully compatible. Grünenthal remains committed to adapt its climate change mitigation plan to the benchmarks and operationalise it to drive progress in tackling climate change. Details on already implemented actions can be found in section [👁 'E1.MDR-A Climate change actions'](#).

E1.MDR-P/E1-2 Climate change policies

At Grünenthal, the **Policy on Occupational Safety, Health and Environmental Protection, and Energy**, or for short the Environment, Health and Safety (EHS) Policy, is a fundamental component of our commitment to sustainability and regulatory compliance which offers orientation for all actions with possible impacts related to the environment, health and safety. It describes Grünenthal's commitment to actively address climate change and reduce greenhouse gas emissions within its operations and value chain, treating these efforts – alongside occupational safety, environmental protection, and energy efficiency – with the same responsibility and systematic approach as applied to quality, productivity, and effectiveness.

The EHS policy further underlines the commitment to comply with all relevant laws, regulations and other requirements related to occupational safety, and health and environmental protection and report on environmental issues.

Grünenthal is committed to protecting the environment by reducing its negative impact on air, water, and soil pollution. The organisation invests in safe, energy-efficient, and sustainable technologies, minimises waste, especially hazardous waste, and prioritises sustainability in resource use and procurement.

The policy does not, however, provide concrete operational guidance. Operationalisation of the policy is handled at each location as well as at Grünenthal's headquarters for larger initiatives.

Besides the EHS policy, Grünenthal uses its leverage and relationships with suppliers to communicate expectations related to its suppliers' environmental management. The company's Responsible Sourcing Standards for Business Partners, the Procurement Policy and the related Responsible Sourcing practices, as well as the Statement on Human Rights and Environmental Standards, cover among other aspects, environmental management in the supply chain and foster a collaborative approach to addressing climate change. The policies each cover a number of aspects and are described in more detail in the respective chapters (see [👁 'E2'](#), [👁 'S1'](#) and [👁 'G1'](#)).

Yuliia Lohvynenko,
Global Sustainability
Manager, Inga Kaiser,
Digital Procurement
Transformation Manager,
Priyatham Salimadugu,
Sourcing Manager



Policy scope

The EHS Policy’s scope includes Grünenthal’s own operations and suppliers. This inclusive scope ensures that environmental standards are upheld across our upstream value chain, without exception. Topics other than emissions and energy aspects are addressed as well, e.g., water management, waste and pollution (see chapter [E2 – Pollution](#)).

Accountability and local adaptation

The CEO is responsible for approving the EHS Policy, underscoring its importance at the highest levels of the organisation. Accountability for implementing the policy lies with leadership teams at each manufacturing site. Each site adopts the policy in the local language and includes site-specific commitments, roles and responsibilities to ensure effective application. Additionally, our Planet Committee, which includes project leads and EHS Managers from our global sites, meets monthly to oversee

initiatives that align with the EHS Policy, including energy efficiency, water conservation and waste management.

Alignment with third-party standards

Grünenthal’s EHS Policy is implemented in alignment with international environmental standards and conventions, including ISO 14001:2015, corporate environmental standards, aspects of the United Nations Sustainable Development Goals, and the Greenhouse Gas Protocol. These frameworks guide our efforts in minimising our environmental footprint and enhancing transparency and accountability.

Stakeholder consideration

The policy-setting process included input from internal stakeholders as well as proxies for external stakeholders, ensuring that diverse perspectives were considered in shaping the EHS Policy. In addition, feedback is gathered during external ISO audits to further refine and improve

the policy. The finalised policy is also available on the Grünenthal corporate website, providing a direct channel for stakeholders to raise concerns and suggest improvements for the Grünenthal Policy content.

Accessibility and implementation

The EHS Policy is made publicly accessible via Grünenthal’s contract manufacturing website Grünenthal PRO. This ensures that all stakeholders, including those directly involved in its implementation, can easily access the document and understand its provisions. Additionally, we continue to develop a robust environmental data management and monitoring system for water, energy, waste, and greenhouse gas emissions, further supporting the operationalisation of the EHS Policy.

**E1.MDR-A/E1-3
Climate change actions**

Grünenthal is committed to advancing sustainability through initiatives focused on energy efficiency, GHG reduction, the adoption of environmentally friendly technologies and practices as well as employee and supplier engagement in sustainability. These actions reflect our dedication to reducing our environmental footprint while driving long-term progress.

Scope of key actions

In order to achieve its environmental targets, Grünenthal has established a comprehensive management system, aligned with its EHS Policy and rooted in internationally recognised standards, including ISO 14001:2015, corporate environmental standards, the United Nations Sustainable Development Goals, and the Greenhouse Gas Protocol. This system enables Grünenthal to systematically collect and analyse data from its manufacturing sites, helping to improve efficiency and for example reduce energy consumption.

Elke Geysen, Head Global Procurement and External Supply Operations, in discussion with Christoph Hausser, Site Director Germany



However, reducing GHG emissions across Grünenthal's value chain requires the participation of all involved organisations. Grünenthal is currently preparing the launch of the supplier engagement programme and aims to use this as leverage to lower emissions throughout its operations.

The annual update of the GHG inventory at our sites and throughout the up- and downstream value chain ensures transparency and tracks our progress. These efforts are guided by our Planet Roadmap, which sets clear goals to reduce emissions, conserve water, and promote sustainable practices such as eco-friendly packaging and responsible sourcing.

Following the ongoing physical and transitory climate risk analysis, Grünenthal plans to identify levers and initiate actions to mitigate and prevent these risks and design actions to best adapt to the changing climate conditions – both within its own operations and along the value chain.

Time horizon for completion

The key actions are aligned with Grünenthal's 2030 strategy, which is built on SBTi principles to meet near-term climate goals.

Actions taken and progress achieved

Own operations:

Grünenthal has made substantial progress in reducing company-wide emissions by adopting the SBTi framework and introducing a Corporate Environmental Impact Assessment (EIA) standard. Investments in energy efficiency and renewable energy across Grünenthal's manufacturing sites in Mitlödi, Origgio, Quito, and Santiago, as well as the headquarters in Aachen, have notably reduced Scope 2 CO₂ emissions. For instance, the installation of a heat pump at the Aachen headquarters has led to an annual reduction of 550 tonnes of GHG emissions (17% of Scope 2 emissions). Additionally, in Ecuador, the signing of International Renewable Energy Certificates (IREC) supports net-zero goals at the Quito site.

Looking forward, Grünenthal is planning to complete a series of actions related to energy efficiency and reduction of energy consumption, such as heat recovery measures, improvement of thermal plant efficiency, and workshops on energy savings in steam production, as well as more regular actions such as room temperature reduction during weekends. Moreover, the newly installed solar plant will start to produce electricity regularly, as it up until now is running on 'test mode' after its implementation in 2024.

Supplier engagement:

Grünenthal has been monitoring the progress of its supply chain in its commitment to set science-based targets as part of the company's supplier engagement preparation. The Responsible Sourcing Standards for Business Partners describe the expectations regarding actions to be taken on climate change mitigation. Grünenthal utilises a sustainability collaboration platform, where some strategic suppliers are requested to share their climate targets' status. As part of its monitoring, Grünenthal checks suppliers' progress through the SBTi website and analyses relevant suppliers' sustainability reports.


Grünenthal has defined three types of suppliers: Advanced, Intermediate and Beginners. Advanced suppliers have a robust GHG inventory, approved science-based targets in line with the Paris Climate Agreement, and are working on their decarbonisation plans, including switching to 100% renewable electricity (Scope 2).

The focus in 2025 will be to engage and create an action plan with suppliers at the Intermediate and Beginners levels. External collaboration is important, and as part of Grünenthal's membership in the Pharmaceutical Supply Chain Initiative, we will work on the Supplier Decarbonisation Committee to jointly develop tools and training materials to support each company's supplier engagement.

» Grünenthal
Insight

Maturity of 2023 top GHG contributors in Grünenthal's supply chain

The chart below describes the progress of suppliers (in absolute numbers) accountable for 67% of Grünenthal's total Scope 3 greenhouse gas emissions having a carbon-reduction target approved by SBTi.



Significant progress has been made, with the number of suppliers having emission targets approved by SBTi increasing from 40 in 2022 to 53 in 2023. Having emission targets is an important step to build a decarbonisation plan.

Key actions taken and planned, expected outcomes, alignment with policy objectives, and time horizons

Category	Examples of key actions	Outcome	Contribution to policy objectives	Time horizon
Energy efficiency and consumption reduction	• Optimisation of central chilling system (Aachen) • Shutdown of Heating, Ventilation, and Air Conditioning (HVAC) and decommissioning of inefficient buildings (Aachen) • Digital twin implementation for cogeneration plant (CHP) control (Aachen) • Replacement of compressed air generators (Aachen, Santiago)	• Reduction in energy consumption (notably gas and electricity) • Reduction in Scope 1 and 2 emissions	Aligned with GHG reduction policy and energy intensity KPIs	• 2023 – 2026
Use of renewable energy	• Full switch to renewable electricity (Aachen, Mitlödi, Origgio, Quito, Santiago) • 100% green energy (Quito) • PPA agreements and photovoltaic installations (Aachen)	• In total 2,559 t CO₂e in 2024 • Transition to 100% renewable power	Supports decarbonisation of electricity use and longterm net zero targets	• Renewable energy contracts completed (2022 – 2024), additional enhancements in 2025 • Photovoltaic Aachen test mode in 2024, full implementation in 2025 • 100% green energy Quito in 2025
Electrification	• Replacement of heating system in corporate centre with efficient electric system (Aachen) • Heat recovery and heat pumps (Origgio)	• 309 t CO₂e reduction in 2024	Moves energy mix away from fossil fuels	• Heating system replacement in Aachen targeted for completion in 2025 • Engineering/planning phase in Origgio in 2026 – 2027
Fuel switching and process improvements	• Transition from natural gas in two buildings • Heat pump project initiated (Mitlödi)	• 1,616 t CO₂e reduction expected by 2025	Substitution of fossil fuels with renewable gas sources	• 2025
Strategic decisions/ other	• Strategic decision to stop cogenerator use or purchase biogas certificates (Aachen, Origgio)	• Elimination of legacy gas consumption • Awareness and behavioural changes	Cultural shift and efficiency optimisation across sites	• Strategic shift planned by 2030

Financial and resource allocation

Grünenthal has allocated significant financial resources towards realising its Planet strategy, especially regarding the Mitlödi heat pump project. Other relevant initiatives relate to energy efficiency and consumption reduction or the electrification of fossil-based systems. Many of these projects relate to heating and chilling processes in particular, and others, for example to the installation of renewable energy generation systems such as the photovoltaic system in Aachen. No exact CapEx/OpEx data for the (planned) actions is being reported this year due to limited data availability.

Climate change metrics and targets

E1.MDR-M Metrics in relation to climate change

Grünenthal evaluates the performance and effectiveness of its environmental actions by using metrics that capture the cost of project implementation, energy in MWh, potential pollution levels, and GHG emissions measured in metric tons. These metrics provide insights into the material impacts, risks and opportunities associated with the company’s sustainability initiatives.

The methodologies used for data collection and analysis rely on robust sources. Energy-related data are derived from meter readings, ensuring precision and consistency in measurement. Meters are calibrated and regularly maintained.

For information related to the calculation of GHG emissions, see section [🔗 ‘E1-6 Gross Scopes 1, 2, 3 and Total GHG emissions’](#).

E1.MDR-T/E1-4

Targets related to climate change mitigation and adaptation

Grünenthal has established clear sustainability targets aligned with its Policy on Occupational Safety, Health and Environmental Protection, and Energy (EHS Policy) objectives. Monthly monitoring and robust evaluation processes ensure that the effectiveness of policies and actions is consistently tracked against material sustainability-related impacts. Each month, the site-level EHS teams convene with the Global EHS function to review performance. During these meetings, each manufacturing site presents an update on monthly performance metrics and outlines corrective actions where deviations from established targets have been identified.

The year 2020 has been selected as the baseline for Grünenthal's emissions target setting due to its status as the first year with complete and consistent emissions data coverage across Scope 1, Scope 2, and Scope 3 categories. This includes all relevant sources such as stationary and mobile combustion, and electricity consumption (both market-based and location-based). The baseline aligns with the company's internal climate strategy and its SBTi-aligned target-setting methodology. Despite the COVID-19 pandemic, operational emissions in 2020 remained representative of typical activity levels, particularly in core manufacturing and logistics, and were comparable to adjacent years. Emissions profiles from 2021 to 2023 confirm the stability and relevance of this baseline for tracking progress.

Scope 1 and 2

Grünenthal aims to reduce the sum of its Scope 1 and Scope 2 emissions by 50% (Scope 1 by 42%, Scope 2 by 77%) compared with its 2020 base year by 2030 (34,544 t CO₂). These reduction targets are in the process of being validated by the SBTi with validation expected to be completed in 2025.



Sandra Matamoros, Global Programme Lead Responsible Sourcing, with colleagues

Grünenthal is initiating projects to tackle the expected levers of its production emissions, such as green electricity and heat pumps. For estimated quantitative contributions to the achievement of GHG emission reduction targets, see section [👁 'Key actions taken and planned, expected outcomes, and alignment with policy objectives'](#). Since the climate risk analysis is still underway, specific climate scenarios have not yet been considered to identify additional impact levers. This will follow once the analysis is complete.

Scope 3

» Regarding Scope 3 emissions, Grünenthal developed a comprehensive action plan to have a near-term Scope 3 carbon-reduction target in 2027. As part of Grünenthal's Science Based Targets initiative (SBTi) near-term targets, the

company will launch a supplier engagement plan to ensure that suppliers, responsible for 67% of Grünenthal's Scope 3 emissions, have validated emission targets by 2028. Once a Scope 3 emission target will be set, this supplier engagement will support in reaching the Scope 3 emission target. Integrating ESG criteria into procurement and increasing awareness of ESG impacts in purchasing decisions is a main component of the current strategy. Additionally, Grünenthal will enhance the quality of its Scope 3 greenhouse gas (GHG) data collection by collaborating with internal stakeholders. This plan ensures that Grünenthal is ready to set ambitious carbon reduction targets. «

In 2027, Grünenthal plans to set a measurable, outcome-oriented target to manage its emissions particularly with regard to Scope 3.

ESRS-aligned targets and progress 2024

Target ¹	Progress 2024	Status
Reduce Scope 1 and Scope 2 greenhouse gas emissions by 50% ² by 2030 compared with 2020 (in line with our SBTi commitment for near-term targets) ³	42% reduction achieved for Scope 1 and Scope 2 since 2020	On track
Reduce greenhouse gas emissions by 4.2% each year until 2030 (absolute reduction, tonnes) (based on a 3% reduction in normalised energy consumption)	6.3% reduction achieved for Scope 1 and 2 in 2024 vs 2023	On track

¹ Targets maintained from previous Responsibility Report; will be reviewed in 2025.
² Thereof Scope 1 reduction by 42%, Scope 2 reduction by 77%
³ Grünenthal has not yet set Scope 3 emission reduction targets, but plans to do so by 2027.

» Further targets and progress 2024

Target ¹	Progress 2024	Status
Engage our key suppliers who account for 67% of our total Scope 3 greenhouse gas emissions to have emission targets that are validated by the SBTi by 2028 (in line with our SBTi commitment for near-term targets)	Decarbonisation status of key suppliers in scope of SBTi Scope 3 target updated. 53 suppliers accountable for 33% of the Scope 3 total GHG emissions in 2023 have approved science-based targets.	On track

¹ Targets maintained from previous Responsibility Report; will be reviewed in 2025. «

Nature and scope of targets

The SBTi reduction targets for GHG emissions are relative in nature and are defined centrally at the Grünenthal headquarters and operationalised at the site level and then managed by EHS managers and leadership teams. These targets encompass greenhouse gas (GHG) emissions of Grünenthal’s own operations where Grünenthal has operational control as well as those of its suppliers, and are aligned with Grünenthal’s broader sustainability ambitions.

Period and milestones

Broken down to yearly targets, progress is evaluated through monthly performance reviews. These regular check-ins help Grünenthal maintain focus on incremental achievements while

working towards its long-term objectives. The targets reported above are set for 2028 and 2030, respectively.

Methodologies, scientific basis, and evaluation processes

To evaluate the effectiveness of its policies and actions, Grünenthal conducts yearly Impact, Risk and Opportunity (IRO) assessments. Strengths, Weaknesses, Opportunities, Threats (SWOT) analyses, performed in accordance with ISO 45001 and ISO 14001 standards, provide additional insight into potential risks and opportunities. Internal audits, global external ISO audits, and performance data from monthly tracking further reinforce the company’s ability to monitor and refine its approach.

» Regarding Scope 3, the Procurement organisation will continue to assess the ESG performance of strategic suppliers based on science-based targets using the sustainability collaboration platform or alternative documents provided by the suppliers. The Responsible Sourcing team will define an action plan and discuss it with the suppliers to promote collaboration and increase the number of suppliers achieving an ‘Advanced’ status. Quarterly progress reports will be shared with the leadership team in Procurement and the External Supply Organisation (ESO) to ensure that metrics remain on track. «

Stakeholder involvement

EHS managers are actively involved in the discussion and refinement of targets for the upcoming year. These targets are aligned with the manufacturing council, members of which include the Head Global EHS & Sustainability, Head Global Quality Assurance and Site Directors, to gain valuable stakeholder input ensuring feasibility and relevance.

Relevant topic clusters

E1-5 Energy consumption and mix

All business areas of our company are classified as high climate impact sectors according to the NACE definition (Delegated Regulation (EU) 2022/1288 of the Commission).

Our production of pharmaceuticals is allocated to Section C, ‘Manufacture of basic pharmaceutical products and pharmaceutical preparations.’

The calculation of our energy intensity thus takes into account the total energy requirement in proportion to net revenue of the Grünenthal Group (please see [Grünenthal Report 2024/2025, Strategy & Financials chapter](#)’ page 31.)¹⁾

¹⁾ The Grünenthal Financial Statement 2024 will be publicly available in the company register (<https://www.unternehmensregister.de/> from August 2025.

» Grünenthal Insight

‘Shine: Together. Powered by the Sun’ – Ceremonial inauguration of biggest solar power system in Aachen region

On 28 August, Grünenthal inaugurated Aachen’s largest solar power system at its headquarters – featuring over 21 km of cable and 116 tonnes of solar modules.

CEO Gabriel Baertschi and the Executive Board Team welcomed prominent guests, including Mona Neubaur, Deputy Prime Minister of North Rhine-Westphalia and Minister for Economic Affairs, Industry, Climate Protection and Energy, and Sibylle Keupen, Mayor of Aachen. The event included a panel discussion on climate protection and renewable energy, followed by a symbolic act: guests and company representatives assembled an oversized plug, accompanied by a brief fireworks display. The evening ended with live music and informal networking.

The system comprises nearly 4,000 solar modules across 18,000 m², generating 1.9 MWp. It will reduce Grünenthal’s CO₂ emissions by 366 tonnes annually – roughly 63 Airbus A380 flight hours. Most of the energy will power the Aachen site; surplus electricity will go into the public grid.

Minister Neubaur highlighted the project’s significance: ‘This shows how companies can help drive the energy transition. Every step towards renewables supports climate neutrality in North Rhine-Westphalia.’

Mayor Keupen added: ‘Grünenthal is putting its commitments into practice, helping expand green power in Aachen.’

CEO Baertschi reaffirmed: ‘As a research-driven pharmaceutical company, we aim to improve patients’ lives and protect future generations. Our goal is to halve net emissions by 2030.’

The inauguration represents a major milestone in Grünenthal’s sustainability strategy and its shift toward renewable energy.

August 2024:
Inauguration
ceremony
(left to right):
Sibylle Keupen
(Mayor of Aachen),
Thorsten Rasche
(Project Lead
Grünenthal),
Gabriel Baertschi
(CEO Grünenthal),
Mona Neubaur
(Deputy Prime
Minister of North
Rhine-Westphalia
and Minister
for Economic
Affairs, Industry,
Climate Protec-
tion and Energy),
Christoph Hausser
(Site Director
Grünenthal
Germany), Dave
Gebauer (CEO
Solarimo), Victor
Barbosa (Head
Global Operations
Grünenthal)



Energy consumption and mix (in MWh)¹

Metric	2024	2023
Total energy consumption	115,381	106,650 ²
Energy intensity (in MWh/million Euro)	62	55
Fuel consumption from coal and coal products	—	—
Fuel consumption from crude oil and petroleum products	1,529	522
Fuel consumption from natural gas	89,046	80,450
Consumption of purchased or acquired electricity, heat, steam, and cooling from non-renewable sources	—	10,089
Total non-renewable energy consumption	90,575	91,061
Share of non-renewable sources in total energy consumption	78.5%	85.4%
Fuel consumption for renewable sources (including biomass, biogas, non-fossil fuel waste, renewable hydrogen)	663	—
Consumption of purchased or acquired electricity, heat, steam, and cooling from renewable sources	24,144	15,589
The consumption of self-generated non-fuel renewable energy	—	—
Total renewable energy consumption	24,807	15,589 ²
Share of renewable sources in total energy consumption	21.5%	14.6%

¹ There was no fuel consumption from other fossil sources, nuclear sources, non-renewable energy production and renewable energy production.
² Reported last year for 2023: renewable energy consumption 22,448 MWh; total energy consumption: 106,650 MWh. The change is due to a switch in calculation methodology in 2024, in which only 100% renewable energy contracts are counted towards renewable energy consumption rather than, as in the past, consumption under contracts with only partial renewable energy share.

E1-6 Gross Scopes 1, 2, 3 and Total GHG emissions

Changes in reporting scope and boundaries
In 2023, Grünenthal established a joint venture with Kyowa Kirin International, forming Grünenthal Meds, of which Grünenthal holds a 51% stake. This influenced the definition of the scope of the reporting and the entities included in Grünenthal’s value chain. According to the GHG Protocol, emissions from equity-shared ventures must be included. However, due to data

unavailability, emissions from Grünenthal Meds were excluded from the 2023 reporting cycle, potentially affecting year-on-year comparability. For the reporting year, Scope 1 and 2 emissions of Grünenthal Meds are included in the report, while Scope 3 emissions are not. Grünenthal applies an ‘operational control’ boundary for GHG reporting, covering 100% of emissions from facilities it fully controls and manages. Certain exclusions, however, were necessary due to data gaps or irrelevance. These include around 1.1% of purchased goods and services spending,

and 25% of downstream transportation spending, due to being out of scope (e.g., payment of financial fees, taxes, etc.). Emissions from sold products were deemed irrelevant, as Grünenthal does not produce goods emitting GHG during use. Additionally, processing emissions from sold products were not calculated due to the diversity of intermediate products and their varied applications. Franchises and investments, not being part of Grünenthal’s operational model, were also excluded from the reporting scope.

» Grünenthal Insight

Fully charged: All Grünenthal manufacturing sites powered by 100% green electricity

All five global manufacturing sites are now powered by 100% renewable electricity – a major step toward a greener future and a clear sign of our commitment to reducing environmental impact.

Our 100% renewable journey: With support from our Environment, Health & Safety and Engineering teams, we have successfully transitioned all sites to fully renewable electricity. Sourced from wind, solar, and other green energy, our facilities now run entirely on clean electricity – lowering our carbon footprint and supporting climate goals.

Our green sources: The Origgio and Aachen sites use green Power Purchasing Agreements (PPAs) to access solar and wind energy. Solar panels have also been installed at Origgio, Aachen, and the Swiss API site, generating clean energy on-site. The Swiss site further sources power from a local hydropower system.

Quito leads the way: Our Quito facility was the first to achieve 100% green energy – not just electricity – as it operates entirely without gas.

All manufacturing sites use

100%

renewable electricity



Solar park at Origgio site

Grünenthal GHG emissions¹

	Retrospective					Milestones and target years			
	Base year 2020	2022	2023	2024	% 2024/ 2023	2025	2030	(2050)	Annual % target/ Base year
Scope 1 GHG emissions									
Gross Scope 1 GHG emissions (t CO ₂ e)	22,102	20,928	18,137	19,512	+7.6%				
Percentage of Scope 1 GHG emissions from regulated emission trading schemes (%)	—	—	—	—					
Scope 2 GHG emissions									
Gross location-based Scope 2 GHG emissions (t CO ₂ e) ²	12,442	8,513	7,927	6,265	−21%				
Gross market-based Scope 2 GHG emissions (t CO ₂ e) ³	10,122	3,481	3,248	540 ⁴	−83.4%				
Significant⁵ Scope 3 GHG emissions									
Total gross indirect (Scope 3) GHG emissions (t CO ₂ e)	N/A ⁶	456,936 ⁷	367,840	350,501 ⁸					
1 Purchased goods and services		290,537	308,085	292,859 ⁹					
2 Capital goods		4,256	4,900						
3 Fuel- and energy-related activities (not included in Scope 1 or Scope 2)		3,660	5,055						
4 Upstream transportation and distribution		8,393	28,729	27,961 ¹⁰					
5 Waste generated in operations		2,028	2,515						
6 Business travel		7,549	9,646	9,632 ¹¹					
7 Employee commuting		4,676	4,952						
12 End-of-life treatment of sold products		98	3,957						
Total GHG emissions¹¹									
Total GHG emissions (location-based) (t CO ₂ e)			393,904	376,278 ¹³					
Total GHG emissions (market-based) (t CO ₂ e)			389,193	370,553 ¹³					
Market-based emissions intensity (t/million Euro)			214	206.09 ¹⁴		N/A	N/A	N/A	N/A
Location-based emissions intensity (t/million Euro)		291	216.5	209.28 ¹⁴		N/A	N/A	N/A	N/A

¹ Grünenthal does not produce biogenic emissions. Scope 1 and 2 emissions of Grünenthal Meds are included, while Scope 3 emissions are not yet included in the report.

² Electricity consumption figures were multiplied by country-specific grid emission factors.

³ Adjustments were made for renewable electricity purchases and local grid improvements.

⁴ Achieved through signing green Power Purchase Agreements (PPA) for the manufacturing sites in Aachen, Mitlödi, Origgio, and Santiago and International Renewable Energy Certificates (IREC) for the site in Quito.

⁵ For 2024, we only display estimates of the total Scope 3 GHG emissions and its significant contributors. In next year's report, we will display actual data for these figures and the insignificant categories listed.

⁶ No target for Scope 3 set yet – base year will be defined at a later point in time.

⁷ Including 135,740 t CO₂e for downstream transportation. Downstream transportation is not reported for following years.

⁸ No Scope 3 data available at reporting date. Total scope 3 GHG emissions for 2024 have been estimated using a spend-based scaling method. This is based on the assumption that categories 3.1, 3.4, and 3.6 – responsible for over 94% of Scope 3 emissions in 2023 – remain the main contributors, allowing total emissions to be approximated from changes in related spend. The scaling factor is calculated as the ratio of total spend in these categories in 2024 compared to 2023. This ratio is then applied to the total Scope 3 emissions reported in 2023 to derive a high-level estimate for 2024. The total Scope 3 emissions were estimated based on the scaling factor of 0.953. Estimated values will be replaced by actual values in the next Responsibility Report for 2025.

⁹ Estimated using a spend-based scaling method based on a spend-based scaling factor of 0.951. Estimated values will be replaced by actual values in the next Responsibility Report for 2025.

¹⁰ Estimated using a spend-based scaling method based on a spend-based scaling factor of 0.973. Estimated values will be replaced by actual values in the next Responsibility Report for 2025.

¹¹ Estimated using a spend-based scaling method based on a spend-based scaling factor of 0.999. Estimated values will be replaced by actual values in the next Responsibility Report for 2025.

¹² Revenue for 2024 is 1,798.2 million Euro (in comparison: 2023 was 1,819.4 million Euro).

¹³ Calculation based on estimated emissions.

¹⁴ Calculation based on estimated emissions and actual revenue (please see ["Grünenthal Report 2024/2025, Strategy & Financials chapter"](#) page 31; Grünenthal Financial Statement 2024 will be publicly available in the company register (<https://www.unternehmensregister.de/>) from August 2025.).

Reduction of emissions resulting from purchased energy:

–83%

Methodologies and assumptions for GHG calculations

All greenhouse gas emissions have been calculated in accordance with the GHG Protocol methodology, which ensures alignment with best practices in emissions reporting and supports transparency and accuracy.

Direct emissions under Grünenthal's control, such as those from mobile and stationary combustion and fugitive emissions, are captured within Scope 1. This includes refrigerant leaks, which were calculated using factors provided by the UK government's GHG Reporting Guidelines.

Indirect emissions associated with electricity consumption are included in Scope 2. These were calculated using both location-based¹ and market-based² approaches. Past reductions, such as 2024 compared with 2023 (–83%), were achieved through signing green Power Purchase Agreements (PPA) for the manufacturing sites in Aachen, Mitlöd, Origio and Santiago, and International Renewable Energy Certificates (IREC) for the site in Quito.

Scope 3 emissions encompass indirect emissions from upstream and downstream activities. Due to challenges in timely data availability in Grünenthal's supply chain, Scope 3 emissions are being reported a year later than Scope 1 and Scope 2 emissions for the respective year. The most recently available Scope 3 data refers to 2023, when Grünenthal enhanced its data collection processes to include additional categories such as employee commuting, the end-of-life treatment of sold products, and upstream transportation. These emissions were quantified using data from the ecoinvent database, which converts spending and weight information into emissions figures. This expanded granularity underscores the company's commitment to refining its emissions reporting and addressing the broader environmental impacts of its operations.

Scope 3 emissions data for Categories 3.1 (Purchased Goods and Services), 3.4 (Upstream Transportation and Distribution), and 3.6 (Business Travel) have been estimated using a spend-based scaling method. In addition to estimating emissions for each category individually, total Scope 3 emissions for 2024 have been estimated by applying a combined scaling factor based on aggregated spend across these three most material Scope 3 categories. This approach is subject to the following assumptions and limitations:

- The estimation assumes a linear relationship between spend and emissions, which may not fully reflect real changes in supplier practices, emissions intensity, or category-specific emissions factors.

- No adjustments have been made for potential structural or behavioural changes between 2023 and 2024 (e.g., changes in procurement strategy, travel policies, or business travel composition).
- All required spend data for 2023 and 2024 was available and has been used for the estimation.
- For Category 3.4, the methodology applied in 2024 is expected to change compared to 2023, including a partial reallocation of emissions between Categories 3.1 and 3.4. However, this estimate applies the 2023 methodology to 2024 spend to enable a like-for-like comparison and should be interpreted accordingly.
- This estimate is not intended for use in tracking progress against emissions reduction targets but is provided to fulfil near-term reporting obligations.
- Significant estimation uncertainty remains, particularly for categories where emissions are not directly proportional to spend or where methodological changes are anticipated.
- The spend data is assumed to be consistently categorised across years. Any changes in how spend was reported or attributed to Scope 3 categories between 2023 and 2024 may affect the accuracy of the scaling.

¹ **Location-based:** Electricity consumption figures were multiplied by country-specific grid emission factors.

² **Market-based:** Adjustments were made for renewable electricity purchases and local grid improvements.

» Grünenthal Insight


Sustainability at Research labs

Throughout 2024, Grünenthal’s Research labs at the Aachen head-quarters maintained their My Green Lab® certification, following a 2022 assessment of key sustainability practices, including cold storage, lab infrastructure, employee awareness, and the implementation of recycling programmes. At the end of 2024, we achieved re-certification for 2025 and 2026. Re-certification takes place every two years.

My Green Lab® is a non-profit organisation whose programme is recognised by the UN’s Race to Zero campaign as a key benchmark for zero-carbon progress. It is widely regarded as the gold standard for lab sustainability worldwide.

Achieving certification from My Green Lab®

Metric	In % 2024
Percentage of research laboratories that are certified by My Green Lab®	100



Innovation
Chemistry
laboratory,
Aachen
headquarters

Reconciliation to financial statements

GHG emissions intensity is calculated as total emissions (tonnes of CO₂e) divided by net revenue. This approach ensures alignment with financial reporting, facilitating transparent and standardised emissions disclosures.

Continuous improvement

Grünenthal remains committed to enhancing the accuracy and scope of its emissions reporting. The company works on improving its data availability and to include previously excluded data sources, particularly from joint

ventures and downstream transportation. In parallel, Grünenthal aims to further decarbonise its operations by transitioning to renewable energy and reducing gas consumption across its global facilities.

» Grünenthal Insight

Reforestation campaign:
#TreesForOurPlanet

Metric	2024	2023
Number of trees planted as part of Grünenthal's #TreesForOurPlanet campaign	9,823	8,147

Grünenthal launched the **#TreesForOurPlanet** reforestation campaign to commemorate the company's 75th anniversary in 2021. The initial target was to plant 7,500 trees within that year. This target was quickly surpassed thanks to the collective efforts of our teams across all regions. The initiative has continued annually, with targets consistently exceeded. By the end of 2024, nearly **40,000 trees** have been planted – an incredible milestone that reflects the commitment of our global workforce. Tree species are selected in consultation with environmental experts to support and enhance **local biodiversity**. While this campaign is not part of a formal carbon offsetting scheme, it reflects our ongoing effort to contributing to broader environmental goals.

Surpassing expectations with nearly

10,000

trees planted in 2024



Employees and families in Mexico at #TreesForOurPlanet activity

E2 – Environmental pollution (land, air, water) including the supply chain

Managing pollution at Grünenthal and in the supply chain

E2.SBM-3 Material impacts, risks and opportunities and their interaction with strategy and business model

Type of impact	Impact
Potentially negative impact	Environmental pollution (land, air, water) including the supply chain

Environmental pollution of land, air and water including the supply chain has been identified as a material, potentially negative impact for Grünenthal. No risks or opportunities for Grünenthal related to pollution were identified during the double materiality analysis.

Grünenthal has implemented robust pollution prevention and management practices within its own operations, and these efforts are now extending to the supply chain. To manage this material issue effectively, Grünenthal has started checking the environmental management systems of its suppliers as part of the ESG risk management system for the supply chain (see Processes in section [E1 Climate change](#) ‘G1.MDR-A’

in the Governance chapter). By collaborating with supply chain partners, Grünenthal intends to initiate meaningful actions that align with our environmental goals and strengthen sustainable practices. Grünenthal is for example defining action plans to develop our suppliers to have EHS standards fulfilling the framework of an ISO certification. Ongoing progress will be tracked and reported transparently, ensuring accountability and continuous improvement in managing this significant impact.

E2.MDR-P/E2-1 Pollution policies

Pollution policies in own operations:

For its own operations, Grünenthal’s Policy on Occupational Safety, Health and Environmental Protection, and Energy (EHS Policy), is key to its efforts in addressing climate change (see chapter [E1 Climate change](#)), as well as air, land, and soil pollution. The policy comprehensively applies to Grünenthal’s operations and suppliers, ensuring alignment with regulatory compliance and international standards. The policy is implemented by the local EHS teams with the support of local leadership teams. EHS performance is regularly reviewed by the site directors and once a year presented to the CEO.

Grünenthal aims for early identification and mitigation of potential impacts. The policy and procedures serve as guidance for robust operational controls and site-specific risk assessments.

Wastewater and waste management

All wastewater sources are systematically identified and documented via detailed drainage plans, including discharge points and receptors. Wastewater undergoes treatment in line with national and international standards, with parameters such as pH, chemical oxygen demand (COD), and total suspended solids (TSS) monitored continuously. Monitoring results are retained for six years to ensure traceability. Waste management policies mandate source segregation, proper labelling, and secure storage, reducing the risk of cross-contamination and facilitating appropriate handling of hazardous waste streams.

Pollution risk reduction measures

Risk assessments are conducted for all high-risk operations, particularly those involving hazardous substances or wastewater discharge. Sites are required to develop and maintain Waste and Wastewater Management Plans as well as Spill Management Plans, which include both mitigation and contingency measures. Preventive maintenance and regular inspections of critical infrastructure – such as tanks, drains, and storage facilities – are integral to pollution control. All new construction projects undergo Environmental Impact Assessments (EIAs), covering the full life-cycle of the project and considering cumulative and transboundary environmental effects.

Incident response and emergency preparedness

To minimise environmental harm in the event of an incident, Grünenthal enforces a standardised spill response protocol that includes immediate containment, root cause investigation, and corrective actions. Emergency contact procedures with relevant authorities are built into site plans. Additionally, the company's Wastewater Standard addresses unplanned discharge scenarios, including those resulting from extreme weather events. Regular training and emergency drills ensure staff preparedness and reinforce a culture of environmental responsibility.

Pollution policies in the supply chain:


For managing pollution in its supply chain, Grünenthal refers to its Responsible Sourcing Standards for Business Partners. They reflect Grünenthal's expectations of its suppliers in terms of environmental management to address air, land and soil pollution in its supply chain, which was identified as material impact by Grünenthal. In order to supervise supplier compliance with our standard, we aim to implement environmental impact assessments across our procurement processes and sourcing strategy, particularly regarding pollution of water, soil, and air and waste management.

The described policies, along with Grünenthal's Statement of Compliance with Human Rights and Environmental Standards, underline our commitment to complying with international standards such as the Minamata Convention

on Mercury (2013), the Stockholm Convention on Persistent Organic Pollutants (2001, 2005), and the Basel Convention on the Control of Transboundary Movements of Hazardous Waste and their Disposal (1989). The responsible use of resources remains a key focus of Grünenthal's environmental stewardship and is crucial to minimising pollution and fostering sustainability. We endeavour to work with suppliers with the same focus.

E2.MDR-A/E2-2 Pollution actions

Grünenthal recognises the detrimental impact of pollution across its value chain, and, in line with its EHS policy, is committed to a holistic approach to minimise it in both its own operations and the supply chain.



Aachen headquarters
Campus

Pollution actions in own operations:

At its own sites, Grünenthal realises projects and action plans addressing waste and water pollution. The company's global wastewater standard provides guidance on managing, sampling and reporting wastewater quality in compliance with local regulations. Manufacturing sites adopt individual approaches for wastewater treatment based on local discharge requirements, with all practices documented and accessible globally. This has proved valuable, as Grünenthal responded effectively to a minor leakage incident at its Mitlödi site in Switzerland in 2023. Grünenthal worked closely with government authorities to mitigate risks and successfully remediate the affected area. As a consequence, a bulk storage and spill response standard was developed. In 2024, there were no leakages at Grünenthal locations.

Pollution actions in the supply chain:

Grünenthal's Third-Party Due Diligence process includes an ESG risk management system to ensure that risks in the supply chain, including those related to human rights and the environment, are mitigated. Grünenthal follows a two-step risk assessment process. Based on industry type and country of location, suppliers with a higher social and environmental risk are deemed ESG sensitive suppliers. These suppliers undergo an ESG in-depth assessment, involving self-assessment questionnaires as well as validation of their certifications such as ISO 14001 and EMAS, and supported by an external service provider.

Additionally, the company has undertaken a solvent recovery project in Santiago in 2024 to reduce emissions from volatile organic compounds (VOC) in hazardous waste contributing to air pollution. It minimises hazardous waste by collecting and segregating organic solvents, which are then transformed into alternative fuel, leading to the recycling of 12,000 litres per year, a 3% increase in recyclable waste, and a significant reduction in VOC emissions.

No exact CapEx/OpEx data for the (planned) actions is being reported this year due to limited data availability.

Pollution metrics and targets

**E2.MDR-M
Metrics in relation to pollution**

Pollution metrics in own operations:

Grünenthal monitors relevant pollutants of its own business activities (see section [E2-4 Pollution of air, water and soil](#) for details).

Pollution metrics in the supply chain:

Grünenthal collects the regulatory required data for pollution of land, water and air in the supply chain.

**E2.MDR-T/E2-3
Targets related to pollution**

Grünenthal is committed to minimising and controlling pollution across its operations and supply chain. Emissions to water are a key focus area, particularly given the challenges of managing wastewater in pharmaceutical production. Special standards apply to sites producing Active Pharmaceutical Ingredients, ensuring stringent measurement and reporting of active ingredient volumes and effluent disposal.

Grünenthal has defined expectations for its suppliers to minimise negative environmental impacts in the Responsible Sourcing Standards for Business Partners, such as engaging on a journey towards zero waste to landfill and zero discharge of harmful substances to water. To date, Grünenthal has not formalised specific targets for pollution prevention relating to air, water or soil in the supply chain as of ESRS E2-3 §20. These forthcoming targets will be measurable and outcome-oriented. They will complement the company's existing efforts and strengthen its ability to mitigate pollution impacts throughout its value chain.

In 2025, Grünenthal plans to set a measurable, outcome-oriented target to manage pollution of its operations as well as in the supply chain.

Relevant topic clusters

E2-4 Pollution of air, water and soil

Pollution from own operations:

Grünenthal measures pollution to air, water and soil from its own operations. In the reporting year, pollution to air and soil did not surpass the threshold for releases according to Annex II of Regulation (EC) No. 166/2006 (E-PRTR).



Pollution to water

Pollutant	Value in mg/l	Value in kg/m³	Value in kg	Threshold for releases according to Annex II of Regulation (EC) No. 166/2006 (E-PRTR) in kg	Site	Calculation methodology
Chloroform (Trichloromethane)	<0.24	<0.00024	<13.17312	10	Quito	US EPA 8260 C/MM-S-65
Carbon Tetrachloride	<0.24	<0.00024	<13.17312	1	Quito	US EPA 8260 C/MM-S-65

Packaging at Aachen site



Pollution from the supply chain:

In the supply chain, no quantitative information on pollutants is yet available. Through Grünenthal's ESG risk management, suppliers lacking international certification have been identified. In 2025, Grünenthal will engage more closely with these suppliers to assess their maturity level in environmental management, including pollution control. As part of this enhanced collaboration, Grünenthal will conduct ESG audits targeting suppliers identified as higher risk.

Pollution-related performance and compliance at Grünenthal operations

Grünenthal uses external measurement laboratories to analyse air emissions and wastewater samples, ensuring that methodologies comply with regulatory requirements and accord with the monitoring frequency stated in the respective permits. The data collected for pollution-related accounting and reporting is derived from external measurement reports, and in some cases estimated.

While direct measurements are prioritised wherever technically feasible and legally required, calculated or estimated values are also used in specific cases where:

- Continuous or spot emission monitoring is not installed,
- The emission source is small or standardised, or
- Reliable activity data and regulatory emission factors are available.

The use of estimation methods is compliant with national and international guidelines (e.g., IPCC, EEA, national environment or health ministries).

Air emissions such as NO_x, CO, and VOCs from various combustion sources (steam generators, gas boilers and cogeneration units) were calculated using volume flow, operational hours, and known concentration values or emission factors, especially where stack measurements are not performed.

Each Grünenthal site complies with local environmental regulations, which may result in differing pollutant measurement methods and scopes. In 2025, as part of the ESRS implementation roadmap, a gap analysis will be conducted to compare pollutants measured at non-European sites with those listed in Annex II of the E-PRTR. The outcome will inform an action plan to ensure that all listed substances are either monitored and reported across all sites or assessed for materiality in accordance with ESRS requirements. Where relevant substances are not currently monitored at non-EU sites, feasibility of consistent measurement protocols will be evaluated for 2025.

The company does not operate installations under the scope of the Industrial Emissions Directive (IED) or EU Best Available Techniques (BAT) Conclusions, and no compliance schedules, derogations or enforcement actions are applicable. Additionally, Grünenthal has not adopted the EU BAT standards for evaluating its environmental performance against BAT-AEL (Best Available Techniques – Associated Emission Levels) or BAT-AEPL (Best Available Techniques – Associated Energy Performance Levels). No instances of non-compliance have been identified to date.



Waste
water
treatment
Origgio
site

» Grünenthal Insight

Waste management

Grünenthal has undertaken several waste management initiatives in 2024 to enhance sustainability and resource efficiency.

Through waste coprocessing at the Quito site, it harnesses the caloric value of waste during incineration to reduce fossil fuel consumption, repurposing the generated energy for hazardous waste decontamination and material cleaning, resulting in an annual reduction of 158.68 tonnes of CO₂ emissions and saving 40,584.33 kWh of energy.

Additionally, the solvent recovery project in Santiago minimises hazardous waste by collecting and segregating organic solvents, which are then transformed into alternative fuel, leading to the recycling of 12,000 litres per year, a 3% increase in recyclable waste, and a significant reduction in volatile organic compound (VOC) emissions.

Furthermore, at the Origgio site, the introduction of a dedicated waste stream for segregating plastic materials has improved


recyclability, contributing to a 5% increase in recyclable waste through enhanced waste management practices and partnerships with new contractors.

In 2024, we have achieved our goal of zero waste to landfill status from manufacturing activities at all manufacturing sites.

Further targets and progress 2024¹

Target	Progress 2024		
	Site	Change	Status
Reduce normalised hazardous non-recyclable waste from manufacturing activities (tonnes/produced units or volume) by 2% per manufacturing site each year until 2040.	Aachen Packaging Centre	–41%	On track for 4 sites
	Aachen API	–15%	
	Mitlödi	–25%	
	Origgio	+37% ²	
	Quito	–25%	
	Santiago	–17%	
Increase recyclable waste from manufacturing activities (tonnes/produced units or volume) by 2% per manufacturing site each year until 2040.	Aachen Packaging Centre	+0%	On track for 4 sites
	Aachen API	+20%	
	Mitlödi	+3%	
	Origgio	+9%	
	Quito	+3%	
	Santiago	+2%	
Achieve zero waste to landfill status from manufacturing activities at all manufacturing sites by 2024.	Sent zero waste to landfill from manufacturing activities at all manufacturing sites		Completed

¹ Targets maintained from previous Responsibility Report; will be reviewed in 2025.
² Production-related factors led to a short-term increase in hazardous non-recyclable waste.



SOCIAL

- **Own workforce (ESRS S1)**
 - Managing Grünenthal's own workforce
 - Fair working conditions and remuneration
 - Workplace safety and health protection
 - Training and development
 - Diversity, inclusion, and equal opportunities
- **Patient (ESRS S4)**
 - Managing consumers and end-users
 - Personal safety of consumers and/or end-users
 - > Patient safety
 - > Product quality
 - > Safe pain management through responsible use of opioids
 - Access to healthcare
 - Research and development



S1 – Own workforce

Managing Grünenthal’s own workforce

S1.SBM-3 Material impacts, risks and opportunities and their interaction with strategy and business model

Type of impact	Impact
Actual positive impact	Fair working conditions and remuneration (own workforce)
Actual positive impact	Workplace safety and health protection
Actual positive impact	Training and development (HR)
Actual positive impact	Diversity, inclusion and equal opportunities

Grünenthal has identified fair working conditions and remuneration, workplace safety and health protection, training and development, as well as the promotion of diversity, inclusion and equal opportunities to be material positive impacts for its own workforce. There were no material risks or opportunities for Grünenthal related to its own workforce identified during the double materiality analysis.

Types of employees and non-employees subject to material impacts

The company’s workforce primarily comprises individuals with fixed-term or permanent contracts, including regular employees, those in training roles such as interns and apprentices, and inactive employees such as those on parental leave or long-term sick leave. Agency staff and consultants, while essential to some operations, are generally not included in the category of ‘own workforce’. HR data for Grünenthal Meds and Valinor employees is included in this chapter.

Regarding workplace safety and health, the reporting scope extends to include contractors working on Grünenthal premises for accident numbers. While safety data is tracked across the organisation, the primary focus is on manufacturing sites, where risks are most prevalent.

Ensuring fair working conditions and remuneration

Grünenthal strives to create a positive working environment that motivates and engages its workforce. The company is committed to ensuring fair working conditions and remuneration as well as a safe and eco-friendly workplace.

Managing workplace safety and health

Grünenthal takes safety management seriously, with robust processes, systems, and rules in place to ensure a safe workplace for all employees. While no material negative impacts for Grünenthal’s own workforce were identified during the double materiality analysis, there are risks related to the nature of operations at Grünenthal. These include the handling of hazardous materials and execution of high-risk tasks, such as working at heights, hot work (e.g., welding), and confined space entry. Specific high-risk activities are identified through workforce engagement and site-specific risk assessments.

Grünenthal has established a proactive approach to managing risks and establishing a safety-first culture, contributing to workplace safety and health. The company’s Vision Zero initiative reflects its ambition of achieving zero workplace accidents and eliminating lost working days due to incidents. This ambitious vision is supported by mandatory Health & Safety standards such as the standards on Hot Work, Work at Height and Confined Space Entry, as well as preventive measures across all sites. For example, at manufacturing locations, employees actively observe colleagues’ safety behaviour, report not only

accidents but also near misses, and provide constructive feedback to correct potential issues before accidents occur.

Safety topics are regularly shared and discussed in forums such as MDL (Manufacturing Daily Line-up meetings) and safety committees at each site, fostering an inclusive approach to risk awareness. Additionally, training and awareness programmes contribute to employee engagement on these topics such as the Global EHS Day celebration and the Family Day at site to involve children and family with safety awareness.

Fostering training and development

Every employee at Grünenthal is considered a talent, and the company actively promotes growth and development for all team members. Leaders work closely with their teams to create tailored Personal Development Plans (PDPs) and regularly review performance and career progression, covering 100% of Grünenthal employees. The company invests in its people by providing learning opportunities, such as additional responsibilities, training, and mentoring programmes. Employees are encouraged to take ownership of their development, discuss aspirations and identify areas for improvement with their managers.

Promoting diversity, inclusion and equal opportunities

Grünenthal’s comprehensive Diversity & Engagement Strategy unites and expands existing local and global events and initiatives. Its vision is for all employees to feel valued, respected, included and empowered to do their best, bring great ideas to the table and develop their full potential as contributors to the success of Grünenthal and the communities the company serves. It generates a significant positive impact for the company’s workforce by creating an environment where diverse perspectives and experiences are actively celebrated. Employees benefit from



Leen Hofkens, Head Global Human Resources

a culture of inclusion supported by programmes such as leadership workshops, mentoring schemes, and partnerships with external initiatives like 'Mujeres en Farma' in Spain, to promote female leadership in the pharmaceutical industry. These efforts have been recognised with awards for diversity and inclusion, further strengthening Grünenthal's position as an attractive and equitable employer.

To promote diversity and inclusion in recruitment while maintaining merit-based decision-making, structured training on unconscious bias and inclusive leadership has been implemented, reinforcing equitable practices across all functions. The company fosters innovation and engagement by enhancing employee satisfaction and performance through efforts to provide learning opportunities, encourage community involvement, and create a workplace that mirrors the diversity of society.

Understanding of vulnerable groups within its own workforce

Regarding workplace safety and health, Grünenthal recognises that certain groups of employees, such as junior or inexperienced workers, night shift staff, or those exposed to hazardous tasks, may face heightened risks. To address this, the company has implemented tailored training and assessment protocols, including:

- Training plans for employees in specialised areas, such as maintenance and production.
- Strict adherence to minimum age requirements and competency assessments for specific roles.

Grünenthal has developed targeted initiatives to support employees who are more vulnerable to discrimination and inequality such as under-represented groups or individuals with disabilities.

The Diversity & Engagement Strategy explicitly addresses individual differences, ensuring that all employees have access to equal opportunities and a safe, supportive environment.

Human rights safeguards for Grünenthal's workforce

Grünenthal's commitment to upholding human rights (for details see section [S1.MDR-P/S1-1](#)) aims to safeguard fair working conditions and eliminate risks of forced labour, compulsory labour and child labour within its workforce. The company has not identified any of its operations as being at significant risk of incidents of exploitative labour practices.

As part of our Global People Policy, Grünenthal fully supports and adheres to meeting local and international regulations prohibiting child labour. Business partners are similarly required to align with Grünenthal's ethical commitments, which include respecting fundamental rights and refraining from employing underage workers. The company shares its Code of Conduct for Business Partners with suppliers at the beginning of the supplier life cycle management. Additionally, an in-depth ESG assessment asks suppliers defined as ESG sensitive for further information on human rights and environmental standards, ensuring compliance with the German Supply Chain Act.

Geographic considerations

Grünenthal's manufacturing sites are located in Chile, Ecuador, Germany, Italy, and Switzerland. The company's proactive adherence to international ethical guidelines such as the UN Guiding Principles on Business and Human Rights and the OECD Guidelines for Multinational Enterprises, combined with continuous monitoring and risk assessment processes such as the GSCA evaluation, provides assurance that risks of forced or child labour are effectively minimised. The risk monitoring system in compliance with the GSCA framework for the supply chain includes the in-depth ESG assessment, adverse media monitoring and our Ethics Helpline.

S1-2 Processes for engaging with own workforce and workers' representatives about impacts

Employee perspectives in decision-making

Grünenthal integrates workforce insights into its decision-making processes. In Chile, France, Germany, Italy and Spain – where required by local legislation – works councils play a significant role in shaping workforce-related company agreements and policies. For example, in Germany, the works council advocates for employee interests in areas such as compensation, social and personnel issues, occupational health and safety, environmental protection and workplace organisation.

Grünenthal actively considers the perspective of its workforce in shaping and refining its corporate initiatives linked to our corporate strategy as reflected in the Group Scorecard, which summarises the key priorities in the areas 'Transform', 'Innovate', 'Grow' and 'Culture'. Functional leads support the Corporate Executive Board in deciding on the Group Scorecard priorities as needed. The priorities are reviewed and refined each year to reflect focus areas and initiatives for the coming year (which may change for example if they are based on local and global developments and market trends). Facilitated by our Corporate Strategy Team, the Scorecard KPIs are tracked on a quarterly basis to measure performance related to the Scorecard priorities and are shared and discussed with the employees via different communication channels (e.g., global Intranet, global and local Townhalls).

For all responsibility-related initiatives, our company actively involves employees through a range of engagement formats – such as focus groups, surveys, and interviews – tailored to the depth and scope of each initiative.

Mechanisms for employee engagement

Regular communication, such as global and local town halls and intranet articles, informs employees about corporate priorities and performance.

Feedback mechanisms, including performance evaluations and satisfaction surveys, provide opportunities for employees to share their views. For example, the Great Place to Work® (GPTW) survey allows employees to anonymously evaluate the company's leadership and culture.

Grünenthal also celebrates and recognises employee contributions through various awards and community-building events. The most prestigious awards, our Global Excellence Awards, are selected by our Corporate Executive Board annually and recognise exceptional contribution to Grünenthal's Group Scorecard. Additional recognition programmes such as the GO Superheroes and HR Excellence Awards celebrate achievements within functional areas.

Social events, such as regional gatherings and team-building activities, further enhance engagement. These include regular seasonal campus events at Grünenthal's headquarters and the GOlympics event in 2024 within the Global Operations business unit, encouraging collaboration across sites while contributing to charitable causes.

Inclusion of marginalised and vulnerable employees

Grünenthal welcomes and includes employees who may be vulnerable or marginalised. Specific measures, such as the representation of youth and apprentices (Youth Committee) as well as disabled employees through their own elected representatives, ensure their voices are heard and their needs addressed. The Diversity and Engagement Council, comprising leaders across business units, plays a key role in driving inclusion initiatives. The Council advises on Grünenthal's diversity strategy and aims to enhance representation of potentially vulnerable or marginalised groups.

The company also addresses language and accessibility barriers. Communication materials are simplified and translated to ensure they are comprehensible to all employees and the intranet content can be translated to a chosen language.

Removing barriers to engagement

Grünenthal recognises that engagement is most effective when barriers to participation are minimised. For example, in Italy, event planning explicitly considers the needs of employees with disabilities to ensure they can participate fully. Employees on parental or long-term leave are kept informed through accessible updates on the intranet and other communication channels. Flexible working models enable global collaboration and career growth, regardless of location, fostering a sense of inclusion and accessibility.

S1-3 Processes to remediate negative impacts and channels for own workforce to raise concerns

Immediate action and prevention of recurrence

Grünenthal is deeply committed to ensuring effective processes for addressing grievances and remedying negative impacts. If violations of human rights or environmental obligations are identified within Grünenthal's operations, measures are taken to stop the violation and avoid future occurrences. If such violations occur in the supply chain, Grünenthal conducts diligent investigations and works closely with suppliers to resolve the issues. Suppliers are required to allow audits and contractual obligations are designed to enhance compliance (see section [👁️ 'G1-1'](#)). Depending on the severity of a violation, Grünenthal may take actions ranging from requests for remediation up to the termination of the business relationship.

Mechanisms for raising concerns

Grünenthal encourages employees to speak up. To facilitate open communication, Grünenthal provides several mechanisms for raising concerns, including the Ethics Helpline (see [👁️ 'Governance section'](#) below). Employees are also encouraged to share feedback directly with their line managers, Human Resources representatives, local compliance officers, or – where applicable – works councils and union representatives. The effectiveness of grievance mechanisms is continuously monitored as described in section [👁️ 'G1-1'](#).

Protecting employees who raise concerns is a key priority for Grünenthal. The company’s Code of Conduct explicitly prohibits retaliation against whistleblowers and mechanisms are in place to protect their identity and rights.

Promoting awareness and trust

Grünenthal fosters employee awareness of grievance channels through regular training sessions, workshops, and clear communication across multiple platforms, including the intranet and notice boards. The 2024 GPTW Trust Index recorded a score of 78%, reflecting a strong level of confidence among employees in the company’s culture of transparency.

S1-6 Characteristics of Grünenthal’s workforce

Number of employees by gender (in headcount)¹

Gender	Number of employees
Male	2,148
Female	2,203
Other	1
Not reported	0
Total employees	4,352 ²

¹ Table includes personnel numbers from the acquired Valinor and Grünenthal Meds.
² Equivalent to 4,196.42 FTE

Number of employees in countries with significant employment (in headcount)¹

2024	
Country	Number of employees
Germany	1,221
Italy	617
Chile	541

¹ Countries where the undertaking has at least 50 employees representing at least 10% of its total number of employees. Table includes personnel numbers from the acquired Valinor and Grünenthal Meds.

Number of employees by contract type, broken down by gender (in headcount)¹

2024				
Female	Male	Other	Not disclosed	Total
Number of employees				
2,203	2,148	1	0	4,352
Number of permanent employees				
2,091	2,049	1	0	4,141
Number of temporary employees				
112	99	0	0	211
Number of non-guaranteed hours employees				
0	0	0	0	0

¹ Table includes personnel numbers from the acquired Valinor and Grünenthal Meds.



R&D colleagues at Aachen headquarters

Number of employees by contract type, broken down by region (in headcount)¹

2024					
Germany	Rest of Europe	Latin America	USA	Asia	Total
Number of employees					
1,221	1,575	1,358	196	2	4,352
Number of permanent employees					
1,097	1,495	1,351	196	2	4,141
Number of temporary employees					
124	80	7	0	0	211
Number of non-guaranteed hours employees					
0	0	0	0	0	0

¹ Table includes personnel numbers from the acquired Valinor and Grünenthal Meds.

Turnover (in headcount)¹

2024		
Total	733	16.6% ²

¹ Table includes personnel numbers from the acquired Valinor and Grünenthal Meds.
² The average number of employees was used as the basis for calculation.

» Grünenthal Insight

Voluntary Turnover (in headcount)¹

2024		
Total	222	5.1%

¹ Table includes personnel numbers from the acquired Valinor and Grünenthal Meds.

Standardised reporting methodologies

Grünenthal uses a standardised method to report employee data, primarily using full-time equivalent (FTE) calculations for financial reporting

and headcount for sustainability reporting. These figures are derived from employee data recorded on the company’s Human Capital Management (HCM) system. A monthly and annual reporting process ensures consistency and accuracy in data collection and analysis.

Reporting period and frequency

Employee data is reported monthly as well as at the end of the financial year, specifically on 31 December. This methodology provides a consistent point of reference for annual evaluations and comparisons.

Contextual information and data limitations

While FTE and headcount figures form the foundation of employee reporting, certain categories, such as interns and inactive employees (e.g., those on long-term sick leave or parental leave), are not included in monthly or annual HR reporting.

Cross-referencing with financial statements

Employee numbers and related breakdowns are disclosed in Grünenthal’s Responsibility Report and referenced in its financial statements. The latest financial statements are available via the company register, where the last uploaded reports are from 2023 (published in 2024).¹

These cross-references ensure that reported employee data aligns with the most representative figures in financial statements, enhancing transparency and accountability.

S1-17 Incidents, complaints and severe human rights impacts

Reconciliation of fines, penalties, and compensation for discrimination or harassment

Grünenthal had two confirmed cases of work-related discrimination or harassment, both resulting in disciplinary measures and two additional complaints in the reporting year.

Grünenthal operates a robust compliance framework aligned with the GSCA, which focuses on suppliers.

Addressing human rights violations

Grünenthal has established robust mechanisms to address alleged violations of human rights in its own business operations and its supply chain. All reported incidents are investigated by a team led by the responsible Compliance Officer. If a human rights violation is confirmed within Grünenthal’s own business operations, the responsible Local, Regional or Global Ethics Committee acts and takes immediate steps to resolve the issue and prevent recurrence, which may include revising internal procedures or introducing additional controls. If a human rights violation is identified in the supply chain, the Global Ethics Committee will decide on measures ranging from remedial action plans to the termination of the business relationship.

The company’s Statement of Compliance with Human Rights and Environmental Standards explicitly requires suppliers to meet human rights and environmental standards. Grünenthal actively collaborates with suppliers to address any identified risks, ensuring transparency and accountability throughout the supply chain.

¹ The Grünenthal Financial Statement 2024 will be publicly available in the company register (<https://www.unternehmensregister.de>) from August 2025.

Severe human rights issues and incidents

No severe human rights violations or incidents connected to Grünenthal’s own workforce have occurred. The company’s internal governance and monitoring processes aim to prevent such issues, and Grünenthal’s German Supply Chain Act working group ensures a proactive stance on potential risks along the supply chain. For more information on the GSCA working group, see section [👁️ ‘G1.MDR-A’](#).

Colleagues in Portugal during their Grünenthal Gives Day



» Grünenthal Insight

Employee engagement

Further targets and progress 2024

Target	Progress 2024	Status
Increase the participation in local community events, measured through number of hours volunteered (e.g., ‘Grünenthal Gives’)	Employees dedicated more than 4,000 hours to support their local communities and give back to society.	On track
Improve our working environment, to make sure all employees feel valued, respected, included and empowered to do their best, bring great ideas to the table and develop to their full potential		On track

Grünenthal Gives:
Great days for good causes!

The Grünenthal Gives Programme, launched in 2023, allows employees to dedicate a day per year to support their local community, selecting a social area of their preference to contribute based on their interests and expertise.

In 2024, colleagues worldwide engaged in diverse activities including tree planting, food distribution, community cleanups, and volunteering with social institutions.

Highlights included preparing an outdoor area of a hospice, supporting a Ronald McDonald house in Germany and delivering food to over 500 organisations in Spain and Portugal. Teams removed

waste and invasive plants, supported playground renovations, and visited dementia patients. Colleagues in Portugal supported the ‘Just a Change’ association in the renovation of one of the Maria Droste Foundation’s foster homes in Lisbon, a home for young girls living in precarious conditions. Colleagues in Latin America organised events for homeless and elderly people, while others assembled hygiene kits or built prosthetic hands for underserved populations.

Across all regions, participation was overwhelming, reflecting our shared commitment to social responsibility. These efforts exemplify our Corporate Responsibility approach and reinforce our positive impact on people, communities, and the environment.

Fair working conditions and remuneration

For dedicated information on workplace health and safety, please see the [🔗 separate section](#) later in this chapter.

S1.MDR-P/S1-1 Fair working conditions and remuneration policies and company agreements

Policies to manage material impacts, risks, and opportunities related to fair working conditions and remuneration

Grünenthal is dedicated to fostering a workplace that empowers employees to thrive both professionally and personally. The company is committed to addressing any current or future material impacts, risks and opportunities related to its workforce to create a positive and inclusive work environment, ensuring compliance with local laws and exceeding legal requirements through a comprehensive policy framework¹ which includes company agreements. This way, Grünenthal strives to establish itself as an employer of choice while prioritising fairness, transparency and employee wellbeing. Grünenthal is firmly committed to upholding human rights and ensuring fair treatment for all employees, applicants and business partners.

Comprehensive policy framework

At the core of Grünenthal’s approach is the **Global People Policy**, which outlines commitments to fair working conditions, equitable remuneration, and a culture that promotes inclusivity and innovation. This policy applies to all Grünenthal employees, managers and contingent workers worldwide performing work for any legal entity of the Grünenthal Group, including contractors and personnel from outsourced service providers. The policy is fully aligned with international standards, including the International Labour Organisation (ILO) Conventions and the United Nations Universal Declaration of Human Rights. Grünenthal does not have a



Colleagues at employee event at Aachen headquarters

tracking mechanism in place yet. In addition to the Global People Policy, Grünenthal adheres to other key frameworks and standards, including:

- **Code of Conduct:** Guiding ethical behaviour and decision-making of all employees across the organisation. Additionally outlines the company’s expectations regarding human rights compliance.
- **Policy on Occupational Safety, Health and Environmental Protection, and Energy (EHS Policy):** Ensuring safe and healthy working conditions in Grünenthal’s own operations and among its suppliers (see chapter on [🔗 ‘Workplace health and safety’](#) for details).
- **Ethics Helpline Policy:** Providing employees and external stakeholders with a confidential platform for reporting concerns.
- **Statement of Compliance with Human Rights and Environmental Standards:** Reinforcing Grünenthal’s dedication to internationally recognised guidelines such as the UN Guiding Principles on Business and Human Rights, the OECD Guidelines for Multinational Enterprises and International Labour Organisation (ILO) Conventions on Discrimination (Employment and Occupation) (Convention C111, 1958 (No. 111)), Freedom of Association and Protection of the Right to Organise (Convention C087, 1948 (No. 87)) and Equal Remuneration (Convention C100, 1951 (No. 100)). By

¹ The term ‘policies’, in the context of working conditions, explicitly includes the contents of company agreements.

integrating these standards into its operations, Grünenthal ensures respect for human rights across its global supply chains and within its own business units. Grünenthal's broader human rights approach extends beyond its own operations: see chapter  **'G1 – Business conduct'** regarding human rights in the supply chain.

Implementation of these policies is overseen by the respective functional leads, such as the Global Head of HR for the Global People Policy. To ensure consistent standards while accommodating regional and country legislation, local policies are developed, maintained and accountable to the Head of HR for the territory. For Germany, the Head of HR Germany is responsible for all company and works council agreements for Germany.

Key contents of working conditions policies and agreements

Grünenthal's policies are designed to provide attractive working conditions by offering diverse roles, growth opportunities and an extensive range of benefits including healthcare and pension, in the context of the local market. Benefits may include medical insurance, company car, fitness allowance as well as membership and service fees, training or education, additional holidays, special discounts and other support. These policies fully comply with local laws and regulations while incorporating collective bargaining agreements and company-wide standards that go beyond statutory requirements. Other key areas covered include:

- **Working time regulations based on local legislation:** General schedules, daily working hours, special leave policies, and bridging days (Germany).
- **Compensation structures:** Transparent frameworks for base salaries, variable pay, allowances, and rules for work on Sundays or public holidays.
- **Employee development:** Personal development plans, training opportunities, and tailored local social services.

- **Workplace safety:** see  **dedicated section** below.

Communication and accessibility of policies

Grünenthal prioritises transparency and accessibility in communicating its policies. The company employs multi-channel strategies to ensure employees understand their rights, responsibilities and the resources available to them. Key measures include:

- **Training campaigns:** Comprehensive programmes in local languages to educate employees about policy updates and their implications.
- **Support platforms:** Dedicated channels for employees to seek clarification and raise concerns, supported by managers, HR representatives, and works councils.
- **Policy accessibility:** Policies are made available on the company's intranet or local workspaces, ensuring ongoing access for all stakeholders.

S1.MDR-A/S1-4 Fair working conditions and remuneration actions

Grünenthal demonstrates a strong commitment to fostering a supportive and inclusive work environment by implementing flexible policies, innovative initiatives, and robust measures that address material impacts, mitigate risks, and deliver positive outcomes for its employees. These efforts are closely aligned with the company's broader sustainability and business goals, creating a workplace where employees can thrive both professionally and personally. In geographies with active works councils (Chile, France, Germany, Italy and Spain), the local works councils are involved in discussions regarding new agreements.

For health measures, exchange with employees takes place. Following our Great Place to Work® surveys, we conduct workshops, focus group discussions, and interviews – where needed – to gain deeper insights from employees on how Grünenthal can further enhance its health measures. The outcomes of these follow-up activities

are then integrated into local HR plans and initiatives. In Germany for example we include specific questions in the Great Place to Work® survey on health measures also following a legal frame (Psychologische Gefährdungsbeurteilung).

Grünenthal's **SmartWork Hybrid Model** enables eligible employees, i.e., all employees whose activities permit participation and if they are personally suitable, to manage their flexible working arrangements. This approach allows for a combination of remote and on-site work, tailored to individual roles and responsibilities. The policy emphasises trust and focuses on results rather than strict working hours or locations.

Employees are supported with the necessary infrastructure to ensure productivity from any location, and family-friendly measures, such as an on-site childcare centre at the Aachen headquarters, enhance work-life balance. This policy has been progressively implemented since 2021.

In addition to the SmartWork approach, Grünenthal has implemented trust-based working hours for exempt employees.

To track and ensure effectiveness of actions, Grünenthal uses the exchange with local works councils and the Great Place to Work® survey, which takes place every other year. Additionally, there are other non-standardised surveys run by local HR teams, tailored to specific needs, such as occasional mood check polls.

No exact CapEx/OpEx data for the (planned) actions is being reported this year due to limited data availability.

Fair working conditions and remuneration metrics and targets

S1.MDR-T/S1-5 Fair working conditions targets

In 2025, Grünenthal plans to set measurable, outcome-oriented targets to ensure fair working conditions for the company's workforce. » Nonetheless, progress in the topic is managed with the non-ESRS-aligned target below.

Grünenthal’s overarching goal is to positively impact the lives of its employees while enabling their best performance.

For the purpose of achieving this overarching goal and managing the identified material impact of ‘Fair working conditions and remuneration’, Grünenthal continues to pursue the following non-ESRS-aligned target: «

» Further target and progress 2024

Target ¹	Progress 2024	Status
Ensure full alignment with relevant Human Resources (HR) regulations, health and safety standards, and legislation related to freedom of association	Audited by Authorities for Social Security and Tax (Germany). All our countries operate to the minimum standards of the local labour law and its regular updates, and industry and company collective bargaining agreements. Countries are audited by authorities on a regular basis.	On track

¹ Target maintained from previous Responsibility Report; will be reviewed in 2025. «

Inclusive target setting and strategy development

Grünenthal actively involves its workforce in shaping and refining its strategies (see «S1-2 Workforce engagement’ above). Priorities are reviewed and refined each year to reflect focus areas and initiatives for the following year (which may change for example based on local and global developments and market trends). The metrics to measure the success of the key initiatives are defined and reported by employees in the different business areas in close collaboration with the management board members. During this process, they are supported by the Corporate Strategy team. This not only allows for incorporation of employee input and feedback but also ensures shared ownership.

Tracking progress and learning from feedback

Grünenthal employs robust mechanisms to monitor performance of its positive impacts. These include:

- Annual reviews of strategic initiatives, including through the annual Grünenthal Responsibility Scorecard, integrating feedback from employees, market trends, and global developments.

- Surveys such as the Great Place to Work® (GPtW) and 360-degree Leadership feedback to assess employee engagement and satisfaction.

S1-8 Collective bargaining coverage and social dialogue

In Germany, 96% of Grünenthal employees are covered by collective agreements such as collective bargaining agreements or company agreements which meet at least the standards set in the collective bargaining agreements but go beyond them in scope and content. These agreements establish comprehensive working conditions and terms of employment for most of Grünenthal’s workforce in Germany. The remaining 4% of employees not covered by these agreements include those at the equivalent Global Grade 16 job level (Vice President) or higher. In Italy, employees have the option to be represented by a works council and currently 22% of employees have chosen this option. However, the outcomes of collective agreements negotiated between Grünenthal and the works council apply to all employees, irrespective of their individual representation status. For employees outside Germany and Italy, relevant data on collective bargaining agreement and works council coverage is not currently consolidated.

Non-employees within Grünenthal’s workforce, such as contractors or agency workers, are not subject to the company’s collective bargaining agreements.

Collective bargaining coverage and social dialogue

	Collective bargaining coverage	Social dialogue
Coverage Rate	Employees – EEA (for countries with >50 employees representing >10% of total employees)	Workplace representation (EEA only) (for countries with >50 employees representing >10% of total employees)
0 – 19%	—	—
20 – 39%	—	Italy
40 – 59%	—	—
60 – 79%	—	—
80 – 100%	Germany ¹ , Italy	Germany

¹ This figure includes employees covered directly through collective bargaining agreements or works agreements, which meet at least the standards set in the collective bargaining agreements but go beyond them in scope and content.

» Grünenthal Insight

Social protection

At Grünenthal, all employees in our own workforce are covered by social protection through public programmes or company benefits, ensuring income security in cases of sickness, unemployment, employment injury, parental leave, and retirement. Social security frameworks vary across countries in which we operate, and Grünenthal provides additional benefits where applicable to complement national systems.

At present, Grünenthal has not identified employee groups excluded from social protection schemes across its operational countries. Ongoing assessments ensure all employees have adequate income security through public or employer-sponsored measures. Further evaluations may be conducted to confirm full compliance with social protection requirements.

Income protection in case of sickness, unemployment coverage, employment injury and disability protection, parental leave benefits as well as retirement security is granted according to local labour and social laws.

Work-life balance

Grünenthal is committed to supporting employees in balancing their professional and personal responsibilities by providing access to family-related leave in accordance with national social policies and through collective bargaining agreements. All employees are entitled to relevant leave provisions, with additional benefits provided in certain countries. In Germany¹, 58² employees took family-related leave. Additionally, in the majority (all) of our countries we offer an Employee Assistance programme (EAP) allowing them to access mental health and psychological support services for professional or private matters. In January 2025, Grünenthal introduced family starting time, a voluntary additional leave for spouses or partners. So far, six family starting time requests have been received.

To remain competitive and attractive to potential employees, we offer enhanced benefits. Germany provides extensive family-related leave entitlements. Employees receive additional paid holidays for marriage, birth of a child (for fathers), and bereavement. Additional paid leave is also granted for family caregiving responsibilities. Currently, four employees make use of such part-time work arrangements to accommodate ongoing caregiving duties.

¹ Global data is not yet available.

² Part-time: 26 employees, full-time: 43 employees; the total is higher than 58 because of employees who did both in 2024.



*Employee event
at Aachen
headquarters*

Grünenthal ensures representation for employees across Europe through its European Works Council (EWC). National organisations with at least 150 employees, currently including Germany, Italy and Spain, are entitled to appoint members to the EWC. This council facilitates dialogue between employer and employee representatives at a European level, enabling the sharing of perspectives to support the growth, competitiveness and employment of Grünenthal across Europe.

S1-10 Adequate wages

The company's Compensation Philosophy provides a comprehensive framework for designing and managing compensation programmes, ensuring adequate wages for all employees in line with industry benchmarks. It aims to provide a common basis for all remuneration and benefits programmes in our organisation. It recognises the importance of balanced but differentiated remuneration structures based on local market and business needs.

Job scope, market competitiveness and performance are the key elements of our remuneration framework. The following principles are embedded into its global strategy to ensure equity, market alignment, and recognition of individual contributions:

1. Fair Remuneration: Using the Willis Towers Watson job evaluation system, Grünenthal ensures that employees in comparable roles are compensated equitably, and salaries are based on objective, gender-neutral criteria, reflecting role complexity, responsibilities, and organisational impact. Positions are matched against a job listing in either industry or pharmaceutical benchmark. The matched job drives the compensation to include salary and target bonus based on the role's scope and impact. Employees in comparable roles are compensated equitably, supporting internal consistency. Salary audits identify pay gaps, and corrective measures are implemented where needed to maintain equity.

2. Market-Competitive Remuneration:

Salaries are benchmarked against the relevant external market at a job-specific level, with regular reviews and adjustments ensuring alignment with market standards. This approach helps Grünenthal remain competitive in attracting and retaining talents.

3. Performance-Based Remuneration:

Grünenthal's Pay for Performance programme rewards individual and team achievements, linking them to broader organisational objectives. This offers clear incentives for excellence and provides financial rewards for high performance. Employees benefit from salary increases and performance-related bonuses, reinforcing a culture of excellence and accountability.

Compensation framework

Grünenthal's compensation structure revolves around a globally clear framework for defining salary bands and salary progression. Base salaries reflect the responsibilities and impact of each role, with adjustments guided by local market trends, individual performance, and placement within the salary band. This value is either categorised by local collective bargaining agreements or assessed on the basis of the job evaluation system. There are different kinds of variable remuneration. Type and amount of variable pay depend on the job. Bonuses are governed by a short-term incentive programme, reflecting both personal and organisational success. Additional benefits tailored to local markets, including fringe benefits, further enhance employee retention and satisfaction.

To ensure transparency, Grünenthal provides employees with detailed information about their job level, the criteria for salary progression, and how their pay compares to market benchmarks. The framework supports consistency by calibrating performance ratings and applying clear salary bands that align with the company's broader business strategy.

Workplace safety and health protection

S1.MDR-P/S1-1 Workplace health and safety policy

For managing the safety and health related material impact, Grünenthal has two main policies in place, covering 100% of Grünenthal employees. The **EHS Policy** is the overarching commitment that operational activities must be aligned with. Operationally, the **Health and Safety (H&S) Critical Standards** and **Health and Safety Excellence Standards** guide solid behaviour and processes, as detailed in the next section.

H&S Critical Standards and H&S Excellence Standards

These documents are based on best practices and learning from the past and define specifications, procedures and guidelines to ensure people, products, services and systems are safe, consistent and reliable.

The H&S Critical Standards cover the topics of site governance and assurance, contractor management, work at height, lock out tag out, hot work, electrical safety, emergency preparedness, confined space entry, hazardous materials handling, safety behaviour, safe operations of fork lift trucks, and machine guarding.

The H&S Excellence Standards guide employees in excavation, occupational health & safety, construction, equipment and project commissioning, lifting operation and lifting equipment, warehouse operation and racking, compressed gas cylinders and pressurised systems, scaffolds and mobile elevated working platforms, as well as cutting tools and hand safety.

These standards are available and applied to all manufacturing sites and assessed regularly, where each location is assessed on relevant aspects of each category.

Scope of the policies

The EHS Policy applies to all Grünenthal employees, contractors and suppliers. It encompasses all activities and operations within our organisational remit, ensuring alignment with our overarching sustainability objectives. We are ensuring that health and safety are taken into account regarding the procurement of goods and services and at the start of new projects. We also expect our suppliers to actively promote occupational safety and health protection. Additionally, we have a Contractor Safety Standard in place, aiming to ensure the safety of contractors working at Grünenthal sites. The Standard covers the management of contractors from the contractor approval process, the controlled site access, the permit to work, and up to the controlled site exit. The local H&S site team and job supervisor conduct periodic random inspections of approved contractors on site to ensure good contractor management practice.

Accountability and governance

The EHS Policy is signed off by members of the Corporate Executive Board, reflecting its strategic importance and the commitment of Grünenthal's highest leadership.

Grünenthal's EHS departments, supported by site directors and safety committees, play a central role in managing health and safety impacts. These internal functions implement targeted actions to address negative impacts and drive positive outcomes, ensuring alignment with the company's zero-accident vision.

Alignment with third-party standards

The development and implementation of the policies are informed by internationally recognised standards, including ISO 45001. This benchmark guides our approach to occupational safety, and health protection, reinforcing Grünenthal's dedication to global best practices. Manufacturing sites are certified according to ISO 45001.

Stakeholder engagement and accessibility

We actively promote awareness of occupational safety, health protection, environmental stewardship, energy efficiency, and sustainability among

our employees and relevant stakeholders. See section  'S1-2 Workforce engagement' for more information.

The policies are made accessible to all potentially affected stakeholders and those responsible for its implementation via Grünenthal's internal intranet platform. This ensures transparency and enables easy access for consultation, fostering alignment and accountability across the organisation.

S1.MDR-A/S1-4 Workplace health and safety actions

Grünenthal's health and safety strategy is driven by a zero-accident vision, underpinned by the use of leading indicator KPIs such as near-miss reporting and behavioural safety observations.

Seven-step strategy

In 2020, we implemented a seven-step strategy to enhance health and safety. The action plan is made up of six operational steps or achievements, with the aimed for result being step 7 – 'Vision zero' (zero accidents at Grünenthal).

1. A behavioural observation programme was implemented for accident investigation. The programme helped identifying potential hazards and implementing corrective measures. In high-risk areas such as production, inexperienced workers receive specialised training to ensure their safety.
2. Next, the H&S Critical Standards (see  'S1.MDR-P') were developed, and a gap analysis and maturity assessment conducted in relation to the standards for each site.
3. Step three is the achievement of 100% scores regarding H&S Critical Standards along with the development of comprehensive risk assessment and action plans for each manufacturing site.
4. Step four refers to the definition of countermeasures of risk assessment and a programme for safety culture through engagement.

5. Step five entails implementation and gap analysis for the H&S Excellence Standards (see  'S1.MDR-P').
6. Step six describes the achievement of 100% scores for all H&S Standards (Critical and Excellence), with active participation of employees in H&S improvement for their work areas.
7. The final milestone, step seven, is the achievement of zero accidents at the workplace.

Risk assessment and inclusion of vulnerable workforce perspectives

Grünenthal conducts comprehensive risk assessments for activities at each site, actively involving machine operators. These assessments cover for example machine operation, exposure risks during processes, and high-risk tasks. This inclusive approach ensures that potential barriers to engagement are identified and addressed, enabling all employees, including those in vulnerable situations, to contribute to safety discussions.

Workforce engagement in identifying operational improvements

In cases of incidents or accidents, Grünenthal employs a participatory approach to investigation and improvement. This includes affected individuals and witnesses directly, as well as department heads to identify root causes and implement corrective actions.

Scope of key actions

Our safety initiatives are focused primarily on manufacturing sites, where operational complexities require stringent risk management. Additionally, our suppliers are required to self-disclose safety performance, extending our safety framework across the value chain.

Time horizon for implementation

Actions at manufacturing sites are defined based on individual risk assessments and priorities. This ensures that resources and efforts are allocated effectively to mitigate risks and enhance safety standards within a structured timeframe. The seven-step strategy started in 2020 and does

not have a fixed end-date. As the journey is ongoing, relevant assessments are conducted and appropriate measures implemented each year to move closer to reaching zero accidents at the workplace.

Resources allocated

Each Grünenthal site has a dedicated Environment, Health and Safety (EHS) team to oversee the implementation of health and safety measures. We conduct external risk assessments at API sites and ensure all locations maintain ISO certifications. While exact financial figures are not disclosed in this year’s report due to limited data availability, health and safety expenditures form an integral part of the annual budget, covering both capital expenditure (CapEx) and operational expenditure (OpEx).

The financial resources allocated to health and safety initiatives, including EHS team operations, external risk assessments and certification costs,

are embedded within the company’s annual budget. These expenditures are aligned with Grünenthal’s overall commitment to operational excellence and sustainability.

Workforce involvement in decision-making

Grünenthal ensures that workers and their representatives play an integral role in shaping health and safety programmes. For specific information on their involvement in the design and implementation of safety measures, see section  ‘S1-2 Workforce engagement’.

Workplace health and safety metrics and targets

S1.MDR-M/S1-14 Workplace health and safety metrics¹

Metrics used to evaluate performance

Grünenthal employs a comprehensive set of metrics to evaluate health and safety performance, with a key focus on achieving its

zero-accident vision. Leading indicators are especially for the manufacturing sites, where safety and health risks are highest:

- Work-related injuries
- Work-related ill health
- Rate² of work-related (recordable) accidents
- Days lost³ to work-related (recordable) injuries and ill health
- Fatalities (accidents resulting in casualties)

Safety and health related data covers both employees and non-employees working on Grünenthal premises, such as contractors or agency staff.

Health and safety metrics

	2024 ¹	2023
Work-related injuries	22	29
Work-related ill health	0	2
Rate of work-related (recordable) accidents	2.78	3.62 ²
Days lost to work-related (recordable) injuries and ill health	788.2	382 ²
Fatalities	0	0
% of employees covered by ISO-certified H&S management system	100% at manufacturing sites 37% of total workforce	100% at manufacturing sites 37% of total workforce ²

¹ In 2024, no non-employees were affected by work-related accidents.
² Not part of the auditing scope for the Grünenthal Responsibility Report 2023.

¹ Health & Safety data related to Grünenthal Meds and Valinor are not included in this report.
² Calculated by dividing the number of accidents by the total number of hours worked by all employees and multiplied by one million.
³ Generally, ‘days lost’ refers to calendar days. However, in the reporting period, some business areas have reported work days instead.

Methodologies and assumptions behind metrics

Metrics are presented and discussed at the monthly EHS review meetings between global EHS and site EHS representatives. All accident and near-miss data is reported using the Quentic system, which is also used to automatically compile the numbers from all Grünenthal manufacturing sites.

Accidents from non-manufacturing sites (affiliates) are compiled manually by global EHS through meetings with the site representatives.

Workforce engagement in tracking performance

Performance against these targets is tracked regularly, with EHS Managers providing monthly updates to the Senior Leadership Team (SLT). Additionally, safety meetings at both site and global levels ensure ongoing engagement and accountability.

External validation

All Grünenthal manufacturing sites are certified under ISO 45001, an internationally recognised standard for occupational health and safety management systems. Additionally, external assessments are conducted at API sites to verify compliance of EHS processes with safety protocols. Periodic reviews by insurance companies further validate the robustness of our health and safety measures.

S1.MDR-T/S1-5

Workplace health and safety target

Grünenthal has implemented the zero-accident vision and is currently defining a measurable, outcome-oriented target for workplace safety and health protection by the end of 2025.

The target-setting process for internal objectives such as 'Vision Zero' involves EHS Managers and Site Directors from each site, who collaborate to develop and refine goals. These are subsequently



Apprentice at Aachen headquarters

aligned with the Global Operations Board to ensure strategic oversight and accountability. The involvement of these key stakeholders ensures that targets are practical, relevant, and site-specific.

S1-2 Workforce engagement in managing health and safety impacts

Engagement to inform decisions and activities

In addition to general engagement channels (see section  ‘Managing Grünenthal’s own workforce’ above), Grünenthal actively engages its workforce to manage actual and potential health and safety impacts. Safety committees are established at each site, providing a formal platform for employees to share their perspectives and contribute to decision-making. Additionally, regular Manufacturing Daily Line-up (MDL) meetings are held, ensuring continuous dialogue and feedback from the workforce.

Stages, types, and frequency of engagement

Engagement occurs at multiple stages and through various channels:

- **Safety committees:** These committees (in manufacturing sites) meet monthly or quarterly, depending on site-specific needs, to discuss and address safety-related concerns and initiatives.
- **Manufacturing Daily Line-up (MDL) meetings:** These meetings are conducted daily or weekly, serving as an ongoing platform for workforce engagement and communication of key safety updates and actions. Participants include:
 - **Site MDL:** Site Director and site leadership team
 - **Function MDL:** Head of Department and reporting functions

- **Area MDL:** Managers and team leaders/ coordinators/laboratory heads
- **Shopfloor MDL:** Team leaders/coordinators and operators
- **Shift handover:** Coordinators

Operational responsibility for engagement

The Site Director holds operational responsibility for ensuring workforce engagement. This role oversees the effective implementation of engagement activities, ensuring that input from the workforce informs the organisation’s approach to managing health and safety impacts.

S1-3 Channels for raising health and safety concerns

Specific channels for raising concerns

In addition to general channels for raising concerns (see section  ‘Managing Grünenthal’s own workforce’ above), Grünenthal provides its workforce with accessible and reliable channels to raise health and safety concerns. At each manufacturing site, a fully staffed **Environment, Health and Safety (EHS) Department** is available to address H&S matters directly. Moreover, employees at the manufacturing sites can use the Quentic and MS Forms systems to raise EHS-related concerns or report accidents, incidents, near misses, or make behavioural safety observations (BSO). The raised and addressed issues are being reviewed, tracked and reported in the monthly EHS review meetings between global EHS and site EHS representatives. Actions are raised and monitored against the reported issues. This procedure ensures the effectiveness of the channels for raising concerns.

Additionally, during the Shopfloor MDL meetings, operators can report to their supervisors, who can in turn inform EHS Managers of any EHS-related issues.

Accessibility of channels for the workforce

All members of Grünenthal’s workforce, including employees and contractors, have access to EHS Managers at their respective sites. These managers act as primary points of contact, offering direct access to address safety-related concerns or needs.

Training and development

S1.MDR-P/S1-1 Training and development policies

The **Global Management of Training and Qualification Policy** defines the framework for adequate training and qualification of all Grünenthal employees. This ensures that they can fulfil their duties and responsibilities and that all legal requirements are met, including documentation. The policy applies to all employees globally and provides clear processes to document and align training with quality standards. Employees are encouraged to seek additional training or coaching if they feel underqualified for specific tasks, fostering a culture of continuous learning and accountability.

The **Global People Policy** sets out principles for talent development and inclusion, promoting a workplace where employees can thrive and grow. Grünenthal adopts the 70/20/10 learning strategy, which emphasises practical experiences, collaborative learning, and formal training:

- **70% on-the-job learning**, enabling development through real-world experiences.
- **20% learning from interactions**, such as mentoring and collaboration.
- **10% formal training**, including courses and seminars.

Employees are encouraged to take ownership of their personal development through regular conversations with their managers, while leaders play a key role in supporting individual growth by identifying strengths and areas for improvement.

Both policies reflect Grünenthal's commitment to fostering a productive, inclusive and supportive work environment.

Policy implementation and communication

Responsibility for implementing the training and qualification policy 'Global Management of Training and Qualifications' lies with Global Quality Assurance, while the Global People Policy is overseen by the Head Global HR and is ultimately accountable to the Corporate Executive Board. The Global People Policy aligns with international standards, including the United Nations Universal Declaration of Human Rights and key international labour conventions, ensuring Grünenthal meets global benchmarks for non-discrimination, freedom of association and equal remuneration.

Communication and transparency are central to ensuring policy effectiveness. Policies are made accessible through Grünenthal's global MasterControl platform, where employees are trained on new policies and tested on their understanding.

S1.MDR-A/S1-4 Training and development actions

Grünenthal recognises that adaptability and continuous growth are essential in a fast-evolving business environment. To this end, the company's Performance & Development Management approach serves as a cornerstone for employee growth. This framework promotes regular dialogue between employees and their line managers, enabling them to align on development goals and actions that culminate in a robust Personal Development Plan. These plans are tailored to help employees grow professionally and personally, either in their current roles or in preparation for future opportunities.

The Global HR Development team supports equity of access to development resources by providing structured frameworks, tailored training opportunities, and access to diverse learning platforms. These are supplemented by functional training that include mandatory industry and role specific training.



Employees at Aachen headquarters

Grünenthal supports employee capability-building with comprehensive training and development frameworks, particularly at manufacturing sites. Programmes include:

- Buddy systems and mentoring for junior and inexperienced workers.
- Specialised training for high-risk roles, ensuring compliance with safety protocols and minimum age requirements.
- Development initiatives linked to the Succession and Development Management Process, which identifies and nurtures high-potential employees for business-critical roles.

Delivering positive workforce impacts

Grünenthal fosters leadership excellence and personal growth through the Essential Leadership Skills and Personal Attributes (ELSPAs) framework. This ensures that leadership development,

hiring and feedback processes are aligned with the company's values. ELSPAs are embedded into the organisation through interactive e-learning modules, workshops and tailored guidelines, equipping leaders with practical tools to support team growth.

Key programmes that deliver positive workforce impacts include:

- **Global Operations (GO) Leadership Academy:** Training nearly 300 managers globally to enhance leadership, accountability and team engagement.
- **Chief Commercial Organisation (CCO) Academy:** Providing tailored training plans for customer-facing employees, resulting in improved engagement and high participation rates.

- **Recognition awards:** Celebrating employee contributions to reinforce a culture of appreciation.
- **Revised employee onboarding programme:** Set to launch in 2025, this initiative aims to provide new employees with a strong start in global roles.

Workforce training and development and resource allocation
Employee engagement is central to Grünenthal’s strategy (see section [👁️ ‘S1-2 Workforce engagement’](#)).

Grünenthal allocates significant resources to its workforce initiatives. The Global HR Development team partners closely with business areas to prioritise and allocate resources for training and development. Programmes such as the GO Leadership Academy and CCO Academy reflect the company’s investment in creating a high-performing and inclusive workplace.

Due to limited data availability, no concrete CapEx and OpEx for action plans are being reported this year.

S1.MDR-M/S1.MDR-T/S1-5
Metrics and targets used to evaluate performance

While Grünenthal does not yet track training and skills development metrics in accordance with ESRS S1-13, the company uses its own metrics to closely monitor employee development and continually improve the effectiveness of its training efforts.

- **Personal Development Plans (PDPs):** Grünenthal monitors the percentage of employees covered by tailored PDPs, which are established collaboratively with line managers and tracked via our myView reporting. We create regular summary reports per function and geography on the PDPs and share and discuss these insights with HR Business Partners (no individual level). The percentage of PDPs is also a Group Scorecard target.

» **Grünenthal**
Insight

Training hours

Grünenthal tracks its training efforts to monitor employee development and continually improve the effectiveness of its training.

In total, Grünenthal employees accumulated 10,426 hours of training through LinkedIn Learning & Courses in 2024, which translates to about 2.4 hours per employee.

- **LinkedIn Learning Usage:** Grünenthal tracks the number of active licenses and hours of training on the online learning platform via the dashboard function of LinkedIn Learning. We look at the high level data for function and geography and we share and discuss it with the HR Business Partners.

In 2025, Grünenthal aims to set a measurable, outcome-oriented target to effectively and systematically manage the topic of training and development of its workforce. » Nonetheless, progress in the topic is managed with the non-ESRS-aligned targets below. «

» **Further target and progress 2024**

Target	Progress 2024	Status
Offer a wide range of learning and development opportunities, supported by learning platforms that can respond to individual needs and learning styles ¹	• 84% of employees had active Personal Development Plans (PDPs), with 78% updated during the year, surpassing our 75% target. • Employees accessed over 2,500 LinkedIn Learning licenses, viewing 83,000 videos and completing 17,000 courses • 80% of leaders overseeing teams with more than three direct reports completed a 360-degree leadership feedback survey, supplemented by coaching to enhance self-awareness and leadership skills • Web-based training included 30 live sessions covering critical skills like Inclusive Leadership, Coaching for Development & Growth, Communicating with Impact, and Business Finance	On track

¹ Target maintained from previous Responsibility Report; will be reviewed in 2025. «

Intended outcomes for the workforce
Grünenthal’s intended outcomes aim to positively impact the lives of its employees while enabling their best performance. These outcomes include:

- Maintaining a highly engaged, involved and satisfied workforce as a foundation for organisational success.

- Strengthening capabilities at all levels, with a particular focus on leadership development.
- Supporting personal development to ensure both individual performance improvement and effective succession planning.

- Recognising and rewarding performance through structured programmes.
- Supporting employees during organisational change processes.
- Offering continued support for health, well-being, work-life balance and family-friendly programmes.

Diversity, inclusion, and equal opportunities

S1.MDR-P/S1-1 Diversity, inclusion, and equal opportunities policy: Managing workforce impacts

Key contents of the policy

Grünenthal's **Global People Policy** forms the cornerstone of its approach to managing workforce-related impacts. The policy focuses on fostering a work environment that supports professional and personal growth, underpinned by equity, diversity, inclusion and employee engagement. The policy addresses four main topics:

- 1. Human capital fairness:** Promoting fair employment practices and ensuring all employees are treated equitably.
- 2. Equality, diversity and inclusion:** Fostering an inclusive environment where diversity is viewed as a driver of innovation, enabling teams to collaborate effectively.
- 3. Attractive employer:** Creating the best possible conditions for Grünenthal's employees in their professional and private lives by providing an environment where people can thrive in rich and varied roles, offering growth opportunities and an extensive range of benefits.
- 4. Employee engagement:** Encouraging active participation and fostering a culture of mutual respect and psychological safety.

The policy explicitly commits to eliminating any form of discrimination or harassment, and to promoting inclusion by addressing issues related to race, gender, age, religion, sexual orientation, social origin, disability and other protected characteristics. Employees are expected to adhere to these principles and relevant anti-discrimination laws. Through its Diversity & Engagement Strategy, Grünenthal seeks to achieve psychological safety and belonging for all employees, with specific measures to eliminate bias in hiring, compensation and career progression.

Policy scope and accountability

The Global People Policy applies to all Grünenthal employees, managers and contingent workers worldwide performing work for any legal entity of the Grünenthal Group, including contractors and personnel from outsourced service providers.

The Head of Global Human Resources, supported by the Corporate Executive Board, is responsible for overseeing the policy's implementation. The Diversity & Engagement Council, composed of senior leaders across business areas, plays a key role in setting strategic goals, monitoring progress and advising on diversity and inclusion matters.

Alignment with international standards

Grünenthal's Global People Policy aligns with globally recognised frameworks, including the United Nations Universal Declaration of Human Rights (1948) and International Labour Organisation (ILO) Conventions, such as the Discrimination (Employment and Occupation) Convention, 1958 (No. 111), Freedom of Association and Protection of the Right to Organise Convention, 1948 (No. 87) and the Equal Remuneration Convention, 1951 (No. 100).

*Colleagues at
Aachen headquarters
celebrating Pride Month*



» Grünenthal Insight

Celebrating our continued success in creating a Great Place to Work

The results of Grünenthal's biennial Great Place to Work® survey (GPtW) in 2024 reflect continued progress in strengthening our organisational culture and employee engagement across regions.

Key highlights include:

- 88% participation rate, marking our highest response rate to date and significantly exceeding the GPtW global benchmark of 76%.
- A Trust Index score of 78%, representing a two-percentage-point improvement compared to the 2022 survey.
- 83% of employees affirmed that Grünenthal is a great place to work, also reflecting a two-point increase from the previous reporting period.

These results underscore the impact of ongoing efforts to foster an inclusive and supportive workplace environment. They also indicate both consistency in engagement across most countries and meaningful improvements in several key areas.

As a result of the high participation and positive feedback, Grünenthal has received GPtW certification in 20 countries.

Countries certified by Great Place to Work®

20



Great Place to Work®,
Chile

Stakeholder consideration and accessibility

Grünenthal promotes awareness of diversity, equality and inclusion matters among our employees and relevant stakeholders. See section  'S1-2 Workforce engagement' for more information.

To ensure transparency, all policies are available through platforms such as MasterControl, where employees are trained to ensure understanding at all levels. Platforms for raising questions or concerns are available, and employees can consult managers, HR, or works council representatives for clarification.

Grievance mechanisms and continuous improvement

Grünenthal has established robust grievance mechanisms, including the Ethics Helpline, which allows employees and external stakeholders to report any concerns, including potential incidents of discrimination, confidentially and anonymously in their preferred language. The Ethics Helpline is a confidential internet-based platform managed by Grünenthal's Global Compliance Team and provided and maintained by a third-party vendor. It can be used 24/7 by employees including those of our business partners or any other individual. Every complaint or concern is investigated by our Compliance organisation, and if the allegation refers to a potential substantial violation of human rights and/or environmental protection obligation, the Human Rights Officer shall directly undertake the investigation. Grievances are thoroughly investigated, with findings used to improve internal processes and training.

To mitigate risks such as biased job requirements, Grünenthal retrospectively monitors diversity of the new hires. Training for creating inclusive job

descriptions, standardised interview processes, and bias-reduction are in place for hiring managers to ensure merit-based decisions. Discrimination or bias, if identified, is promptly addressed through remedial actions, including process changes and enhanced monitoring.

Accessibility to individuals with disabilities

The company is also committed to ensuring that its facilities are accessible to individuals with disabilities.

S1.MDR-A/S1-4 Diversity, inclusion and equal opportunities actions**Advancing diversity and inclusion**

Grünenthal is committed to fostering a culture of inclusion and achieving gender parity in leadership roles. The Leadership Learning Labs are a cornerstone of Grünenthal's efforts, a programme designed to develop inclusive leadership skills. This initiative equips leaders with tools to recognise and address biases, foster diversity, and build inclusive teams. Additionally, Grünenthal organises cultural celebrations, such as International Women's Day and the World Day for Cultural Diversity and Girls in Science to enhance understanding and strengthen team cohesion. Multilingual communication efforts and English language classes further support inclusion by ensuring accessibility for all employees.

To further strengthen its inclusive culture, Grünenthal integrates feedback mechanisms such as its biennial Great Place to Work® survey. In 2024, the survey included additional statements focused on key aspects of inclusion, such as diversity as a strength, respect for individual identity, openness to differing opinions, and managerial support for diverse perspectives.

The survey results, presented during the Global Townhall and shared with the Diversity & Engagement Council, indicated positive trends. For instance, 86% of employees viewed diversity as a strength, while 81% felt encouraged by their managers to share differing opinions. These results provide actionable insights that guide Grünenthal's continuous improvement efforts in building an inclusive workplace.

Grünenthal has implemented comprehensive measures to promote equal pay and pay equity. These include a transparent job family and levelling framework, which ensures that salaries are based on objective, gender-neutral criteria. Regular salary reviews, transparent progression structures, and equitable pay for employees returning from leave further reinforce this commitment. The company is also taking steps to enhance transparency in recruitment. For instance, Grünenthal is excluding prior salaries from recruitment decisions and plans to have the pay range or rate posted in job advert and/or to have it available on request to all candidates before any interview. Future plans also include disclosing potential pay gap data in accordance with the EU pay transparency directive.

Governance and strategic oversight for diversity & engagement

The Global HR Development Team is responsible for implementing training and initiatives, while the Diversity & Engagement Council provides oversight and ensures alignment with corporate objectives. Composed of senior executives from various business areas, the Council meets quarterly to review progress and advise on strategic goals. Additional governance is provided by the Corporate Responsibility Board, which oversees diversity-related targets and activities.

Resource allocation

No exact CapEx/OpEx data for the (planned) actions is being reported this year due to limited data availability.

Diversity, inclusion and equal opportunities metrics and targets

S1.MDR-M/S1-9 Diversity, inclusion and equal opportunities metrics

We have decided to measure the gender share in our executive leadership positions, defined as global grade 16 or higher. We extracted data from our human capital management system as of 31 December 2024, to calculate the relative share of female and male employees within this leadership tier.

Top management level diversity¹

	Female		Male		Total
	Headcount	Share	Headcount	Share	Headcount
Total	36	35%	66	65%	102

¹ Top management refers to all employees assigned a grade 16 or higher (Vice President Level) within Grünenthal's role-based classification system.

Employee age distribution

	Total (headcount)	Share
under 30	463	11%
30 – 50	2,413	56%
over 50	1,406	33%

In terms of age diversity, Grünenthal established standardised age brackets to ensure consistency in reporting over time. Corresponding data was also extracted from the MyView (SAP) system as of 31 December 2024 to determine representation across defined age groups.

Currently, diversity metrics for Grünenthal Meds and Valinor are limited to gender distribution across the overall workforce. The reported figures on gender representation within top management, as well as employee age distribution, do not include Grünenthal Meds and Valinor as no detailed data is available. The scope of the employees of the two companies is less than 5%.

S1.MDR-T/S1-5 Diversity, inclusion and equal opportunities targets

The company actively involves stakeholders, including executive leadership, cross-functional teams, employees and the Diversity & Engagement Council, in shaping its targets. Insights are gathered through interviews, surveys and workshops, enabling strategies that reflect both global objectives and local needs.

Grünenthal evaluates the effectiveness of its policies and actions through internal monitoring, external ESG ratings and annual reviews. Tools such as the Great Place to Work® (GPtW) survey and 360-degree leadership feedback survey provide actionable insights into areas for improvement. Findings are analysed by working groups, which propose actions that are reviewed by leadership and integrated into organisational strategies.

» Grünenthal's current targets align with international commitments, including equity, diversity, and inclusion principles outlined in the Responsibility Report. Looking ahead to 2025, the company aims to further advance gender parity in leadership roles and expand diversity awareness initiatives. These objectives will be finalised in 2025. «

To ensure the effectiveness of its diversity-related actions, Grünenthal incorporates defined metrics into its Global Scorecard and Corporate Responsibility Scorecard. These metrics track progress on cultural and diversity-related targets and provide a foundation for continuous improvement. To support transparency and engagement, these metrics are shared and discussed with relevant workforce representative bodies and communicated to the wider workforce through channels such as Townhalls. Feedback from employee surveys and training sessions is regularly reviewed to refine and adapt initiatives.

In 2025, Grünenthal aims to set a measurable, outcome-oriented target to effectively and systematically manage the topic of diversity, inclusion and equal opportunities of its workforce. » Nonetheless, progress in the topic is managed with the non-ESRS-aligned targets below.

These targets are tracked regularly to ensure consistent progress and alignment with the company’s broader strategic priorities. «

» Further targets and progress 2024

Target ¹	Progress 2024	Status
Move closer each year towards achieving gender parity² in leadership³ and executive⁴ roles. The following, previous targets were consolidated into the above target since they all contribute to the same overall objective: • Offer a workplace that mirrors the diversity of society and takes a leading role for equity, diversity and inclusion • Increase the diversity of our workforce	As of December 2024, 42% of leadership positions and 36% of executive leadership positions are held by women.	On track
Ensure all policies and practices will be inclusive and encourage diversity and equity by the end of 2025	Completed Gender Pay Gap pilot analysis ⁵	On track

¹ Targets maintained from previous Responsibility Report; will be reviewed in 2025.

² All employment decisions at Grünenthal are based solely on job-related factors, including the skills, qualifications, and experience of the individual, without regard to gender, race, ethnicity, or any other personal attributes which are unrelated to the job.

³ Employee with 1 or more direct reports

⁴ Leader at grade GG16+

⁵ As we prepare for compliance with the EU Equal Pay Directive (2026), we are not reporting the unadjusted gender pay gap this year. This underlines our commitment to pay transparency and equal pay for work of equal value and ensures that we are prepared for a company-wide understanding of the data and potential gaps and actions. «

» Leadership positions held by women:

42% «

Ana Inacio, Global Head Established Medicines, with colleagues




» Grünenthal Insight

Celebrating cultural diversity

Operating in 27 countries with colleagues from over 60 nationalities, cultural diversity is integral to Grünenthal’s identity and a driver of innovation and collaboration. The Corporate Hub in Lisbon celebrates cultural diversity through various activities during the year. In 2024, the Hub hosted for example its first ‘Latin Day’, celebrating the cultures of Brazil, Colombia and Panama. Employees from these countries contributed to the event by sharing aspects of their cultural heritage, including traditional food, music and personal insights.

Our commitment to inclusion is embedded in our daily work through the Global Diversity and Engagement Council, local champions, and feedback from the biennial Great Place to Work® survey. Activities included internal and LinkedIn Learning courses on intercultural communication, sharing personal traditions, and supporting initiatives that promote dialogue. These efforts foster a workplace culture grounded in mutual respect and global collaboration.



Corporate Citizenship

As a global company, Grünenthal takes its social responsibility very seriously. It is important for us to make a meaningful contribution to broader society. For this reason, we send donations to support measures, initiatives and institutions that align with our donation criteria. We have defined four strategic categories:

Strategic categories for Corporate Citizenship



Social responsibility activities



Environmental protection activities



Activities that promote health and wellbeing



Ad-hoc disaster relief

Number of Corporate Citizenship projects and initiatives

Strategic category	Number of projects 2024	Number of initiatives 2023
Ad-hoc disaster relief	3 projects: Financial donation to the Red Cross in favour of the people affected by the flood disaster in Spain; Disaster relief to help those affected by the severe storms in Brazil and the wildfires in Chile	3 initiatives: Financial donation to the Red Cross for emergency aid after the severe earthquakes in Turkey and Syria; Disaster relief for Brazil after the landslides in São Paulo and for Chile after the wildfires in the south of the country
Social responsibility activities (before: philanthropic activities)	20 projects: To support initiatives that work for the wellbeing of society and the protection of vulnerable groups, e.g. people with disabilities, children from socially disadvantaged families	6 initiatives: To promote regional projects to improve hospice and palliative care and the mobility of people with disabilities
Activities that promote health and wellbeing (before: healthcare support activities)	11 projects: Focus on supporting palliative care, e.g. by funding the work of national or regional hospice foundations or NGOs in the field of medical care	8 initiatives: Focus on supporting pain and palliative care, e.g. by funding riding holidays for children with cancer or the work of regional hospice foundations
Environmental protection activities	2 projects: To support activities that promote the responsible use of natural resources, e.g. the expansion of renewable energies by local associations	N/A

» Grünenthal Insight

Enabling life-changing surgeries through Interplast

In 2024, Grünenthal contributed to Interplast, an organisation enabling volunteer medical missions in developing regions. Our donation supported a surgical team's mission to Bo, Sierra Leone, where 67 life-changing plastic surgeries were performed, primarily for children with burn contractures. The collaboration with local healthcare professionals exemplifies the impact of shared commitment to global health equity and meaningful, on-the-ground engagement.

Donating 110,000 Euro to help victims of natural disasters

In response to a series of devastating natural disasters, Grünenthal has donated a total of 110,000 Euro to support affected communities across Latin America and Europe.

Following the worst flooding in Rio Grande do Sul's history, which impacted over two million people, Grünenthal's Brazilian affiliate quickly mobilised to provide temporary housing, essential supplies, and transportation for affected employees. A local crisis committee was formed to coordinate longer-term needs and Grünenthal donated 30,000 Euro to Ação da Cidadania to support broader relief efforts.

In Spain, catastrophic floods resulted in over 200 fatalities and extensive infrastructure damage. Grünenthal's Iberian and Corporate Executive Boards offered direct assistance, and the company donated 30,000 Euro to the Red Cross. Local teams also helped distribute critical supplies and several colleagues traveled to the hardest-hit areas to support the recovery efforts as volunteers.

After wildfires swept through Chile's Valparaíso region, Grünenthal contributed 50,000 Euro and supported union-led supply drives for affected communities. Reflecting on the scale of the disaster, the company reaffirmed its commitment to aiding long-term recovery efforts.

Grünenthal has donated more than

1 million

euros for disaster relief since 2021.



Interplast Germany e.V.

Promoting community support and raising awareness through corporate running events and marches

In 2024, over 100 Grünenthal employees participated in the Aachen corporate run, supporting local social causes through a donation-based initiative. Each participant generated a 100 Euro donation, totalling 12,800 Euro across three organisations: Breakfast4kids, Bürgerstiftung Lebensraum Aachen, and Ukrainer in Aachen e.V. Employees voted on fund allocation, actively shaping the impact. The initiative combined health promotion with civic engagement, reinforcing our commitment to local communities and employee-driven social responsibility.

In October 2024, Grünenthal Spain organised the first Solidarity March Against Pain in Madrid to highlight the burden of chronic pain, which affects over a quarter of the Spanish population. More than 150 participants – including patients, healthcare professionals, and Grünenthal colleagues – joined the initiative, supported by 37 organisations. Each kilometre walked contributed to the Theodora Foundation, aligning awareness-raising with tangible support for hospitalised children through creative emotional care. In total, 3,500 Euro was collected and donated to this organisation.

Grünenthal employees at Solidarity March Against Pain in Madrid



S4 – Patient

Managing consumers and end-users

S4.SBM-3 Material impacts, risks and opportunities and their interaction with strategy and business model

While there were no material risks or opportunities identified for Grünenthal during the double materiality analysis, the following impacts originating from Grünenthal’s activities as a manufacturer of medicine for consumers and end-users – in Grünenthal’s case, patients – were identified:

Type of impact	Impact
Personal safety of consumers and/or end-users	
Potential negative impact	Patient safety
Potential negative impact	Product quality
Potential negative impact	Safe pain management through responsible use of opioids
Access to healthcare	
Actual positive impact	Access to healthcare
Research and development	
Actual positive impact	Improving patients’ quality of life through innovative medicines

Personal safety of consumers and/or end-users

Grünenthal’s products are primarily aimed at the treatment of patients in pain, complemented by a range of products which address numerous indications across multiple therapeutic areas. If used as intended, the products are not inherently

harmful but have a positive impact on patients. Thus, potential negative impacts are related to individual incidents rather than systemic in nature. Grünenthal includes all consumers and end-users who could be materially impacted by the company’s operations in the scope of this disclosure. This encompasses patients who use Grünenthal products, patient experts, caregivers and patient organisations, and also intermediaries such as healthcare organisations and healthcare professionals, who play an important role in educating about our products and prescribing them responsibly. Patients in particular rely on accurate and accessible information, and education by their healthcare professionals to avoid negative impacts of Grünenthal products through misuse.

Rigorous testing quality control, and regulatory compliance ensure the safety, reliable availability, efficacy and quality of pharmaceutical products. This protects patients, helps improve their health and fosters trust. While any medicine may cause side effects, Grünenthal’s priority is to ensure that the therapeutic benefits of the medicine outweigh the risks.

Our comprehensive Pharmacovigilance system ensures effective and timely risk identification and mitigation throughout the entire life-cycle of Grünenthal’s medicinal products (see [👁️ ‘S4.MDR-T’](#) for an in-depth description). This enables healthcare professionals to be fully informed and prevent or mitigate potential risks. Additionally, it enhances patient awareness of product-associated risks, making it easier for them to relate any adverse events to the product. The Pharmacovigilance Department’s key actions (see [👁️ ‘S4.MDR-A’](#) for an in-depth description) improve product safety and risk awareness, benefiting patients, patient experts, caregivers, patient and healthcare organisations as well as healthcare professionals, ultimately contributing to safer healthcare outcomes.

Certain patient groups may face specific risks depending on the nature of the product and the disease being treated. Special risk groups include:

- Paediatric patients.
- Elderly patients.
- Pregnant patients.

It is critical for Grünenthal to maintain a reliable supply of its products to ensure that patients, especially those at greater risk and who rely on pain medication, receive their treatments and can successfully manage their pain.

No material risks or opportunities for Grünenthal have been identified at this time.

Access to healthcare

Manufacturing essential pharmaceutical active ingredients is critical to global healthcare. Grünenthal is committed to balancing profitability with social responsibility, ensuring the availability and affordability of essential medicines for patients in underserved regions. Given the widespread unmet need for acute, chronic, and palliative pain management, Grünenthal prioritises these regions and therefore contributes to improved public health.

Research and development

There is a substantial unmet need in chronic pain management, as current treatments do not fully address patient needs, and some can pose safety, tolerability or addiction concerns. Grünenthal seeks to develop innovative pain management medicines that offer improved efficacy with fewer tolerability and safety risks. To enhance decision-making in clinical development, Grünenthal integrates human data-driven insights and novel algorithms to optimise the design of clinical

trials. The use of digital biomarkers, such as smart watches and telemetry devices to monitor patients' mobility, heart rates and sleep patterns, may provide deeper insights into potential new therapies and reduces the burden on patients of recording this data.

Innovative medicines may present unforeseen safety risks during clinical trials. As all new drug candidates may show a safety signal in development, Grünenthal adheres to strict regulatory requirements to ensure patient safety. Rigorous preclinical testing and risk identification measures are implemented early in the development process to minimise potential safety concerns. By applying these safeguards, Grünenthal upholds the highest patient protection standards throughout drug development while advancing pain management solutions.

S4-2 Processes for engaging with consumers and end-users about impacts

Grünenthal's engagement with consumers and end-users is structured within the framework of regulatory compliance and product safety requirements. Regarding patient safety, the company does not engage directly with patients or healthcare professionals beyond the established interactions with competent regulatory authorities. These interactions ensure that all safety measures, including risk assessments and product safety updates, align with global, national, and regional requirements.

Beyond regulatory engagement, Grünenthal provides mechanisms for patients and healthcare professionals to access information regarding its products. The company maintains a Medical Information Service to respond to safety-related inquiries and ensures that product information, including patient leaflets and prescribing guidelines, is available through official channels. While these engagements remain indirect, they ensure that all patients, including particularly vulnerable patients, and healthcare professionals have access to accurate and up-to-date information.


Grünenthal engages reactively through its product quality complaints mechanism, which allows healthcare professionals and patients to report concerns related to drug safety, quality and efficacy. These interactions are essential for ensuring that any reported concerns are reviewed and addressed systematically.

S4-3 Processes to remediate negative impacts and channels to raise concerns

Grünenthal maintains formal channels for consumers and end-users to raise concerns about patient safety, product quality and access to healthcare. These channels are designed to ensure that safety-related issues, adverse events and product quality complaints are systematically recorded, assessed and addressed in compliance with regulatory obligations. While our Ethics helpline policy specifies that individuals are protected from retaliation when using the helpline, Grünenthal has no dedicated policy for the reporting channel regarding possible negative impacts of Grünenthal products. This process

is heavily regulated, protecting individuals from retaliation. Moreover, they can also make their reports under the protection of confidentiality.

Patients and healthcare professionals can report suspected adverse drug reactions or safety concerns through Grünenthal's corporate website, under the protection of confidentiality and against any reprisals. The company's pharmacovigilance system ensures that all reported cases are entered into a safety database for evaluation, with necessary updates to product information implemented following approval by national authorities. Grünenthal also provides a Medical Information Service, allowing healthcare professionals – as one of Grünenthal's key stakeholder groups to seek guidance on safety-related enquiries. This service as well as the sales force offer them additional support, helping to clarify questions and build trust in the system. Product quality complaints can be submitted through the designated reporting channels provided on Grünenthal's local websites and product leaflets. Reports are systematically tracked and investigated, ensuring that identified



Patient in consultation with doctor

concerns are resolved in a timely manner. The effectiveness of this system is assessed through ongoing monitoring and trend analysis, allowing Grünenthal to proactively address emerging safety or quality issues.

The operational responsibility lies with the Head of Global Quality Assurance, supported by Quality Assurance management and Qualified Persons, who ensure timely and effective responses. Feedback is provided to the reporting party, and actions are taken to address the concerns raised.

For more information, see chapter [👁️ ‘G1 Business conduct’](#).

Personal safety of consumers and/or end-users

Patient safety

S4.MDR-P/S4-1 Patient Safety Policy

Key contents of the policy

Grünenthal’s Drug Safety Policy provides a comprehensive framework for a global, quality-assured pharmacovigilance system. Its key objective is to effectively identify and mitigate safety concerns across the entire lifecycle of all its medicinal products and therefore for all potential patients. This applies to human-use products for which Grünenthal holds legal responsibilities, such as marketing authorisations, or acts as a sponsor of clinical trials. The policy also applies to delegated responsibilities managed through licence partners. We are committed to adhering to global, national, and regional legal or regulatory requirements while ensuring the performance of our pharmacovigilance system is consistently overseen by the Qualified Person for pharmacovigilance and monitored by all relevant corporate entities. In the reporting year, no significant changes were made to the Drug Safety Policy.

Policy scope and accountability

The Drug Safety Policy applies to all Grünenthal employees across its legal entities with marketing authorisations or sponsorship roles in clinical trials. The Corporate Executive Board is ultimately accountable for the implementation of this policy.

Alignment with international standards

Grünenthal’s pharmacovigilance system aligns with internationally harmonised guidelines such as the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), topic E2E Pharmacovigilance Planning and E2D Post-approval Safety Data Management.

The system is also fully compliant with key legal and regulatory frameworks, including EU Directive 2001/83/EC and the Federal Food, Drug, and Cosmetic Act (Chapter 21) of the US Food & Drug Administration FDA.

By aligning with the individual international guidelines named in the sections describing policies used to manage impacts on consumers and end-users in this section and the ones following, Grünenthal naturally respects patients’ human rights and OECD Guidelines for Multinational Enterprises. For more details on Grünenthal’s general approach to human rights, see [👁️ ‘S1-1 Fair working conditions and remuneration policies and company agreements’](#).

Stakeholder consideration and accessibility

By complying with these international and regional regulations and guidelines, the Drug Safety Policy reflects the interests of key external stakeholders – such as health authorities, healthcare professionals, and patients – while prioritising transparency and safety. When implementing these guidelines, Grünenthal incorporates input from internal stakeholders involved in regulatory compliance, including the Regulatory Affairs, Medical Affairs, and Quality Assurance teams. These internal stakeholders can access the Drug Safety Policy through the Grünenthal Training Management System, which provides targeted training to ensure a comprehensive understanding and proper implementation.

S4.MDR-A/S4-4 Patient safety actions

Key actions undertaken by the pharmacovigilance department

Consumers and end-users play a vital role in supporting positive patient outcomes, as pharmacovigilance relies on spontaneous reports of safety information related to Grünenthal’s products. The pool of spontaneous reports is the foundation for all key actions undertaken by the Pharmacovigilance Department, ultimately ensuring that new and important information regarding the benefit-risk profile of our products is available to patients and healthcare professionals. The key actions upholding patient safety and ensuring regulatory compliance, which extend from Grünenthal’s business activities to the downstream value chain to consider potentially all affected patients, comprise:

1. Ensuring the collection of safety information from all available sources, such as literature, spontaneous reporting systems, and solicited data collection systems. This data is stored on a central database, assessed and reported to competent authorities and partner companies per legal and contractual obligations.
2. Reviewing available data to identify new safety signals and assess and validate new safety signals when applicable. This process enables the identification of new risks or new aspects of known risks associated with the use of Grünenthal products.
3. Implementing appropriate risk minimisation measures on identifying new or evolving risks. This includes updating Summaries of Product Characteristics and Patient Information Leaflets as part of routine risk minimisation, or introducing additional measures where necessary.
4. Preparing periodic reports that summarise safety information, new signals, and risks, subsequently submitted to competent authorities.

5. Overseeing all processes to ensure compliance with national laws and the effective operation of safety systems, thereby delivering expected results. This includes tracking of metrics and dissemination of training.
6. Creating and managing a comprehensive pharmacovigilance system master file, which includes detailed documentation of the pharmacovigilance system, including annexes that outline Marketing Authorisation Holder status and ongoing activities.

All actions apply in all countries where Grünenthal's products are authorised. As part of Grünenthal's compliance with applicable EU regulations, the company regularly prepares Risk Management Plans (RMPs) to document the safety profile of its medicinal products, including important risks and required pharmacovigilance activities to mitigate or remediate material negative impacts on patients. Where necessary, Grünenthal implements additional risk minimisation measures, such as educational materials developed in close alignment with Competent Authorities and targeted at healthcare professionals or patients.

Proposed measures, including packaging or formulation adaptations, are reviewed and approved by Competent Authorities. Coordination with other marketing authorisation holders may be required for aligned implementation. Grünenthal's pharmacovigilance system is regularly inspected by Competent Authorities worldwide. Observations are addressed through corrective and preventive action (CAPA) plans, whose implementation is subject to authority verification.

Leveraging business relationships

The Grünenthal Group has dedicated pharmacovigilance agreements with partner companies to effectively manage material impacts on consumers and end-users. These agreements clearly define the respective responsibilities, tasks, and decision-making rights of all parties involved. They also establish frameworks for the

seamless exchange of safety-related information, supporting timely and coordinated responses to emerging safety concerns.

Timeline and financial resources

The Pharmacovigilance Department's key actions are ongoing and will continue as long as Grünenthal holds its Marketing Authorisation. Grünenthal tracks the progress of key actions disclosed in previous years through metrics (see  'S4.MDR-M'). Financial resources for these activities were allocated in the 2024 Pharmacovigilance Budget, ensuring that the necessary capabilities and infrastructure were in place to effectively safeguard patient safety. Exact CapEx and OpEx figures are not part of this year's report due to limited data availability. To maintain a high standard of regulatory compliance and operational efficiency, Grünenthal invests in regular external training. This ensures that Grünenthal Drug Safety personnel remain up-to-date with their qualifications. Additionally, Grünenthal upgrades software and tools and develops proprietary IT innovations to perform key actions more efficiently.

S4.MDR-M/S4.MDR-T/S4-5 Patient safety metrics and targets

Metrics for patient safety

The Grünenthal Group uses multiple metrics to monitor and evaluate the performance and effectiveness of its pharmacovigilance system to best manage patient safety. These are 1) compliance with individual case safety reports submitted to health authorities within due time and 2) the number of general pharmacovigilance training assignments for all Grünenthal employees.

Percentage of individual case safety reports performed for health authorities within due time

- Timely and accurate reporting of individual case safety reports (ICSRs) to health authorities is a critical element of our approach to manage patient safety and regulatory compliance. The percentage

of ICSRs submitted within the required timeframes serves as a key indicator of the effectiveness of our pharmacovigilance system. This metric enables us to proactively mitigate potential adverse impacts on patient wellbeing, product safety, and business continuity. Grünenthal receives safety information through multiple channels, including online forms and a widely publicised email address, both accessible to external stakeholders, including healthcare professionals and patients. All reports are reviewed by the Case Processing team and processed in the Argus database, which is configured to meet country-specific regulatory timelines and automatically generates reports for health authorities. The Apex tool then evaluates timeliness and compliance, enabling the Pharmacovigilance team to monitor performance via the defined metric.

Number of pharmacovigilance training assignments

- Ensuring that employees are adequately trained in pharmacovigilance requirements is essential for managing potential risks related to patient safety, regulatory compliance, and product stewardship. The number of pharmacovigilance training assignments completed represents a key indicator of our efforts to embed safety awareness and operational responsibility across our workforce. This metric supports the effective management of potential adverse impacts, enhances risk mitigation capabilities, and reinforces our commitment to responsible business practices. All new colleagues are automatically assigned the relevant training based on their internal job codes within the digital MasterControl training platform. Completion of each training module must be confirmed through a formal sign-off by the employee. The system automatically tracks the assignment status and monitors completion rates.

All metrics are designed in alignment with national and regional regulations.¹These metrics aim for 100% compliance, recognising that operational constraints may occasionally prevent achieving this ideal. To address performance gaps, pre-defined thresholds are in place, initiating Corrective and Preventive Action Plans whenever a metric falls below the established standard.

» Grünenthal Insight

External validation and assurance

Grünenthal’s **pharmacovigilance system** undergoes regular external validation to ensure adherence to applicable laws, guidelines and patient safety standards. These evaluations are conducted by globally recognised regulatory bodies, including the Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM) in Germany, the US Food and Drug Administration (FDA), the Medicines & Healthcare Products Regulatory Agency (MHRA) in the UK, the Saudi Food and Drug Authority

(SFDA) in Saudi Arabia, Swissmedic in Switzerland, and the drug regulator in France, L’Agence nationale de sécurité du médicament et des produits de santé (ANSM). Furthermore, each Marketing Authorisation Holder is legally required to maintain a dedicated annual audit plan, which is reviewed and aligned with the Qualified Person for Pharmacovigilance. This audit plan is based on a risk-based approach, with periodic reviews of all processes and outcomes within the Drug Safety framework.

Pharmacovigilance metrics

	Scope	Count in 2024	Score	Target
Number of pharmacovigilance training assignments (Module 1) ¹ completed via e-learning in the last 12-month cycle.	Global level	4,502 of 4,541	99.10%	93%
	Headquarters level	1,582 of 1,599	98.90%	93%
Percentage of individual case safety reports performed for health authorities within due time.	To all health authorities (global level)	8,970 of 9,303	96.40%	97%
	To EMA (Europe)	3,782 of 3,998	94.60%	97%
	To health authorities (Latin America)	213 of 228	93.40%	97%
	To FDA (USA)	256 of 262	97.70%	97%

¹ General pharmacovigilance training relevant to all employees. An additional module of pharmacovigilance training is offered to departments responsible for activities affected by pharmacovigilance regulations (e.g., commercial areas setting up market research activities).

Patient safety targets

In 2025, Grünenthal aims to set a measurable, outcome-oriented target to effectively and systematically manage the topic of patient safety. In the reporting year, Grünenthal had no active ERSR-aligned targets for patient safety.

The primary objective of Grünenthal’s Drug Safety Policy is to maintain a positive benefit-risk balance for its products. This includes informing patients and healthcare professionals about

potential risks associated with product use and implementing appropriate risk mitigation strategies, such as providing educational materials when necessary. In line with this objective, Grünenthal’s overarching pharmacovigilance ambitions are to:

1. Ensure the adequate and effective identification and mitigation of safety concerns throughout the lifecycle of medicinal products.

- 2. Maintain compliance with global, national and regional legal and regulatory requirements.
- 3. Provide oversight by the Qualified Person for Pharmacovigilance and corporate governance regarding pharmacovigilance system performance and safety risks.

¹ Including EU Directive 2001/83/EC, EU Directive 2001/20/EC, EU Regulation (EC) No. 726/2004, EU Regulation (EC) 1901/2006, EU Implementing Regulation (EU) No. 520/2012, the Human Medicines Regulations 2012 (UK), 21CFR314.80 (USA) and pharmacovigilance regulations from all countries where Grünenthal holds a Marketing Authorisation.

» Grünenthal Insight

Putting information in the palm of every patient’s hand

To improve patient safety and information access, Grünenthal Chile introduced QR codes on contraceptive pill blister packs. This innovation allows users to instantly retrieve up-to-date instructions and supplementary information digitally, reducing the risk of misuse. Implemented in collaboration with the Institute of Public Health, this first-of-its-kind initiative required regulatory updates. By eliminating the need for extra packaging, it also supports more sustainable practices. The success builds on earlier experience in the public system and led to Grünenthal Chile being shortlisted for the 2025 Pharmapack Awards in the ‘Patient-Centred Design’ category.



Manufacturing site Chile

» The overarching ambitions are currently operationalised with the following targets: «

» Further targets and progress 2024

Target ¹	Progress 2024	Status
Achieve 97% ‘on-time’ submissions to authorities worldwide for Individual Case Safety Reports (ICSR)	See table above. Safety reports received after the due date from some licence partners to Grünenthal, causing late reporting to the authorities.	Behind plan
Maintain or exceed the current level of recognised compliance with global pharmacovigilance standards	Maintained current level of recognised compliance with global pharmacovigilance standards (positive outcome of inspections, such as in UK, Peru and Saudi Arabia)	On track
Maintain or exceed the current level of recognised compliance with the guidelines for Good Clinical Practice of the International Council for Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH-GCP) standards and other applicable guidelines ²	Maintained compliance with the ICH-GCP standards and other applicable guidelines	On track

¹ Targets maintained from previous Responsibility Report; will be reviewed in 2025.
² Rephrased from 2024 to be more accurate. Previously: 100% compliance with the ICH-GCP standards and other applicable ethical standards. «

» The scope of these targets extends to all Grünenthal products, and they apply continuously as long as Grünenthal remains the Marketing Authorisation Holder for its products. They

are further detailed in key pharmacovigilance processes and metrics related to material sustainability matters.

The targets are based on national and regional regulatory frameworks, such as Directive 2001/83/EC, the Federal Food, Drug, and Cosmetic Act (Chapter 21) of the US Food & Drug

Administration FDA, and international harmonised guidelines, including the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) topics E2E Pharmacovigilance Planning and E2D Post-approval Safety Data Management. «

Relevant proxies at Grünenthal are included in the target setting process, performance tracking and considering further actions based on performance.

Product quality

S4.MDR-P/S4-1
Product Quality Policy

Key contents of the policy

Grünenthal's Good Practice (GxP) Quality Policy establishes the framework under which our Global Quality Assurance Department designs, implements and maintains an effective Pharmaceutical Quality Management System. This system ensures that all products provided by Grünenthal, for any patients, are safe, reliable and comply with regulatory requirements. To uphold this commitment, Grünenthal's Global Quality Assurance ensures compliance with internal codes, international guidelines and national regulations, focusing on:

- Quality Management System – Ensures all products, processes, documentation, and product dossiers meet their intended use requirements.
- Quality risk management – Implements measures to prevent, minimise or eliminate risks affecting product safety, efficacy or quality.
- Event management, recalls and product quality complaints – Provides processes to assess and address adverse events, recalls or complaints, ensuring timely investigation and resolution.

- Organisation and personnel – Establishes training programmes to ensure personnel understand the Quality Management System, industry codes of practice, and company Standard Procedural Documents.
- Facilities, utilities, equipment and computerised systems – Ensures that these components are properly designed, maintained and decommissioned as needed.
- GxP processes and controls – Develops and validates robust processes and systems in accordance with applicable regulatory requirements.

In the reporting year, no significant changes to the GxP Quality Policy were made.

Policy scope and accountability

The Grünenthal GxP Quality Policy applies to all employees within the Grünenthal Group who are involved in GxP-related activities. Leadership is responsible for ensuring compliance with quality assurance policies and procedures. Ultimate accountability for implementing and overseeing the GxP Quality Policy lies with the Grünenthal Corporate Executive Board.

Alignment with international standards

Grünenthal's GxP Quality Policy ensures full compliance with international and national regulations in all territories where the company's products are distributed. This includes EU Directive 2001/83/EC, EU Regulation (EC) No. 726/2004, EU Good Manufacturing Practice Guidelines (EudraLex Volume 4), ICH Guidelines Q8 to Q12 and USA CFR Chapter 21 Parts 210 – 211.

Stakeholder consideration and accessibility

Global Quality Assurance integrates key stakeholder interests, including those of patients, healthcare professionals, and regulatory authorities, by ensuring compliance with internal codes of practice and relevant international and national regulations.

Signals or complaints from end-users in the market are systematically processed through a Complaints Investigation Process. This mechanism ensures that any reported concerns are thoroughly examined, and, when necessary, trigger additional measures. Where relevant, patients and healthcare professionals are informed about the affected product. If patient safety or product quality is at risk, our Recall Process is initiated to promptly remove the product from the market, minimising any potential harm.

Moreover, regulatory authorities conduct regular inspections. Each one is managed through a structured Inspection Management Process, which allows for the rapid assessment of any observed non-conformities. Impact analyses determine the root causes and necessary corrective and preventive actions (CAPA). Should an assessment indicate a potential risk to product efficacy or patient safety, immediate steps are taken to communicate with healthcare professionals and patients or to withdraw the affected product from the market.

Grünenthal uses its training management system to ensure that the GxP Quality Policy is effectively distributed and communicated to relevant stakeholders – the Global Quality Assurance team and leadership roles responsible for or influencing compliance with GxP good quality practices. Additionally, all Grünenthal employees involved in GxP tasks follow a role-specific Training Curriculum, ensuring on-the-job learning. External individuals on Grünenthal campuses are either supervised by Grünenthal personnel or receive equivalent training to maintain compliance. Before collaborating, external partners undergo screening and Quality Auditing to verify that their policies align with Grünenthal's standards.

S4.MDR-A/S4-4 Product quality actions

Key actions under the Quality Management System

The law requires corrective and/or preventive action to address actual or potential negative impacts on consumers and end-users due to product quality. Grünenthal uses quality risk management and root cause analyses to determine the appropriate actions to minimise any negative impact of its products, and ensure that products have the intended effect on patients in a risk-based approach on a case-by-case basis. The company has implemented the following key actions under its Quality Management System to prevent negative patient outcomes:

- Alignment of all GxP processes and systems with all applicable legal and regulatory frameworks.
- Consistent application of a structured quality risk management approach to address potential quality concerns effectively.
- Review, investigation and follow up with feedback on 100% of Quality Events, Deviations, and Product Quality Complaints (including those received from patients and healthcare professionals).
- Assurance that highly qualified Quality Staff operate within a robust Quality Management framework, assuring Right First-Time operations, continuous improvement of product efficacy and patient safety, and continuous improvement of internal processes and systems.
- Maintenance of a Regulatory Intelligence Process to proactively adapt to worldwide pharmaceutical regulations.
- Implementation and continuous monitoring of Product Quality metrics and targets.

» Grünenthal Insight

Advancements in capsule manufacturing

Grünenthal's recent investment in its Chilean plant enhances patient safety and treatment reliability through 100% weight-controlled capsule filling and individual capsule identification. This ensures precise dosing and consistent quality. Advanced technology allows for the combination of up to three substances in a single capsule, supporting complex therapies. By accommodating a wide range of capsule formats, the facility ensures high flexibility in production – ultimately delivering safer, more effective treatments to patients worldwide.

We all together continue demonstrating that everything we do, every day, is about delivering our very best for our patients.

Joachim Bauer

Head Global Quality Assurance during Grünenthal's fourth Global Quality Day



Any observed negative trends or missed targets are investigated as deviations in line with our internal procedures. Root causes are systematically identified and addressed through a Corrective and Preventive Action (CAPA) plan to mitigate or remediate potential adverse impacts.

Scope of key actions

The key actions apply to all GxP-related processes, operations, and systems within Grünenthal. The GxP framework encompasses Good Manufacturing Practice, Good Distribution Practice, Good Clinical Practices and Good Laboratory Practices (see [👁️ ‘S4-1 Research and development policy’](#)).

Leveraging business relationships and engagement in industry initiatives

Grünenthal has implemented Technical Quality Agreements with partner companies that define responsibilities, tasks, information sharing and decision rights in order to best manage negative impacts that could affect patients. Moreover, Grünenthal engages with other pharmaceutical companies on issues concerning patient health and safety as an active member of the European Federation for Pharmaceutical Industries and Associations.

Timeline and financial resources

Maintaining an active and effective Quality Management System is an ongoing, permanent regulatory requirement mandated by all global health authorities. As such, Grünenthal’s Quality Management System remains continuously operational to meet evolving compliance standards. All activities of the Global Quality Assurance department (GQA) relate to the material sustainability issue of product quality. The annual Global Quality Assurance Budget provides the necessary financial resources to support the implementation and sustainability of the quality management initiatives. Specific CapEx/OpEx information is excluded from this year’s report due to limited data availability.

S4.MDR-M/S4.MDR-T/S4-5
Product quality metrics and targets

Metrics for product quality

Grünenthal’s Quality Management System performance is assessed through a set of metrics. These metrics are analysed to facilitate continuous improvement, ensuring compliance with ICH Q9 (Quality Risk Management). Performance outcomes are reported to relevant management and executive personnel.

The core metric used for monitoring Product Quality is:

Number of external quality certifications held by Grünenthal’s manufacturing sites

Grünenthal has a comprehensive quality management system across its manufacturing sites in place to ensure the consistent delivery of safe, high-quality and reliable products. A key metric within this system is the number of external quality certifications held by our manufacturing sites. These certifications, issued by accredited third-party bodies, validate that our manufacturing processes meet internationally recognised safety and quality standards. The original quality certifications are retained locally at each site, while copies are centrally archived. These certifications are renewed at least every three years in accordance with applicable legal requirements. At the global level, a quarterly review process is in place to verify the continued validity of each certification. If a renewal is due, the process for recertification is promptly initiated.

Product quality metrics

		2024	2023
Number of external quality certifications held by Grünenthal’s manufacturing plants	Total	16	17
	Chile	3 ¹	4
	Ecuador	3	3
	Germany	3	3
	Italy	5	5
	Switzerland	2	2

¹ The reported numbers are cumulative. The change from 2023 to 2024 in Chile is due to the decision not to renew distribution to the Colombian market.

» Grünenthal
Insight

Further internal metrics for measuring product quality

Grünenthal’s Quality Management System metrics are designed to monitor and assess key quality processes that ensure consistent quality risk management. Depending on the metric, these are gathered automatically by the management systems or manually. In any case, metrics are regularly reviewed during GQA department meetings.

The **Product quality complaints rate** (in parts per million) represents the number of marketing units involved in justified product quality complaints, relative to the total number of units distributed (as 12 months rolling average). The calculation is based on the assumption that all complaints are accurately reported, categorised and represent genuine product quality issues. This allows the metric to serve as an indicator of manufacturing consistency, product reliability and customer experience. The metric may be affected by underreporting of incidents, regional discrepancies in reporting behaviour, and instances where complaints may relate to external causes rather than intrinsic product defects.

The **Deviation investigation on-time** metric tracks the timeliness of quality deviation investigations. It calculates the percentage of deviation investigations closed within the organisation's defined timeframe of 20 working days. The metric assumes that timely closure of investigations correlates with effective deviation management. It is intended to provide insight into the operational efficiency of quality assurance processes and their role in safeguarding product quality, regulatory compliance and continuous improvement. Factors limiting this metric include delays in reporting or documentation, variations in the complexity of individual investigations, and the potential risk of prioritising speed over the thoroughness of root cause analysis and corrective actions.

Product quality complaint investigation on-time monitors the percentage of product-related complaint investigations concluded within the organisation's established timeframe of 20 working days, in line with internal quality system standards.

The underlying assumption is that timely resolution of complaints indicates effective complaints management, which is critical for maintaining compliance, ensuring product quality and preventing recurrence of quality issues. Performance against this metric may be impacted by delayed reporting, incomplete documentation, variation in the complexity of complaints or prioritisation of timeliness over effectiveness.

The **CAPA closure on-time** metric reflects the percentage of Corrective and Preventive Actions (CAPA) closed by their predefined due dates. It is calculated as the percentage of CAPAs closed on time divided by the total due within the reporting period. This metric is based on the assumption that deadlines are appropriately set based on risks and closure criteria are consistently applied. All CAPAs undergo effectiveness verification as part of the CAPA Closure process. Limitations include variations in CAPA complexity and potential prioritisation of timeliness over the depth of issue resolution.

	2024	2023
Product quality complaints rate	5 ppm ¹	3 ppm
Deviation investigation on-time	90%	80%
Product quality complaint investigation on-time	95%	85%
CAPA closure on-time	95%	87%

¹ The increase in complaints from 3 parts per million (ppm) remains well below Grünenthal's internal target of 10 ppm, which reflects a conservative benchmark.

Product quality targets

Currently, Grünenthal does not have a reportable measurable, outcome-oriented target set for its product quality. In 2025, Grünenthal aims to set a measurable, outcome-oriented target for product quality that aligns with the objectives of the GxP Quality Policy. For information related to tracking the effectiveness of policies and actions, see information on metrics.

Safe pain management through responsible use of opioids

Grünenthal is committed to ensuring the safe and appropriate use of its medicines, particularly opioid-based treatments for pain management. Recognising both the essential role of opioids in addressing severe pain and the risks associated with their misuse, the company has implemented the **Opioid Responsibility Framework**. This framework ensures a shared understanding within Grünenthal and provides clear guidance to external stakeholders on the ethical and scientific principles underpinning opioid use.

S4.MDR-P/S4-1 Responsible use of opioids policies

Key contents of the framework

Grünenthal's **Opioid Responsibility Framework** regulates our internal processes while also involving our business partners effectively.

At the core of this framework is the **Opioid Charter** (The Grünenthal Charter on the Responsible Medical Use of Opioid Analgesics in Pain Patients), which defines Grünenthal's commitment to developing, commercialising and distributing opioid analgesics in line with the highest ethical and industry standards. The company actively works to minimise the risks of non-medical use while maintaining patient access to effective pain management.



Els Hollanders, Global Lead Medical Governance & Operational Excellence, with colleagues at Medical Affairs Workshop 2024

Additionally, the **Opioid Communication Guidance** sets out principles for responsible promotional content. It ensures that all language and imagery used in presentations, publications and marketing materials provide a factual and balanced representation of opioid-based treatments.

The **Opioid Statement** (Statement regarding the responsible use of opioid-based medicines) serves as a concise reference outlining key considerations for opioid-based pain management. It addresses the risk-benefit profile of these medicines and is integrated into all opioid-related promotional materials, ensuring clarity and transparency across communications. In the reporting year, we updated the Opioid Statement by strengthening and clarifying the language, drawing on guidance from the U.S. Centers for Disease Control and Prevention (CDC). The revised version sharpens the emphasis that opioid medications are not authorised for all types of pain.

In addition, Grünenthal has implemented **Compliance and Responsible Opioid Usage Guidelines for Commercial Partners**, which aim to improve Grünenthal's management of opioid-related risks associated with its Commercial Partners – contractual partners who commercialise Grünenthal's products.

Scope and accountability

The Opioid Responsibility Framework is applicable to all opioid analgesics that are part of Grünenthal's product portfolio and all employees with duties directly or indirectly associated. Moreover, healthcare professionals are included in the scope where relevant, as patient contact occurs through them. The regional Responsible Opioid Usage Boards (ROUB) implement the framework, while the global ROUB will supervise and ensure adequate implementation.

Alignment with international standards

Grünenthal has implemented its Opioid Responsibility Framework beyond regulatory requirements. Our Opioid Statement as one central document of our Opioid Responsibility Framework refers to the Centers for Disease Control and Prevention (CDC) Clinical Practice Guideline for Prescribing Opioids for Pain – United States 2022, the OECD Health Policy Addressing Problematic Opioid Use in OECD Countries, as well as other key relevant publications on the responsible use of opioids. For further information, see Grünenthal's Opioid Statement on its corporate website.

Stakeholder considerations and accessibility

The Opioid Responsibility Framework has patients' health, safety and wellbeing at its core – their needs are the ones most relevant in this regard. The framework and associated policies are available in their respective version (for external or internal use) on the internet and intranet, respectively. Moreover, the Opioid Statement for example, is included in all opioid-related communication materials.

S4.MDR-A/S4-4

Responsible use of opioids actions

Key actions under the Opioid Responsibility Framework

The main ongoing action under the Opioid Responsibility Framework in the reporting year was two-fold: First, the training of employees in the Opioid Responsibility Framework and second, fostering commitment to responsible use among Commercial Partners through risk-based classification into different tiers of partners (see section [👁️ 'G1 Business Conduct'](#)) and respective risk-based mitigation measures, such as document reviews and training for partners.

Grünenthal has established a global Responsible Opioid Usage Board (ROUB) at headquarters level, which supports the Corporate Executive Board in overseeing the governance of the

responsible use of opioids. The ROUB comprises relevant functions such as the General Counsel, the Chief Medical Officer, the Global Compliance & Responsibility Officer and a Senior Legal Counsel. The global ROUB is an escalation and challenging body for fundamental decision-making on all topics regarding the commercialisation of opioids. At the same time, it monitors and controls adherence to the Opioid Responsibility Framework via the local opioid boards.

All regions, in which Grünenthal commercialises opioids, have local Grünenthal Responsible Opioid Usage Boards. These boards produce biannual reports detailing adherence to training requirements and conversion rates for the mandatory use of the Opioid Statement in all interactions of sales teams and other Grünenthal employees with healthcare professionals.

The regions are also required to conduct spot-checks on opioid-related materials and provide feedback on their findings. Furthermore, they share minutes from their opioid board meetings, which occur at least twice a year. Each region operates under its own Standard Operating Procedure for opioid board governance.

If any Grünenthal entity identifies insufficiently trained healthcare professionals on the responsible use of opioids or other findings regarding key actions on the responsible use of opioids, an action plan is required to address the gap and mitigate potential negative impacts.

Grünenthal established a dedicated governance framework for the responsible use of opioids in 2020. This framework is continuously reviewed and refined by local and global Responsible Opioid Usage Boards (ROUB) to ensure it remains effective and responsive to emerging risks.

Any potential or actual negative impact identified through routine monitoring or spot-checks triggers a defined response. Local ROUBs implement immediate action plans for less severe findings, such as rescheduling missed training. More serious cases are escalated through the Ethics Helpline process, as outlined in Chapter  'G1', ensuring thorough investigation and remediation.

Where material patient impacts are reported, Grünenthal's drug safety department leads the response. If root cause analysis identifies issues related to commercial practices, the global ROUB assesses and recommends necessary changes. This may include adjustments to product design, marketing or sales processes.

The company ensures that remedy processes are accessible and effective through a structured governance system, supported by clear escalation routes and continuous oversight. Where appropriate, Grünenthal also engages in cross-industry collaboration to support responsible opioid use more broadly.

Scope of key actions

The scope of actions includes Grünenthal's own operations related to opioids and its partners downstream.

Employees in sales within the commercial organisation undergo annual training on the Opioid Statement and medical training on the responsible use of opioids. These personnel are required to inform all relevant (healthcare professionals with whom we communicate about our opioids) healthcare professionals about the Opioid Statement on a regular basis, at least annually, with their activities recorded in the Customer Relationship Management (CRM) system. The Opioid Communication Guidance specifies when and how the Opioid Statement is to be integrated into internal and external materials.

Depending on risk-based tiering criteria, promotional opioid-related content from Commercial Partners is subject to governance-led medical reviews before review and dissemination.

Framework for business partners commercialising opioids

We have designed a dedicated framework for our business partners that commercialise opioids on our behalf. Depending on the level of risk exposure (the business partner's scope of activities such as healthcare interactions and use of promotional materials), a set of compliance clauses has been drafted ensuring a tailored risk mitigation strategy.

Leveraging business relationships and engagement in industry initiatives

Grünenthal leverages its relationships with business partners to foster advocacy for safe pain management through the responsible use of opioids. To this end, the Opioid Responsibility Framework promotes responsible communication and marketing practices throughout the value chain.

Grünenthal actively participates in external activities, such as field visits and conferences related to pain management, for example the International Association for the Study of Pain (IASP) World Congress on Pain, the European Pain Federation (EFIC) Congress and PAINWeek. The Opioid Statement is consistently communicated in all our interactions at such conferences and in field visits to raise awareness and address the safe treatment of pain through the responsible use of opioids.

Timeline and financial resources

These actions are carried out without interruption to maintain compliance and safeguard patient safety. Through these structured and continuous efforts, Grünenthal ensures the effectiveness of its Opioid Responsibility Framework in promoting patient safety and mitigating risks associated with opioid products.

Due to limited data availability, no concrete CapEx and OpEx for action plans are being reported this year.

Effectiveness tracking and assessment

Grünenthal evaluates its actions using context-specific standards and metrics. Grünenthal regularly conducts reviews of literature and guidance on opioid use and pain management to ensure the relevance and accuracy of the Opioid Statement. For instance, in March 2024, it was determined that the Opioid Statement required an update based on the latest available literature and guidance, and the respective changes were made.

S4.MDR-M/S4.MDR-T/S4-5
Responsible use of opioids
metrics and targets

Metrics for the responsible use of opioids

Grünenthal evaluates the performance and effectiveness of its Opioid Responsibility Framework through the following metrics:

- Number of employees who received (refresher) training on Grünenthal's responsible use of opioid-based medicines in the reporting year

Awareness of the risks associated with opioids, and the handling of such risks in a responsible manner, must be reinforced through continuous training. This ensures that all employees involved in the commercialisation of these medications understand how to act responsibly, including what actions to take and which to avoid. Such training represents a key pillar of Grünenthal's governance framework and rules concerning the responsible use of opioids. This further ensures that all information provided to healthcare professionals – as the central authorities responsible for assessing and weighing the risks and benefits of opioid medication – is balanced and up to date. This approach helps to maintain access to opioid treatments for patients where the benefits of

treatment outweigh the risks, while helping to prevent harm in cases where the benefit-risk assessment concludes that opioid treatment cannot be clinically justified.

- Number of healthcare professionals who received in-person communication about Grünenthal's responsible use of opioid-based medicines

As opioids are prescribed by healthcare professionals, and healthcare professionals serve as the central authorities responsible for evaluating the benefits and risks of opioid medications, it is they – rather than the patients – who Grünenthal addresses through the additional warnings outlined in our Opioid Statement. The metric on healthcare professionals Opioid Statement communication reflects the effectiveness of these warnings and therefore contributes to ensuring that all relevant aspects of opioid usage are appropriately considered. In doing so, we help to ensure that patients for whom the benefit-risk assessment is favourable retain access to opioid treatments, while potential harm is avoided where the risks outweigh the benefits.

- Number of commercial partners trained on Grünenthal's Opioid Communication Guidance

By providing partner training on the Opioid Communication, we aim to expand our governance and safeguarding measures to our partners. This is necessary as the primary responsibility for commercialising our products may lay with these partners. Through the targeted training, we ensure that our high standards are adhered to and that the information they provide to healthcare professionals remains balanced and appropriate. This enables healthcare professionals addressed by our partners to assess the risks and benefits for patients in an informed manner. The metric reflects the effectiveness of these efforts in relation to our partners.

The metrics are tracked through records of training sessions in the digital MasterControl platform or local tracking systems in the regions, attendance data from face-to-face training sessions on the Opioid Responsibility Framework, and calendar invitations, attendee lists and review logs for materials. The Global Medical Affairs team compiles the metrics data and submits the results for inclusion in Grünenthal's Responsibility Report in alignment with global compliance requirements. The metrics are evaluated at the global level by the ROUB annually, with regional and partner-specific assessments conducted twice a year.

Responsible use of opioids metrics

	2024	2023
Number of employees who received (refresher) training on Grünenthal's responsible use of opioid-based medicines in the reporting year. ¹	1,718	1,632
Number of healthcare professionals who received in-person communication about Grünenthal's responsible use of opioid-based medicines.	115,788 ³	170,046
Percentage of commercial partners ² trained on Grünenthal's Opioid Communication Guidance	83%	79%

¹ Previously; Number of employees that received face-to-face (this includes virtual face-to-face training) (refresher) training on Grünenthal's responsible use of opioid-based medicines in the reporting year.

² Business partners active in the reporting year that promoted and resold Grünenthal's products including opioid containing products and/or non-opioid containing products for which Grünenthal is the Market Authorisation Holder.

³ Grünenthal stopped promoting Tapentadol in most countries in 2024 and we expect that the number will go down significantly in the future.

» Grünenthal Insight

*Patient sharing his experiences
during Global Quality Day in affiliate
in Santiago, Chile*



Patient sessions at Grünenthal's Global Quality Day

In 2024, Grünenthal's fourth Global Quality Day engaged approximately 1,500 colleagues worldwide in raising awareness of how their work impacts patients' lives. Interactive events at all five manufacturing sites featured chronic pain patients and representatives from patient organisations, who shared personal experiences with conditions such as diabetic nerve pain, osteoarthritis, and complex regional pain syndrome. A global online session connected employees across regions, with active participation from the Corporate Executive Board. CEO Gabriel Baertschi reaffirmed Grünenthal's patient-centric approach, highlighting the role of quality in improving patient outcomes.

*Gudula Petersen,
Global Patient
Engagement Lead,
with a patient
representative from
a regional diabetes
patient organisation
during Grünenthal's
fourth Global
Quality Day*



Responsible use of opioids target

In 2025, Grünenthal aims to set a measurable, outcome-oriented target for safe pain management through the responsible use of opioids. Currently, Grünenthal does not follow such an ESRS-aligned target.

» In alignment with the overarching objective of the Opioid Responsibility Framework, Grünenthal has set the below target which aims to address safe pain management through the responsible use of opioids, namely, to expand the network of business partners committed to the Compliance and Responsible Opioid Usage Guidelines for Commercial Partners. «

» Grünenthal Insight

Further responsible use of opioids metrics

In addition to the ESRS-aligned metrics, Grünenthal evaluates the performance and effectiveness of its Opioid Responsibility Framework the following company-specific metrics:

	2024	2023
Commercial business partners active in the reporting year that promoted and resold Grünenthal's opioid containing products to which Grünenthal's Opioid Responsibility Framework for Business Partners was communicated.	100%	100%
Commercial business partners active in the reporting year that promoted and resold Grünenthal's opioid containing products who formally committed to Grünenthal's Opioid Responsibility Framework for Business Partners.	100%	94%

» Further targets and progress 2024

Target	Progress 2024	Status
Continuously develop and improve Grünenthal's leading Opioid Responsibility Framework	We have updated the Responsible Use of Opioids Statement by strengthening and clarifying the language based on the U.S. Centers for Disease Control and Prevention (CDC) guidance to emphasise that all opioid medications are not authorised for all types of pain. This target will not be continued for 2025 because no material changes are expected going forward. We will however continue to optimise related processes.	Completed
Expand the network of business partners that have committed to our Opioid Responsibility Framework for Business Partners ¹	Achieved for 2024. 100% of commercial business partners active in the reporting year that promoted and resold Grünenthal's opioid containing products formally committed to Grünenthal's Opioid Responsibility Framework for Business Partners. All new partners signed in 2024 do not commercialise opioids.	On track

¹ Target maintained from previous Responsibility Report; will be reviewed in 2025. «

The Global Corporate Responsibility Board has established and set the relevant metrics in internal discussions in alignment with medical and drug safety functions. These have then been rolled out at regional level.

Performance data is included in Grünenthal's Responsibility Report and monitored via a data control matrix.

- Target setting: There is no direct involvement of consumers or end-users in target setting.

- Tracking performance: There is no direct consumer or end-user engagement in the decision on how to track performance.

We are applying the Grünenthal Opioid Responsibility Framework as a standard.

» Grünenthal Insight

Improve the accessibility and user experience of medical educational materials relating to the responsible use of pain medication

Grünenthal promotes the responsible use of pain medication to improve patient outcomes and reduce risks of misuse. Through the CHANGE PAIN initiative, active since 2009 and endorsed by the European Pain Federation (EFIC) and Pain Alliance Europe (PAE), the company delivers tailored education to healthcare professionals and patients across Europe. In 2024, over 32,000 professionals participated in training events, while more than one million users accessed digital resources. By providing accessible, locally adapted tools and platforms, Grünenthal supports informed treatment decisions, builds trust, and empowers patients to manage pain safely and effectively.



Increase awareness of responsible pain medication use, supported by Continuing Medical Education initiatives with external partners

To contribute to our ambition of increasing awareness of the responsible use of pain medicines and offering Continuing Medical Education (CME) in collaboration with external partners, we have provided an educational grant to Medscape. This grant was for the independent development and delivery of a CME-accredited educational programme related to the responsible use of pain medicines. This was launched in 2024 with the title Primary Care Best Practices in Managing Neuropathic Pain and more than 12,000 physicians engaged with the programme since its launch in February 2024. Notably, 85% of participants indicated they intend to modify treatment plans or change screening/prevention practices based on the training.

Further targets and progress 2024

Target	Progress 2024	Status
Continuously improve the accessibility and user experience of medical educational materials about the responsible use of pain medication	People impacted by our non-branded educational activities in pain management, including the number of: • Educational (virtual and face-to-face) events: 32,531 • Website visitors in the year: 1,013,086	Completed
Increase awareness of responsible pain medication use, supported by Continuing Medical Education initiatives with external partners	Provided an educational grant to Medscape for the independent development and delivery of a CME-accredited programme on Primary Care Best Practices in Managing Neuropathic Pain.	Completed

Nuclear Magnetic Resonance spectroscopy at Grünenthal



Access to healthcare

S4.MDR-P/S4-1

Access to healthcare policy

Access to healthcare has been newly identified as a material topic for Grünenthal, highlighting its importance in reducing healthcare disparities and improving patients' quality of life specifically in low- and middle-income countries. To address this, we are developing a new Access to Healthcare strategy including a global policy, scheduled for formal launch by the end of 2025. The policy's implementation will be overseen by our Responsibility Team, which ensures the integration of ethical, regulatory and social standards across Grünenthal's operations, driving meaningful and sustainable outcomes. Grünenthal had no dedicated access to healthcare policy during the reporting period.

S4.MDR-A/S4-4

Access to healthcare actions

As part of our operational targets for access to healthcare in 2025, the key actions in this field are currently under development as there are no active ESRS-aligned actions for this topic yet. While Grünenthal has a track record of providing drug donations to patients in need, for example in Venezuela and Ukraine, we are committed to adopting a new strategy and strong governance to maximise the impact in this field. Due to limited data availability, no concrete CapEx and OpEx for action plans are being reported this year.

S4.MDR-M/S4.MDR-T/S4-5

Access to healthcare metrics and targets

In 2025, Grünenthal aims to set a measurable, outcome-oriented target for facilitating access to healthcare. As part of our operational targets for access to healthcare in 2025, we are focused on developing metrics, interim targets and objectives as well as a robust governance.

» Grünenthal Insight

Awareness & accessibility (A&A)

Further targets and progress 2024

Target	Progress 2024	Status
Increase the focus, reach and impact of our global and local activities for awareness and accessibility via external communication	We executed a communications plan to raise awareness and improve accessibility, providing status updates to key internal stakeholders, including the Commercial Leadership Team.	Completed
By having a clear strategy for governance, transparency and accountability, we ensure that our awareness and accessibility initiatives have a lasting impact on patients' lives	We re-evaluated our A&A governance with approval from the Corporate Responsibility Board and updated our A&A strategy to focus on access to healthcare as a key material topic. A new Access to Healthcare strategy, including a global policy, is set for formal launch by the end of 2025.	Completed
Use our global network to collaborate with external partners to identify best leverage opportunities for our unique expertise to have a lasting impact on improving pain management	In 2024, we successfully completed our drug donation programme in Venezuela, providing medications to medical centres supporting pain treatments for palliative care and cancer patients.	Completed

Patient engagement metrics

	Absolute number 2024	Absolute number 2023
Patient programmes ¹	19	13
Collaborations with patient organisations ²	58 ³	72

¹ Our patient programmes help patients either directly or via healthcare professionals by increasing disease awareness and enable them to access the most appropriate treatment possible and attain optimal treatment outcomes.

² The collaborations can be either led by patient organisations and sponsored by Grünenthal or co-created with them with the goal to raise disease awareness or to provide education and support to patients to better manage their condition (for example patient surveys, disease awareness campaigns, tools and materials for patients).

³ Since we scaled back activities for one of our development assets in the second half of the year, the number of collaborations with patient organisations is slightly lower than in 2023.

» Grünenthal Insight

Grünenthal’s patient engagement model

Grünenthal’s patient engagement model fosters collaboration with patients across the product lifecycle. In 2024, a global network of patient engagement champions held regular sessions and workshops, exploring topics such as using AI technology to improve patient information and education. Patient voices were integrated through participation in meetings and events, including Global Quality Day, where 1,500 employees heard firsthand experiences. The PEER intranet platform shared 39 initiatives and led to over 20,000 visits, supporting exchange of good practices. A framework to measure engagement impact was developed with the University of Maastricht, enabling data-driven evaluation via a new dashboard from 2025. This sustained effort underscores our commitment to making patient engagement more visible and actionable across our organisation.



Patient living with diabetic nerve pain describing the relevance of pain for people living with diabetes during Grünenthal’s annual DACH Tagung

Grünenthal’s patient engagement model





Italian team using AI to visualise pain relief

During Pain Awareness Month in September 2024, Grünenthal Italia launched an AI-driven initiative through the Dimensione Sollievo community to visualise patient perspectives on pain relief. Patients were asked to describe what relief looks like and how life might change in a world free of chronic pain. Their responses were transformed into ten AI-generated images using DALL·E 3, blending dreamlike and everyday scenes. The project reached over 24,000 social media followers, fostering dialogue and raising awareness about chronic pain. It highlighted the evolving role of AI in healthcare storytelling and promoted a positive outlook on pain management.

The #KNOWvember campaign in the US raises awareness about diabetic nerve pain

In November 2024, Grünenthal's US subsidiary, Averitas, supported the US Pain Foundation's KNOWvember campaign to raise awareness of Diabetic Peripheral Neuropathy (DPN). The initiative used social media, videos, webinars, and live events to educate patients and healthcare

professionals on prevention, detection, and management. Campaign emails were opened 55,300 times, and the webinar Navigating the Diagnosis and Management of Diabetic Nerve Pain was viewed over 11,000 times. By promoting open dialogue and sharing practical tools, the campaign enhanced public understanding and supported improved care for those living with diabetic nerve pain.

Our Grünenthal Foundations

Grünenthal supports several foundations that share a common mission: to improve access to healthcare and enhance people's quality of life through medical, social, and scientific initiatives.

The Grünenthal Foundation for the support of Thalidomide-affected people enables fast and practical support for individuals affected by Thalidomide. It funds projects that help tangibly improve people's daily lives – for example, by financing the customised adaptation of cars, kitchens, or bathrooms to promote greater independence. In doing so, the Foundation helps close the gap between public pensions and the practical needs of those affected.

The Grünenthal Foundation for Palliative Care, established in 1998, promotes research and care for people living with severe or terminal illnesses, especially in Europe and Latin America. In 2003, it enabled the creation of Germany's first Chair of Palliative Medicine at the University Hospital Aachen, which continues to receive annual funding.

The Fundación Grünenthal in Ecuador aims to improve the quality of life for children, older adults, and low-income communities in the outskirts of Quito and rural regions by supporting medical and social projects.

The Grünenthal Foundation Spain, founded in 2000, promotes societal knowledge, patient training, and public health strategies. In 2024, it released reports on migraine and lower back pain and co-published a patient guide with the Josep Carreras Foundation.

The Grünenthal Foundation Portugal, founded in 2001, supports scientific research in pain management.

Research and development

S4.MDR-P/S4-1
Research and development policy

Key contents of the policy

Our research and development (R&D) framework encompasses three key regulatory pillars:

- Good Clinical Practice (GCP): Ensures ethical conduct during clinical trials and safeguards the welfare of human participants.
- Good Laboratory Practice (GLP): Focuses on rigorous preclinical research, governing non-clinical laboratory testing.
- Good Manufacturing Practice (GMP): Oversees the production processes to maintain the quality and safety of pharmaceutical products.

Grünenthal-specific Standard Operating Procedures (SOP) and project-related Clinical Development Plans further support our commitment to develop innovative medicines. Together, these guidelines ensure that all parties involved in the clinical development process adhere to strict standards, minimising risks and safety issues for patients. They provide the framework that guides our R&D efforts to enhance the development of new medicines using cutting-edge methods, tools and data evaluation. The insights and advancements gained from these efforts help shape the criteria for clinical candidates during research and are subsequently integrated into clinical development plans for relevant programmes. In the reporting year, no significant changes to the R&D framework occurred.

Policy scope and accountability

The key regulatory pillars of our R&D framework, which equally applies to all patients, are international quality standards established by regulatory

authorities such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA) and other international regulatory bodies. The practices they outline are designed to ensure that pharmaceutical products are consistently produced and controlled according to quality standards. Accordingly, there are no exclusions or limitations within the regulatory pillars.

Our Clinical Development Plans outline the transition from exploratory to confirmatory research, detailing objectives, success criteria, studies and milestones across all development stages.

The responsibility for implementing the R&D framework lies with the employees of the organisation, including Project Leads and project teams. The accountability lies with the Head of Research, the Head of Development and the Chief Scientific Officer (CSO) who is a member of Grünenthal's executive committee.

Gillian Burgess, Head of Research, with her team (left to right) Marcel Froehlich, External Innovation Manager and project lead for Digital Biomarkers, Lars von Wedel, Head Advanced Analytics and project lead for Deep Phenotyping, Florian Jakob, Head Drug Discovery Engine and project lead for De Novo Molecule Generation



» Grünenthal Insight

Clinical trials transparency

Grünenthal is committed to responsible clinical trial data sharing to support patient safety, public health, and legitimate scientific research. In line with this, we endorse the transparency principles set out in 2014 by the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the Pharmaceutical Research and Manufacturers of America (PhRMA). Relevant clinical trial information is made publicly available on our corporate website to ensure accessibility and accountability.

Stakeholder considerations and accessibility

Patients remain the primary stakeholders under our R&D framework. To assess efficacy and safety of new drugs, patients are actively recruited into trials throughout the entire clinical development process. Continuous training and education of personnel involved in the performance of clinical studies are essential for maintaining compliance with GMP, GLP and GCP. Patients participating in trials are informed about the nature of the regulations and standards and provide informed consent before enrolment.

S4.MDR-A/S4-4

Research and development actions

Key actions in the field of research and development

The key actions in the field of research and development are part of three subprojects:

1. The De Novo Molecule Generation sub-project focuses on the research and development of Machine Learning tools to design new molecules with the potential to relieve pain. Key actions include:

- Integration of targeted in-house artificial intelligence (AI) methods to design potent and novel molecules, for example to prevent the opening of ion channels that produce a pain signal in pain neurones (ion channel inhibitors).
- Development of Machine Learning models predicting unwanted activity of ion channels contributing to the electrical activity of the heart (hERG activity), to support all research programmes in selecting safer molecules for synthesis with lower cardiovascular risks.

2. The Deep Pain Patients Phenotyping sub-project is dedicated to advancing Machine Learning tools to evaluate big volumes of data in novel ways to identify outcomes for pain patients (deep phenotyping). Key actions include:

- Implement deep learning AI model using neural networks to predict data evolution over time (neural ordinary differential equations (ODE)), enhancing accuracy in complex predictions and confirmation of reproducibility of published results from clinical studies in pain patients.
- Evaluate and optimise the above neural ODE methodology using data from a completed phase I study.

- Apply neural ODEs to gain additional insights into safety and scientific aspects in a phase I study.
- Use neural ODEs to support study design and dose assessment for a phase II study in a rare indication.

3. The Digital Biomarker sub-project explores the potential of measurable characteristics, such as sleep patterns, that indicate biological processes, disease progression, or treatment response, collected via digital devices (digital biomarkers), to supplement patient-reported outcomes. Key actions include:

- Assess whether algorithms from an external project on digital mobility outcomes monitoring the daily gait of people with mobility problems require adaptation for application in pain studies conducted by Grünenthal.
- Analyse mobility and sleep data collected via medical grade wearable devices in an internal clinical study, for example the use of a topical patch for the treatment of neuropathic pain.
- Assess mobility and patients' compliance data from an external project using biometric and biological data for the diagnosis and treatment of pain patients.

Once proposed improvements derived from these sub-projects receive endorsement, we integrate them into the strategy for future programmes by updating Clinical Development Plans and study protocols.

The key actions undertaken by the R&D organisation focus on developing innovative methods, generating data-driven outcomes and implementing advanced tools.

The main scope of developing innovative methods is to accelerate and improve ongoing research projects focusing on several targets involved in pain pathways. The research projects

team can benefit from Machine Learning models to design potent and novel molecules, and predicting unwanted activity to better develop promising new assets in pain.

The main scope of generating data-driven outcomes and implementing advanced tools is to support the clinical development of internal pain assets. The project teams are supposed to benefit from new predictive scientific data and insights into safety to better design the upcoming clinical studies. In addition, they may benefit from the recommendation and implementation of new digital endpoints into clinical studies aiming to assess patients’ activity, mobility and sleep. These new digital endpoints will provide additional and more objective data on the treatment effect of new pain drugs.

Key limitations within these actions can be unexpected outcomes coming with new data, limited budget to perform additional studies, or limited internal capacities.

Timeline and financial resources

The targeted time frame for the completion of these key actions extends until the fourth quarter of 2025.

Budget allocation is guided by an internal prioritisation of projects, ensuring that resources are directed towards initiatives with the highest strategic importance. Due to limited data availability, no concrete CapEx and OpEx for action plans are being reported this year.

Effectiveness tracking and assessment

Project teams, research teams, and the research and development board systematically review and discuss findings and outcomes derived from R&D activities and decide on action points. These discussions, action points and quantitative and qualitative progress are captured in meeting minutes.

S4.MDR-T/S4-5
Research and development targets

In 2025, Grünenthal aims to set a measurable, outcome-oriented target for material impacts related to the topic of Research and development. » Nonetheless, progress in the topic is managed with the following non-ESRS-aligned targets. «

» Further targets and progress 2024

Target	Progress 2024	Status
Reduce cycle time and thus resources required ¹ for new candidate discovery through ML (baseline 2021, 18 months; goal in 2025, 14 months)	Delivered a follow-on candidate molecule for a research target, with Machine-Learning-supported design	On track
Improve ² clinical trial design through ML-based patient phenotyping (baseline 2021, 0 trials; goal in 2025, 2 trials)	Supported trial design for the nociception (NOP) receptor agonist project using Machine Learning. Developed neural ordinary differential equations (ODEs) to support pharmacokinetic/ pharmacodynamic (PK/PD) modelling for internal programmes such as our nociception (NOP) receptor agonist	On track
Improve ³ understanding of treatment effects in clinical studies and post-approval through objective measurement of mobility and sleep (baseline 2021, 1 study; goal in 2025, 2 studies)	Developed strategies for the use of digital biomarkers and ensured their implementation in upcoming clinical studies at Grünenthal	On track

¹ Resource requirements include budget and time.
² Improvements include more objective decisions being made on the basis of outcomes derived from ML-based patient phenotyping.
³ The improvement of patients’ sleep and mobility will be directly measured by the digital wearable and analysed by the clinical team. The aim is to show that new drugs not only improve pain but also quality of life, sleep and mobility. «

The overarching objective of all three subprojects is to enhance Grünenthal’s ability to create innovative medicines for patients in need via data analytics and machine learning. The objective for the first sub-project is to develop better molecules and to more efficiently use Machine Learning approaches. The objective for the second sub-project is to improve disease understanding and clinical trial designs by evaluating data from internal and external databases. The objective for the third sub-project is to improve the understanding of treatment effects of new drugs in Grünenthal’s pipeline by accessing patients’ mobility, activity and sleep data via digital sensors or wearables. » The Head of Research and

the ESG core team members established annual targets and milestone for all three metrics in the field of R&D in 2020, and perform annual reviews and updates. The annual scorecard defines the specific deliverables or milestones to systematically track progress, with all targets set to be achieved by the end of 2025.

For the first target ‘Reduce cycle time and resources required for new candidate discovery through Machine Learning’, we apply various Machine Learning approaches to predict specific properties of molecules, enabling the identification of the most promising molecules for synthesis and further experimental profiling.

For the second target ‘Improve clinical trial design through Machine-Learning-based patient phenotyping’, we leverage different approaches in Machine Learning and analytics to evaluate completed study data to derive novel insights such as patient phenotypes or previously unrecognised disease progression patterns. We expect that such additional insight can enhance the design of future clinical trials, making them more targeted and ultimately benefiting patients in need.

For the third target ‘Improve understanding of treatment effects in clinical studies and post-approval through objective measurement of mobility and sleep’, the team aims to assess patients’ mobility and sleep data collected by digital devices or wearables during clinical studies. Currently, drug efficacy in pain-related clinical trials is primarily assessed by using patient reported outcomes, which are subjective and supervised parameters. In contrast, patients’ data collected via digital wearables such as mobility, activity and sleep provide objective, unsupervised and real-time parameters. The overarching objective of this target is to assess whether the data measured by digital wearables will provide additional evidence of drug effectiveness in patients in future pain clinical studies at Grünenthal.

Although patients were not directly involved in the target setting process, relevant insights into their perspectives and needs were integrated through alternative methods. This included findings from stakeholder dialogues, exchanges with healthcare professionals, and analyses of existing data sources. Among these were interviews with pain specialists and key opinion leaders, analysis of internal and external patient databases, results from previous clinical studies and recommendations from the literature. «

» Grünenthal Insight

Metrics for research and development


Progress on the key actions is tracked using one Grünenthal-specific metric per sub-project:


- **De Novo Molecule Generation sub-project:** Cycle time for new candidate discovery through Machine Learning (ML).
- **Deep Pain Patients Phenotyping sub-project:** Clinical trials using ML-based patient phenotyping.
- **Digital Biomarker sub-project:** Studies using objective measurement of mobility and sleep, directly measuring improvements of patients’ sleep and mobility through a digital wearable.

For the three metrics, the project teams defined metrics and outcomes during the preparation phase, establishing a baseline. In cases where further validation or strategic alignment is necessary, decisions regarding metrics are escalated to the relevant senior manager or board for approval. This escalation is required in cases where the preplanned metrics and goals set up during the preparation phase did not materialise or lead to a different outcome than anticipated.

R&D colleagues at Aachen headquarters







GOVERNANCE

- **Business conduct (ESRS G1)**
 - Managing business conduct
 - Ethical business culture, corruption and bribery
 - Responsible use of AI

G1 – Business conduct

Managing business conduct

Grünenthal has not identified material risks or opportunities related to business conduct for the organisation, however it has identified the following material impacts on governance-related topics:

Type of impact	Impact
Actual positive impact	Ethical business culture
Potentially negative impact	Corruption and bribery
Potentially positive impact	Responsible use of AI

Ethical business culture, corruption and bribery

G1.MDR-P/G1-1/G1-3 Ethical business culture, corruption and bribery policies

Integrity is one of the five core values that define Grünenthal’s culture and shape the behaviour of its employees. We believe in fostering a speak-up culture, where employees feel empowered to identify and report questions, concerns or doubts. Grünenthal also insists that all business partners act lawfully and with integrity. We promote our culture through dedicated people initiatives and by applying our Code of Ethics. To evaluate the effectiveness of our cultural efforts, we rely on insights from the Great Place to Work® (GPTW) survey and review trends and cases reported through our ethics hotline. Grünenthal follows a strong set of policies, targets and measures to manage its material impacts related to ethical business culture, compliance and the prevention of corruption and bribery in particular, and managing relationships with partners. The following sections provide details on these matters and of further relevant processes.

Grünenthal regards legal compliance and ethical business practices as fundamental and self-evident responsibilities. The company therefore implements its comprehensive global and local policies and procedures to ensure compliance and prevent corruption and bribery. These policies align with regulatory requirements, international standards and Grünenthal’s organisational values, ensuring consistent governance across Grünenthal’s own global operations.

Code of Conduct

Our mature compliance management system is accompanied by a clear framework, which is based on a global Code of Conduct that brings together specific policies that outline our high standards for legal, ethical and responsible business conduct. These policies cover topics including anti-corruption, anti-money laundering, data privacy and digital ethics. In addition, our policies provide guidance to facilitate safe pain management through the responsible use of opioids.

The Code of Conduct applies to all employees and all business operations ensuring consistent global adherence to ethical, legal and responsible standards in daily operations.

Global Procurement Policy

Grünenthal’s Global Procurement Policy establishes comprehensive guidelines for the procurement of goods and services. The policy integrates principles of fairness, competition, and confidentiality while ensuring that procurement practices align with the company’s Code of Conduct for Business Partners and Grünenthal’s Statement of Compliance with Human Rights and Environmental Standards. The policy’s framework encompasses three aspects. Firstly, the standard procurement processes cover demand-to-contract, supplier relationship management, and purchase-to-pay procedures. Secondly, they encourage the procurement of goods and services in a manner that upholds ESG principles. And thirdly, special provisions address unique or non-standard procurement scenarios.

The policy was recently updated to incorporate the Responsible Sourcing Programme, further strengthening Grünenthal’s commitment to ethical supply chain practices.

Responsible Sourcing Standards for Business Partners

In 2024, Grünenthal established the Responsible Sourcing Standards for Business Partners to communicate the company’s ESG expectations (requirements and ambition) for their suppliers. These standards outline efforts to increase the company’s supply chain ESG maturity and data transparency. They also support efforts to contribute to the 1.5° C goal of the Paris Climate Agreement, and to meet increasing regulatory requirements (for example the German Supply Chain Act) through close collaboration.

Code of Conduct for Business Partners

The Code of Conduct for Business Partners reflects Grünenthal’s responsibility to operate in full compliance with applicable laws and regulations and with the highest ethical standards beyond its own operations. This responsibility explicitly incorporates international human rights standards and covers forced labour. The document mandates legal compliance, integrity and respect in all business partner interactions, highlights health and safety as a priority, and it provides mechanisms for employees of business partners to report concerns without fear of reprisal. Its application scope extends compliance obligations to the supply chain, requiring sub-suppliers to uphold equivalent standards.

Policies on the prevention of corruption

Grünenthal’s Anti-Corruption Policy serves as a cornerstone for its preventive efforts, providing clear guidance on avoiding corruption in any business interactions. It clarifies acceptable practices for avoiding conflicts of interest. Employees are instructed to avoid granting or receiving any advantage that could improperly influence

business decisions, ensuring all actions are based on legitimate business interests, fair market value and proper documentation. Approval flows and value thresholds are locally defined in collaboration with compliance teams, to safeguard against improperly influencing the business decision of a third party.

The Grünenthal Healthcare Interactions Policy and the Patient Interactions Policy provide guidance for compliant interaction with patients and healthcare professionals. With the Anti-Corruption Policy, the Healthcare Interactions Policy and the Patient Interactions Policy, Grünenthal therefore provides clear guidance, including practical examples, to ensure compliance and prevent improper influence, especially in interactions with healthcare organisations and healthcare professionals.

Key safeguards include rules on gifts, hospitality, sponsorships and donations, complemented by local implementation measures, standard contract templates and a fair market value tool to prevent overcompensation. Comprehensive training, such as Healthcare Interactions Training (HCI Training), along with third-party due diligence, ensure consistent application across all activities.

Ethics Helpline Policy

In accordance with EU and national legislation, Grünenthal provides a confidential platform available for anyone within or outside of Grünenthal to report concerns or breaches of compliance and related topics such as human rights violations or working conditions in the supply chain. The policy protects good-faith reporters and ensures that concerns are addressed promptly and thoroughly by our compliance organisation, or even the Supervisory Board.

Policy implementation and stakeholder engagement

Key policy documents, including the Responsible Sourcing Standards for Business Partners, are publicly available on Grünenthal's corporate



Hannah Engels, Head Global Compliance & Responsibility (middle), with Tobias Schäfers, Head of Responsibility and Pia Weckendorf, Head Internal Audit

website, while others are made available to the relevant stakeholders only, such as the Global Procurement Policy or the Code of Conduct for Business Partners. The latter for example is disseminated to suppliers during the onboarding process before a business relationship is entered into and periodically thereafter ensuring clarity on expectations and responsibilities from the outset of the business relationship. Depending on the associated risk, suppliers are required to sign the document.

Relevant proxies for affected stakeholders were included in the policy process to consider their interests, however no direct involvement of stakeholders took place.

Accountability

The Corporate Executive Board is the most senior level responsible for policy implementation. Leadership teams approve training matrices to ensure employees receive targeted training on relevant policies.

The governance and responsibilities for partner- and procurement-related policies are as follows:

- **Global Procurement Policy:** Head of Global Operations and Head of Global Procurement and External Supply Organisation.
- **Responsible Sourcing Standards for Business Partners:** Head of Global Operations and Head of Global Procurement and External Supply Organisation.
- **Code of Conduct for Business Partners:** Global Compliance & Responsibility Officer.

Alignment with third-party standard

Grünenthal is committed to respecting human rights and complying with environmental standards, in accordance with our corporate values and national law, and international guidelines, conventions and principles. To maintain industry-leading compliance practices, Grünenthal respects and aligns with industry standards (e.g., the European Federation of Pharmaceutical Industries and Associations (EFPIA), the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) regulation and the Principles for Responsible Supply Chain Management from the Pharmaceutical Supply Chain Initiative), but also the Universal Declaration of Human Rights (UDHR) from the United Nations, the Paris Agreement on climate change adopted on 12 December 2015, and the Labour Standards of the International Labour Organisation (ILO) to cover topics related to cooperation with business partners and ensuring human rights along the value chain.

Our commitments are also reflected in our company guidelines, such as our Code of Conduct, Code of Conduct for Business Partners, Global People Policy, Environmental, Health & Safety Policy, Responsible Sourcing Standards for Business Partners, and Enterprise Risk Management Policy.



Sebastian Köhler, General Counsel

Policy accessibility

Grünenthal ensures policies are accessible and understood across the organisation. They are distributed through a read-and-sign system on Grünenthal's policy management platform, MasterControl. All employees are also required to participate in mandatory compliance training courses (for details see sections [☞ 'G1-1 continued'](#) and [☞ 'G1-3 Prevention and detection of corruption and bribery actions'](#)). In addition, key policies, including the Code of Conduct, Code of Conduct for Business Partners, Anti-Corruption Policy, are available on Grünenthal's corporate website to promote transparency with external stakeholders. Regular communication of our Anti-Corruption Framework to employees and leadership reinforces a culture of integrity, ensuring all interactions are ethical, transparent, and compliant with regulatory standards.

All compliance policies and relevant training materials are available in several languages, including English, French, German, Italian, Portuguese and Spanish.

Ethical business culture, corruption and bribery

**G1.MDR-A
Ethical business culture actions**

To uphold its ethical business culture, Grünenthal maintains adherence to applicable compliance standards and aims to continuously strengthen its governance framework. In 2024, we finalised the implementation and embedding of the German Supply Chain Act (GSCA) requirements into our processes. The GSCA imposes significant due diligence obligations on companies in Germany. The Act aims to ensure compliance with human rights and environmental standards related to topics such as child labour, occupational health and emissions of hazardous substances, throughout the supply chain. Grünenthal appointed a Human Rights and Environmental Officer on 1 January 2024, responsible for monitoring the effective implementation of the German Supply Chain Act into the various areas of responsibility within the company.

To comply with the legal requirements as described above (e.g., GSCA) and industry standards, Grünenthal has implemented a **Third-Party Due Diligence (TPDD)** process and **ESG Risk Assessment and Monitoring**.

Third-party due diligence process

This risk-based TPDD system is tailored to address the varying levels of supplier risks depending on the type of product or service, geographical location, and spend. The TPDD framework includes:

- **Due diligence questionnaire:** Potential business partners that meet certain requirements, e.g. turnover thresholds, complete a detailed questionnaire during onboarding, collecting governance, contact, and operational data for risk evaluation. This data is enriched with automated findings from independent sources, e.g. sanction lists, subject to human review.
- **Risk categorisation:** Suppliers are categorised as high, medium, or low risk. High-risk suppliers undergo more stringent due diligence measures, including higher levels of internal approval.
- **Compliance training:** Training sessions and presentations ensure that employees and stakeholders are well-versed in the TPDD process and its compliance requirements.
- **Continuous monitoring and updates:** Grünenthal reviews and updates the TPDD process regularly to ensure alignment with evolving regulatory requirements and emerging risks.

This structured approach enables Grünenthal to maintain robust compliance with standards such as the German Supply Chain Act (GSCA) while addressing ethical and reputational risks proactively.

ESG risk assessment and monitoring

As part of Grünenthal's comprehensive Third-Party Due Diligence process, an ESG risk management system was implemented at the end of

2023 to ensure that relevant risks, including those related to human rights and the environment, can be mitigated. Grünenthal follows a two-step risk assessment process. In the first step, suppliers are assessed based on abstract risks such as the type of business activity and country of location. Based on this assessment, a risk profile is created, and prioritisation is carried out, identifying higher-risk suppliers, known as ESG-sensitive suppliers. In the second step, specific human rights and environmental risks related to these ESG-sensitive suppliers are assessed through an in-depth ESG assessment. This process gathers additional information through questionnaires and requests for certificates to ensure further transparency in the supply chain. Here, medium- and high-risk suppliers are subject to closer oversight. Following the defined governance, an internal review process to define the action plan ensures transparency and accountability. The procurement organisation is responsible for starting the supplier dialogue for the implementation of the preventive/remedial actions and close monitoring is part of Procurement's internal metrics.

Training and capacity building

The ESG risk management system has been rolled out to the Procurement and External Supply Organisation (ESO), with corresponding training material and communication templates provided to ensure effective implementation. The programme includes training on the ESG risk assessment process, roles and responsibilities, and reporting. Awareness sessions on Grünenthal's risk prioritisation and internal exchanges with relevant stakeholders, as well as regular updates on metric performance and progress, have been key for fully understanding the ESG risk management.

Industry collaboration

Grünenthal actively collaborates with other companies through the Pharmaceutical Supply Chain Initiative (PSCI). This partnership promotes shared standards and practices for responsible supply chain management, leveraging collective expertise to address complex ESG challenges, such as initiatives for decarbonisation in the supply chain or API wastewater testing capabilities.

Governance and reporting

Grünenthal has a robust governance structure in place to oversee ESG risk management and promote ESG practices in the supply chain and compliance with the German Supply Chain Act. The German Supply Chain Act Working Group includes a representative each of Human Resources, Environment, Health and Safety, Compliance, Procurement and Responsible Sourcing, and is responsible to approve the risk prioritisation, suppliers' ESG risk status and related measures.

A supply chain sustainability management and collaboration platform supports the in-depth ESG assessment, adverse media monitoring, and progress on preventive and remedial measures communicated to the suppliers identified with higher risk.

As an integral part of the ESG Risk Assessment and Monitoring, the ESG risk management in the supply chain is monitored through regular reporting and defined metrics:


- Percentage of suppliers assessed for ESG risks.
- Response rate: Percentage of suppliers answering the ESG in-depth assessment.
- Number of medium- and high-risk suppliers under close monitoring.

Regular reporting on these metrics ensures ongoing evaluation and shows the progress as well as points for improvement, and therefore improves Grünenthal's practices regarding ESG risk monitoring.

In 2024, Grünenthal conducted its supplier risk assessment on around 50% of the ESG sensitive suppliers, and the remaining 50% is to be assessed in 2025. The company identified about 23% of those suppliers assessed with a medium risk. For these suppliers, Grünenthal has started a supplier dialogue to identify the potential gaps

and eventually create an action plan to achieve Grünenthal ESG standards. All other assessed suppliers were identified with a low ESG risk.

Supplier risk assessment 2024



Other actions in 2024 included an update of the Healthcare Interactions training and a review of contract templates. We are continually developing new training courses for our employees and updating existing ones to meet changing legal requirements.

Due to limited data availability, no concrete CapEx and OpEx for action plans are being reported this year.

G1.MDR-A/G1-3
Prevention and detection of corruption and bribery actions

Grünenthal’s anti-corruption and anti-bribery measures are continually refined to adapt to regulatory changes and emerging risks. The organisation’s Global Compliance Management System (CMS) integrates compliance, business ethics and risk management into a cohesive framework. Regular updates are made to policies, training materials and operational tools, ensuring Grünenthal remains at the forefront of compliance best practices.

The Global Compliance & Responsibility Officer and the compliance team actively monitor these initiatives, providing regular updates to the Corporate Executive Board, Supervisory Board and Advisory Board. This dynamic approach allows Grünenthal to identify areas for improvement and implement changes that strengthen its commitment to ethical conduct.

Detection and reporting mechanisms
In order to identify and report potential incidents of corruption, Grünenthal employs a range of mechanisms that ensure accessibility and confidentiality. Employees are encouraged to report any concerns through several channels as outlined in section [👁️ ‘G1-1 continued’](#) below. This system guarantees confidentiality and reinforces trust among employees and stakeholders.

Compliance audits, led by Internal Audit, form an essential part of Grünenthal’s detection strategy. These audits, conducted on a rotational schedule, assess corruption risks and include site assessments. In 2024, Grünenthal reported that all planned site assessments were completed, with no significant corruption risks identified.

Procedures for addressing incidents
Grünenthal has established comprehensive procedures for investigating and addressing corruption and bribery allegations.

The Compliance Organisation is responsible for conducting investigations into alleged compliance violations. Investigations are conducted neutrally, discreetly, and in strict compliance with labour and data protection laws. Grünenthal’s Compliance Officers play a pivotal role in advising the business on compliance matters and in case of incidents, lead investigations. They are separate from the chain of management involved in the matter by having a solid reporting line to the Global Compliance & Responsibility Officer, therefore ensuring independence. They regularly provide updates to the Local Leadership Teams ensuring transparency and accountability.

Ethics committees meet as needed to decide on appropriate measures to be taken in cases where reported compliance incidents have been investigated, and a violation has been identified. They ensure that decisions are guided by a standardised charter.

Training and awareness
Our comprehensive anti-corruption framework is communicated to all employees and to the Executive and Advisory Board members. Training is an integral component of Grünenthal’s anti-corruption strategy. All employees and the Executive Board Team receive mandatory compliance training tailored to their roles (see section [👁️ ‘G1-1 continued’](#)). Specific target groups, such as employees interacting with healthcare professionals, participate in annual Healthcare Interactions Training (HCI), which covers the implementation of legal and other obligations into Grünenthal’s processes. Topics such as appropriate interactions with healthcare professionals and healthcare organisations, ethical handling of gifts and fair market value compensation of third-party services are addressed in detail. Practical examples and Grünenthal-specific case studies are incorporated into these training sessions to enhance understanding and applicability.

G1.MDR-M/G1.MDR-T/G1-4

Ethical business culture, corruption and bribery, metrics and targets

Ethical business culture, corruption and bribery metrics

To track the effectiveness of its governance measures, Grünenthal tracks and reports the number of confirmed cases of corruption within the organisation during the reporting period as a key indicator of policy effectiveness and adherence to legal, ethical and responsible standards. Corruption cases are captured in the Ethics Help-line tool. Three site assessments were conducted regarding corruption under the annual internal audit plan, identifying no significant corruption risks. Grünenthal found no confirmed cases of corruption in 2024, including among actors across its (local) value chains.

With regard to anti-corruption training, the following metrics are being tracked through the training tool MasterControl:

Third Party Due Diligence metrics

Number of active business partners in the reporting year which have undergone a third-party due diligence assessment and breakdown by risk level ¹
Number of business partners considered a 'no-go' ² in the reporting year as a result of a third-party due diligence process

¹ Referring not to the suppliers' ESG risk sensitivity as mentioned above but instead to their overall business risk.

² Business partners with whom Grünenthal decides not to start a business relationship or stop an existing one due to compliance, ethical or reputational concerns.

The number of active business partners refers to business partners with whom there were financial transactions (payments) in 2024 and 2023 and which underwent a TPDD assessment. The corresponding metric helps to understand if the risk criteria and process is well calibrated.

Anti-corruption training metrics

	2024	2023
Number of employees in the relevant target group ¹ that received anti-corruption training via our comprehensive Code of Conduct, Conflict of Interest and Corporate Responsibility ('CCC') e-learning in the year. ²		
Corporate Responsibility	520	655
Conflict of Interest	524	657
Code of Conduct	519	672
Number and percentage of employees in the relevant target group ³ that received anti-corruption training via our tailored face-to-face (including virtual) training on Healthcare Interactions (HCI) in the year ²	96% (1,339 of 1,392)	97% (1,249 of 1,294)

¹ All new non-production employees and new members of the Corporate Executive Board

² Includes numbers for Grünenthal Meds, excluding Valinor

³ All employees who interact with healthcare professionals, healthcare organisations and/or patients

With regard to TPDD, the following metrics are being tracked through SAP, CRM and ORO:

	2024	2023
Number of active business partners in the reporting year which have undergone a third-party due diligence assessment and breakdown by risk level ¹	Total assessments: 3,941 With the following breakdown: Low risk: 3,249 (82.4%) Medium risk: 675 (17.1%) High risk: 17 (0.4%)	Total assessments: 5,405 With the following breakdown: Low risk: 4,207 (78.8%) Medium risk: 1,165 (21.6%) High risk: 33 (0.6%)
Number of business partners considered a 'no-go' ² in the reporting year as a result of a third-party due diligence process	1	2

The second metric on 'no-gos' helps to understand if the process works effectively and prevents Grünenthal from starting business relationships that can negatively impact our reputation.

The TPDD metrics are assessing compliance, ethical and reputational risks arising from business relationships across our organisation. The ESG risk assessment and monitoring assesses risks specifically related to human rights and the environment in our supplier relationships.

Ethical business culture, corruption and bribery targets

In 2025, Grünenthal aims to set a measurable, outcome-oriented target for the two material impacts of ethical business culture and corruption and bribery. » Nonetheless, progress in the topic is managed with the non-ESRS-aligned targets below.

The existing target focuses on qualitative improvements to the Compliance & Ethics Framework, rather than quantitative measures. It applies to Grünenthal’s own activities, as well as its upstream (supply chain) and downstream (distribution and sales) value chain. It is directly linked to Grünenthal’s policies, which operationalise the organisation’s strategy and management decisions related to business conduct. Each policy aims to reinforce and evolve the framework over time. «

Supplier-related targets concern climate aspects in particular and are described in more detail in chapter «E1 Climate change».

» Further target and progress 2024

Target ¹	Progress 2024	Status
Continuous development of its state-of-the-art Compliance & Ethics Framework to ensure alignment with business conduct policies, regulatory requirements and stakeholder expectations	Expansion of the training portfolio to address emerging topics, including digital ethics and ESG-related issues	On track

¹ Target maintained from previous Responsibility Report; will be reviewed in 2025. «

G1-1 – continued

Mechanisms for reporting and investigating concerns

Grünenthal provides several accessible channels for employees and external stakeholders, such as business partners and local communities, to report concerns and unethical behaviour, including any behaviour inconsistent with the Code of Conduct, compliance policies or local laws. Reports can be made directly to managers, HR, the Legal department, the works council or the Compliance Organisation. Additionally, and in conformity with the requirements for anonymous

» Grünenthal Insight



Introducing our Human Rights Officer

The enforcement of the Supply Chain Act in Germany marks a significant milestone in upholding human rights and environmental protection standards within global supply chains. Under the act, Grünenthal is required to identify, prevent, and mitigate human rights and environmental risks throughout its global operations.

Hannah Engels, Global Compliance & Responsibility Officer at Grünenthal since the beginning of 2024, also serves as the company’s Human Rights Officer – a role mandated by the German Supply Chain Act. In this capacity, she monitors compliance with the Act across the organisation. However, ensuring compliance is a shared responsibility that requires collaboration across all Grünenthal sites, and functions in Germany and worldwide. Our collective efforts in this regard are outlined in our Responsibility Framework, which reflects Grünenthal’s ongoing commitment to the highest ethical standards, human rights, and environmental protection – in pursuit of our vision for a World Free of Pain.

concerns on Grünenthal’s corporate website, in contracts and in Grünenthal’s Code of Conduct for Business Partners. This system operates 24/7 in seven languages, ensuring accessibility and confidentiality. Importantly, IP addresses are not traced, and reports can be submitted in the reporter’s native language. Grünenthal’s Code of Conduct underscores the importance of open and transparent reporting while guaranteeing full confidentiality for those who choose to raise concerns.

The effectiveness of grievance mechanisms is continuously monitored. Reports submitted via the Ethics Helpline are reviewed by the Compliance Team or the Chairman of the Supervisory Board in case a member of the Compliance & Responsibility organisation is accused, with remedial actions initiated as necessary. Grünenthal’s Human Rights Officer oversees the assessment of processes where human rights or environmental issues are affected. Grünenthal is conducting risk-based reviews and audits to

ensure alignment with best practices. Outcomes and trends are then reported to the Corporate Executive Board and Supervisory Board.

Reported incidents will be investigated discreetly and neutrally by the Compliance Organisation following a plausibility check and in accordance with applicable data protection laws. The organisation employs a tiered decision-making structure to ensure appropriate oversight. Local and Regional Ethics Committees handle compliance incidents within their jurisdiction, while the Global Ethics Committee addresses cases with significant implications, such as systemic violations or incidents involving senior management.

Investigative processes follow a standardised charter to maintain consistency. Depending on the nature of the reported allegation, departments such as HR or Internal Audit may be involved. If the allegation refers to a potential substantial violation of human rights and/or environmental protection obligations, the Human Rights Officer will directly undertake the investigation. All investigations adhere to the principles of fairness, transparency and the presumption of innocence, allowing individuals involved to present their perspectives.

Safeguards for reporting irregularities and prevention of misconduct

Grünenthal ensures a safe environment for employees and stakeholders to report irregularities. Retaliation against those who report concerns in good faith is strictly prohibited and treated as a compliance violation. The organisation has committed to protecting whistleblowers' confidentiality, and individuals making malicious or false reports are held accountable.

Grünenthal employs a range of preventive efforts to mitigate risks and promote ethical practices. Key policies include the Anti-Corruption Policy, which provides detailed guidance on interactions with public officials, gifts, and the Healthcare Interactions Policy, which governs engagements with healthcare professionals. Where applicable, our policies are supported by tools such as fair

market value calculators, system-based approval workflows, and global/local contract templates to prevent misconduct and ensure consistency. To make sure these measures are effective, Grünenthal conducts regular anti-corruption site assessments as part of its annual audit plan, typically carrying out two local Compliance Audits and two local Business Activities Audits each year, with audit locations selected based on a risk-based assessment of local entities. These assessments are complemented by audits that evaluate adherence to policies and identify potential risks.

Training and awareness initiatives

Training is central to Grünenthal's Compliance Management System. All new employees are automatically enrolled in e-learning called 'CCC Training', with dedicated modules on 'Corporate Responsibility', 'Conflict of Interest', and 'Code of Conduct', and received via our training system MasterControl, and our Compliance Framework (Code of Conduct including main Compliance Policies). Additionally, each year the Corporate Executive Board as well as regional/local Leadership Teams approve a training matrix that includes target-group-specific and locally relevant courses on topics such as data privacy, healthcare interactions and business partner compliance. Employees in roles with high risk of corruption and bribery, such as sales functions, receive multiple tailored face-to-face training courses annually, while all staff participate in e-learning modules on key compliance areas. To ensure adequate accessibility for all, compliance policies and relevant training materials are available in seven different languages.

Continuous improvement and monitoring

Grünenthal actively monitors its compliance systems to ensure their effectiveness. Internal Audit conducts regular compliance audits, and findings are reported to the Corporate Executive Board and Advisory Board. This reporting structure ensures that leadership remains informed and can get actively involved in strategic compliance decisions. Additionally, GPTW survey results and external ESG ratings provide valuable insights to refine Grünenthal's compliance framework further.

Responsible use of AI

G1.MDR-P Responsible use of AI policies

As part of its digitalisation journey, Grünenthal is dedicated to responsibly developing and deploying digital technologies, including artificial intelligence (AI) systems, in compliance with all applicable laws and its digital ethics framework. The responsible use of AI fosters our company culture by enhancing productivity, promoting innovation and supporting employee wellbeing in a transparent and ethical manner. In light of the EU AI Act, which came into effect in mid-2024, Grünenthal is implementing a comprehensive AI Governance Framework which includes a dedicated policy to govern the responsible use of AI systems by its employees and third parties acting on its behalf.

Scope and approval of the AI Policy

The EU AI Act provides companies with a two-year adaptation period, during which Grünenthal is assessing its AI use-cases and is developing a framework for compliance. As such, a formal Policy on the Use of AI Systems will be finalised and rolled out in 2025.

The forthcoming AI Policy will regulate the responsible use of AI systems as defined by the EU AI Act, including those developed or deployed by Grünenthal and by third parties acting on its behalf.

Collaborative policy development process

Grünenthal has established a network of AI Ambassadors, each representing a functional area, to support the policy development process. These ambassadors, will provide input based on their respective domains to ensure the policy's relevance and comprehensiveness. This collaborative approach fosters internal alignment and ensures that the policy reflects Grünenthal's operational and ethical priorities.



Susanne Bransgrove, Responsibility Manager, with Pablo Sastre Puche, Head of Data Privacy & AI Governance

Implementation and communication

Once finalised, the AI Policy will be published on Grünenthal’s intranet and distributed to all employees through the company’s policy management platform, MasterControl. Specially tailored AI literacy training will be provided for specific target audiences, such as those more likely to encounter high-risk use-cases, including Human Resources related use-cases, to facilitate understanding and compliance.

G1.MDR-A Responsible use of AI actions

Grünenthal is committed to ensuring the responsible and ethical use of AI systems through the implementation of a robust AI Governance Framework. This framework will align with regulatory requirements, including the EU AI Act and Grünenthal’s Digital Ethics Charter, to ensure that

every AI use-case delivers a net positive impact. It also facilitates the transparent and sustainable use of AI technologies. This framework aims to use the benefits of AI systems, including improved decision-making, enhanced healthcare, scientific discovery, and increased efficiency and productivity, while implementing safeguards against potential costs to human rights, such as the right to health, privacy, employment and information security. To further strengthen AI governance, Grünenthal has established a community of AI ambassadors representing functional areas to drive AI literacy and governance across the organisation, and promotes AI literacy among employees through guidance and training materials. Additionally, the company conducts evaluations of high-risk AI use-cases and integrates contract clauses to ensure ethical AI use by third parties.

Development of the AI Governance Framework

Grünenthal’s AI Governance Framework, which is set to be fully operational by the end of 2025, is designed to manage the ethical, regulatory and operational risks associated with AI systems. The framework includes the following components:

- **AI Policy:** Establishing principles and guidelines for the use of AI systems.
- **AI ambassadors:** A network of designated ambassadors representing functional areas to drive AI literacy and governance across the organisation.
- **AI contract clauses:** Specific contractual obligations for third parties to ensure compliance with AI governance standards.
- **Risk assessments:** Evaluation and management of AI-related risks for human rights.
- **AI literacy:** Guidance and training materials to enhance employees’ understanding and responsible use of AI systems.

The foundational elements of the framework were established in 2024, including the designation of AI ambassadors, drafting of contract clauses and development of the impact assessment methodology. Additionally, the framework’s fundamentals were shared with Grünenthal’s leadership teams, ensuring organisational alignment.

Progress and actions to be completed

By the end of 2025, Grünenthal plans to complete key actions as part of the AI Governance Framework, including conducting a legal assessment on the applicability of the EU AI Act to Grünenthal activities, identifying and evaluating any high-risk AI use-cases, developing AI literacy and further integrating the framework into the company’s operational processes.

These measures aim to align Grünenthal’s AI practices with global regulations and ethical principles, promoting accountability and transparency in all AI-related activities.

Collaboration with external experts

Grünenthal has engaged external expertise for strategic and operational support as well as legal consultation to support the development and implementation of the AI Governance Framework. All other activities have been carried out with internal resources, which will be strengthened further, reflecting Grünenthal's commitment to efficient and sustainable governance practices.

Scope and applicability

The AI Governance Framework applies to all AI systems and use-cases within Grünenthal's operations, third-party AI use-cases undertaken on Grünenthal's behalf, as well as all activities to ensure compliance with regulatory frameworks such as the EU AI Act and Grünenthal's internal Digital Ethics Charter.

Financial resources

Due to limited data availability, no concrete CapEx and OpEx for action plans are being reported this year.

G1.MDR-T/G1.MDR-M Responsible use of AI targets and metrics

A measurable target and supporting metrics will be developed to ensure ongoing monitoring, evaluation and management of Grünenthal's responsible AI practices. Grünenthal will follow the criteria and risk categorisation system of the EU AI Act. The EU AI Act classifies AI systems into four risk categories: unacceptable risk (prohibited), high risk (strictly regulated), limited risk (subject to transparency obligations), and minimal risk (unregulated). This system will ensure that regulations are proportionate to the potential harm posed by different AI applications. In addition, it has designed its own methodology to perform Fundamental Rights Impact Assessments, which will be used to report on risk levels and mitigating actions. It shall focus on AI use-cases with the risk of significant impact on certain human rights, such as the right to health, the right to privacy and the right to employment and fair treatment. » Currently, progress in the topic is managed with the non-ESRS-aligned targets below. «

» Further targets and progress 2024

Target	Progress 2024	Status
Establish an AI Governance Frameworks to ensure ethical and responsible use of artificial intelligence, by providing guidelines for managing risks and addressing impact, fostering trust in AI systems	Defined the core principles of Grünenthal's AI Governance Framework in 2024: - Published global guidance on the responsible and ethical application of Generative and General-Purpose AI systems. - Formulated Impact Assessment Methodology. - Created a network of AI ambassadors. - Drafted and rolled-out AI contract-clauses with vendors.	On track
Further enhance the measurability of digital ethics initiatives	We further enhanced the measurability and will integrate respective metrics in our AI governance framework in 2025.	On track
Collaborate with external researchers to create additional digital ethics guidance	Grünenthal has engaged external expertise for strategic and operational support as well as legal consultation to support the development and implementation of the AI Governance Framework. In 2025, further digital ethics guidance will be produced in the context of the AI Governance Framework.	On track

» Grünenthal Insight

Grünenthal's political influence and lobbying activities

Grünenthal demonstrates transparency and accountability in its approach to political influence and lobbying. These activities are governed by clear oversight to ensure ethical conduct and regulatory compliance. Responsibility for Corporate Public Affairs lies with the Head of Global Corporate Affairs and Communication, who reports directly to the CEO and ensures alignment with the company's strategic and ethical standards.

The company focuses on general representation and engages in limited lobbying on specific legislative topics. This ensures that political and public affairs activities remain broad in scope. Grünenthal is registered in the German Lobbyregister, providing public transparency on its lobbying activities and reinforcing its commitment to compliance and stakeholder trust.

No members of Grünenthal's administrative, management, or supervisory bodies have held equivalent public administration roles within two years of their appointment, safeguarding independence and avoiding potential conflicts of interest. In line with legal requirements, Grünenthal is a member of the Chamber of Commerce (IHK) in Germany and participates in pharmaceutical industry associations in several countries, supporting constructive industry dialogue.

» Grünenthal Insight

United Nations Global Compact

As a United Nations Global Compact (UNGC) participant, we formally commit to the values of the world’s largest initiative for responsible corporate governance. We are committed to the ten universal UNGC principles on human rights, labour standards, environment and climate, and corruption prevention. To firmly embed these principles into our global operations, we have established binding frameworks and policies that apply to all employees worldwide.

Grünenthal submits an annual progress report outlining the steps taken to uphold and advance the principles of the UNGC. This Responsibility Report serves as the progress report of how the ten principles are integrated into our business strategies and operational practices.



UN Global Compact Principle	Section
Human Rights	
Principle 1: Businesses should support and respect the protection of internationally proclaimed human rights; and	S1.SBM-3, S1-17, G1-1
Principle 2: make sure that they are not complicit in human rights abuses.	S1.SBM-3, S1-17, G1-1
Labour	
Principle 3: Businesses should uphold the freedom of association and the effective recognition of the right to collective bargaining;	S1-8
Principle 4: the elimination of all forms of forced and compulsory labour;	S1.SBM-3, G1-1
Principle 5: the effective abolition of child labour; and	S1.SBM-3, G1-1
Principle 6: the elimination of discrimination in respect of employment and occupation.	S1-1, S1.SBM-3, S1-17
Environment	
Principle 7: Businesses should support a precautionary approach to environmental challenges;	E1.SBM-3
Principle 8: undertake initiatives to promote greater environmental responsibility; and	E1-3, E2-2
Anti-Corruption	
Principle 9: encourage the development and diffusion of environmentally friendly technologies.	G1-1
Principle 10: Businesses should work against corruption in all its forms, including extortion and bribery.	G1-3

Grünenthal's contribution to the United Nations SDGs

In 2015, the United Nations adopted Sustainable Development Goals (SDGs) as a blueprint to achieve a better and more sustainable future for all. The SDGs are a call to action to end poverty and inequality, protect the planet, and ensure that all people enjoy health, justice and prosperity. As a leading pharmaceutical company, we are committed to supporting the SDGs in line with our business strategy. We particularly contribute to SDG 3, which aims at ensuring healthy lives and promoting wellbeing for all.



SDG 3: Good Health and Wellbeing

Pain is a huge burden for patients, their families and society as a whole. As a leader in pain management, we focus our activities on topics such as patient safety, product quality, improving patients' quality of life through innovative medicines, promoting the responsible use of opioids, and improving access to healthcare.

Through our business operations and ongoing activities, we also make essential contributions to the following SDGs:



SDG 8: Decent Work and Economic Growth

People thrive in a healthy environment. For this reason, we take action to care for the wellbeing of everyone who works at Grünenthal. We aim to generate sustainable value in crucial areas such as workplace safety and health protection, fair working

conditions, training and development and the merit-based promotion of diversity, inclusion and equal opportunities. We are certified as a Great Place to Work® in 20 countries.



SDG 9: Industry, Innovation and Infrastructure

We need solutions that address huge unmet needs in pain management. This is why a large part of our revenue is reinvested into R&D each year. Our portfolio encompasses more than 1,000 granted patents. We leverage modern technologies to improve outcomes for patients. For example, we are using Machine Learning based on anonymised human data to increase understanding of disease and improve the design of clinical trials. Through our funding programmes such as the EFIC-Grünenthal-Grant and the Brain, Mind and Pain Patient-Centred Innovation Grant, we support scientists in carrying out innovative clinical pain research.



SDG 12: Responsible Consumption and Production


We optimise resource use, minimise waste and integrate sustainability into procurement and operations. We invest in safe, energy-efficient technologies and engage suppliers who uphold high environmental and ethical standards. Responsible resource use is central to Grünenthal's environmental strategy and essential to reducing pollution and promoting sustainability across our value chain.



SDG 13: Climate Action

We focus on reducing emissions from production-related processes and minimising pollution across our operations and the supply chain. In line with the Science Based Targets initiative, we are setting near-term targets to cut Scope 1 and 2 emissions, while deepening collaboration with suppliers to improve sustainability throughout our Scope 3 footprint.





ESRS INDEX

- Disclosure Requirements in ESRS covered by the undertaking's sustainability statement (IRO-2)

ESRS Index

General disclosures

ESRS 2 – General disclosures

Disclosure Requirement	Page in the report
BP-1 General basis for preparation of sustainability statements	6
BP-2 Disclosures in relation to specific circumstances	6
GOV-1 The role of the administrative and supervisory bodies	8
GOV-2 Information provided to and sustainability matters addressed by the undertaking's administrative, management and supervisory bodies	10
GOV-3 Integration of sustainability-related performance in incentive schemes	11
GOV-4 Statement on due diligence	12
GOV-5 Risk management and internal controls over sustainability reporting	12
SBM-1 Strategy, business model and value chain	14
SBM-2 Interests and views of stakeholders	19
SBM-3 Material impacts, risks and opportunities and their interaction with strategy and business model	23
IRO-1 Description of the processes to identify and assess material impacts, risks and opportunities	24
E1.IRO-1 Description of the processes to identify and assess material climate-related impacts, risks and opportunities	25
E2.IRO-1 Description of the processes to identify and assess material pollution-related impacts, risks and opportunities	25
G1.IRO-1 Description of the processes to identify and assess business-conduct-related impacts, risks and opportunities	25
IRO-2 Disclosure requirements in ESRS covered by the undertaking's sustainability statement	25


Environment

E1 – Climate change

Disclosure Requirement	Page in the report
E1-1 Transition plan for climate change mitigation	28
E1-2 Policies related to climate change mitigation and adaptation	29
E1-3 Actions and resources in relation to climate change policies	30
E1-4 Targets related to climate change mitigation and adaptation	33
E1-5 Energy consumption and mix	34
E1-6 Gross Scopes 1, 2, and 3 and Total GHG emissions	36

E2 – Environmental polution (land, water, air) including the supply chain

Disclosure Requirement	Page in the report
E2-1 Policies related to pollution	42
E2-2 Actions and resources related to pollution	43
E2-3 Targets related to pollution	44
E2-4 Pollution of lair water and soil	44



Social

S1 – Own workforce

Disclosure Requirement	Page in the report
S1-1 Policies related to own workforce	56, 60, 64, 67
S1-2 Processes for engaging with own workforce and workers' representatives about impacts	52, 64
S1-3 Processes to remediate negative impacts and channels for own workforce to raise concerns	52, 64
S1-4 Taking action on material impacts on own workforce, and approaches to mitigating material risks and pursuing material opportunities related to own workforce, and effectiveness of those actions	57, 61, 65, 69
S1-5 Targets related to managing material negative impacts, advancing positive impacts, and managing material risks and opportunities	57, 63, 66, 70
S1-6 Characteristics of the undertaking's employees	53
S1-8 Collective bargaining coverage and social fatigue	58
S1-9 Diversity metrics	70
S1-10 Adequate wages	60
S1-14 Health and safety metrics	62
S1-17 Incidents, complaints and severe human rights impacts	54

S4 – Patient

Disclosure Requirement	Page in the report
S4-1 Policies related to consumers and end-users	78, 82, 85, 93, 96
S4-2 Processes for engaging with consumers and end-users about impacts	77
S4-3 Processes to remediate negative impacts and channels for consumers and end-users to raise concerns	77
S4-4 Taking action on material impacts on consumers and end-users, and approaches to managing material risks and pursuing material opportunities related to consumers and end-users, and effectiveness of those actions	78, 83, 86, 93, 97
S4-5 Targets related to managing material negative impacts, advancing positive impacts, and managing material risks and opportunities	79, 84, 88, 93, 96

Governance

G1 – Business conduct

Disclosure Requirement	Page in the report
G1-1 Corporate culture and business conduct policies and corporate culture	102, 108
G1-3 Prevention and detection of corruption and bribery	102, 106
G1-4 Confirmed incidents of corruption and bribery	107



List of datapoints in cross-cutting and topical standards that derive from other EU legislation

The table below illustrates the datapoints in ESRS 2 and topical ESRS that derive from other EU legislation as listed in ESRS 2 Annex B and indicates where the data points can be found in this sustainability statement and which data points are categorised as ‘not material’.

Disclosure Requirement and related datapoint	SFDR reference	Pillar 3 reference	Benchmark Regulation reference	EU Climate Law reference	Page in the report
ESRS 2 GOV-1 Board's gender diversity paragraph 21 (d)	x		x		8
ESRS 2 GOV-1 Percentage of board members who are independent paragraph 21 (e)			x		8
ESRS 2 GOV-4 Statement on due diligence paragraph 30	x				12
ESRS 2 SBM-1 Involvement in activities related to fossil fuel activities paragraph 40 (d) i	x	x	x		Not relevant
ESRS 2 SBM-1 Involvement in activities related to chemical production paragraph 40 (d) ii	x		x		14 ff.
ESRS 2 SBM-1 Involvement in activities related to controversial weapons paragraph 40 (d) iii	x		x		Not relevant
ESRS 2 SBM-1 Involvement in activities related to cultivation and production of tobacco paragraph 40 (d) iv			x		Not relevant
ESRS E1-1 Transition plan to reach climate neutrality by 2050 paragraph 14				x	28
ESRS E1-1 Undertakings excluded from Paris-aligned Benchmarks paragraph 16 (g)		x	x		29
ESRS E1-4 GHG emission reduction targets paragraph 34	x	x	x		33 f.
ESRS E1-5 Energy consumption from fossil sources disaggregated by sources (only high climate impact sectors) paragraph 38	x				36

Disclosure Requirement and related datapoint	SFDR reference	Pillar 3 reference	Benchmark Regulation reference	EU Climate Law reference	Page in the report
ESRS E1-5 Energy consumption and mix paragraph 37	x				36
ESRS E1-5 Energy intensity associated with activities in high climate impact sectors paragraphs 40 to 43	x				36
ESRS E1-6 Gross Scope 1, 2, 3 and Total GHG emissions paragraph 44	x	x	x		38
ESRS E1-6 Gross GHG emissions intensity paragraphs 53 to 55	x	x	x		38
ESRS E1-7 GHG removals and carbon credits paragraph 56				x	Not relevant
ESRS E1-9 Exposure of the benchmark portfolio to climate-related physical risks paragraph 66			x		Not relevant
ESRS E1-9 Disaggregation of monetary amounts by acute and chronic physical risk paragraph 66 (a)					
ESRS E1-9 Location of significant assets at material physical risk paragraph 66 (c).		x			Phase-in
ESRS E1-9 Breakdown of the carrying value of its real estate assets by energy-efficiency classes paragraph 67 (c).		x			Phase-in
ESRS E1-9 Degree of exposure of the portfolio to climate-related opportunities paragraph 69			x		Phase-in
ESRS E2-4 Amount of each pollutant listed in Annex II of the E-PRTR Regulation (European Pollutant Release and Transfer Register) emitted to air, water and soil, paragraph 28	x				45
ESRS E3-1 Water and marine resources paragraph 9	x				Not material
ESRS E3-1 Dedicated policy paragraph 13	x				Not material
ESRS E3-1 Sustainable oceans and seas paragraph 14	x				Not material

Disclosure Requirement and related datapoint	SFDR reference	Pillar 3 reference	Benchmark Regulation reference	EU Climate Law reference	Page in the report
ESRS E3-4 Total water recycled and reused paragraph 28 (c)	x				Not material
ESRS E3-4 Total water consumption in m ³ per net revenue on own operations paragraph 29	x				Not material
ESRS 2- IRO 1 - E4 paragraph 16 (a) i	x				Not material
ESRS 2- IRO 1 - E4 paragraph 16 (b)	x				Not material
ESRS 2- IRO 1 - E4 paragraph 16 (c)	x				Not material
ESRS E4-2 Sustainable land/agriculture practices or policies paragraph 24 (b)	x				Not material
ESRS E4-2 Sustainable oceans/seas practices or policies paragraph 24 (c)	x				Not material
ESRS E4-2 Policies to address deforestation paragraph 24 (d)	x				Not material
ESRS E5-5 Non-recycled waste paragraph 37 (d)	x				Not material
ESRS E5-5 Hazardous waste and radioactive waste paragraph 39	x				Not material
ESRS 2- SBM3 - S1 Risk of incidents of forced labour paragraph 14 (f)	x				51
ESRS 2- SBM3 - S1 Risk of incidents of child labour paragraph 14 (g)	x				51
ESRS S1-1 Human rights policy commitments paragraph 20	x				51, 54
ESRS S1-1 Due diligence policies on issues addressed by the fundamental International Labor Organisation Conventions 1 to 8, paragraph 21			x		56
ESRS S1-1 processes and measures for preventing trafficking in human beings paragraph 22	x				56
ESRS S1-1 workplace accident prevention policy or management system paragraph 23	x				56, 60

List of datapoints in cross-cutting and topical standards that derive from other EU legislation

Disclosure Requirement and related datapoint	SFDR reference	Pillar 3 reference	Benchmark Regulation reference	EU Climate Law reference	Page in the report
ESRS S1-3 grievance/complaints handling mechanisms paragraph 32 (c)	x				64
ESRS S1-14 Number of fatalities and number and rate of work-related accidents paragraph 88 (b) and (c)	x		x		62
ESRS S1-14 Number of days lost to injuries, accidents, fatalities or illness paragraph 88 (e)	x				62
ESRS S1-16 Unadjusted gender pay gap paragraph 97 (a)	x		x		Only pilot findings on the gender pay gap are available, with no consolidated Group-level data yet in place.
ESRS S1-16 Excessive CEO pay ratio paragraph 97 (b)	x				No consolidated Group-level data yet in place.
ESRS S1-17 Incidents of discrimination paragraph 103 (a)	x				54
ESRS S1-17 Non-respect of UNGPs on Business and Human Rights and OECD paragraph 104 (a)	x		x		55
ESRS 2- SBM3 – S2 Significant risk of child labour or forced labour in the value chain paragraph 11 (b)	x				Not material
ESRS S2-1 Human rights policy commitments paragraph 17	x				Not material
ESRS S2-1 Policies related to value chain workers paragraph 18	x				Not material
ESRS S2-1 Non-respect of UNGPs on Business and Human Rights principles and OECD guidelines paragraph 19	x		x		Not material
ESRS S2-1 Due diligence policies on issues addressed by the fundamental International Labor Organisation Conventions 1 to 8 paragraph 19			x		Not material

Disclosure Requirement and related datapoint	SFDR reference	Pillar 3 reference	Benchmark Regulation reference	EU Climate Law reference	Page in the report
ESRS S2-4 Human rights issues and incidents connected to its upstream and downstream value chain paragraph 36	x				Not material
ESRS S3-1 Human rights policy commitments paragraph 16	x				Not material
ESRS S3-1 non-respect of UNGPs on Business and Human Rights, ILO principles or and OECD guidelines paragraph 17	x		x		Not material
ESRS S3-4 Human rights issues and incidents paragraph 36	x				Not material
ESRS S4-1 Policies related to consumers and end-users paragraph 16	x				78, 82, 85, 93, 96
ESRS S4-1 Non-respect of UNGPs on Business and Human Rights and OECD guidelines paragraph 17	x		x		78
ESRS S4-4 Human rights issues and incidents paragraph 35	x				Not relevant
ESRS G1-1 United Nations Convention against Corruption paragraph 10 (b)	x				102
ESRS G1-1 Protection of whistle- blowers paragraph 10 (d)	x				109
ESRS G1-4 Fines for violation of anti-corruption and anti-bribery laws paragraph 24 (a)	x		x		107
ESRS G1-4 Standards of anti-corruption and anti-bribery paragraph 24 (b)	x				102, 107

we are patient-centric
we live entrepreneurship
we join forces
we act with integrity
we drive performance

We are
Grünenthal
Values & Behaviours

Assurance Report

of the independent Practitioner on a Limited Assurance Engagement in Relation to the Consolidated Responsibility Report

To Grünenthal Pharma GmbH & Co. Kommanditgesellschaft, Aachen/Germany

Assurance Conclusion

We have conducted a limited assurance engagement on the Consolidated Responsibility Report of Grünenthal Pharma GmbH & Co. Kommanditgesellschaft, Aachen/Germany, for the financial year from 1 January to 31 December 2024 (hereafter referred to as ‘the Responsibility Report’). The Responsibility Report was prepared to fulfil the requirements described in section ‘BP-1 General basis for preparation of sustainability statements in Chapter ‘ESRS 2 – General Disclosures’ as basis for preparation of the Responsibility Report (hereafter referred to as ‘specifying criteria’).

The parts of the Responsibility Report marked either by a grey background or by French quotation marks (»...«) are not subject to our assurance engagement.

Based on the procedures performed and the evidence obtained, nothing has come to our attention that causes us to believe that the Responsibility Report is not prepared, in all material respects, in accordance with the requirements of the specifying criteria presented by the executive directors of the Company.

We do not express an assurance conclusion on the parts of the Responsibility Report marked as unassured.

Basis for the Assurance Conclusion

We conducted our assurance engagement in accordance with the International Standard on Assurance Engagements (ISAE) 3000 (Revised): ‘Assurance Engagements Other Than Audits or Reviews of Historical Financial Information’, issued by the International Auditing and Assurance Standards Board (IAASB).

The procedures performed in a limited assurance engagement vary in nature and timing from, and are less in extent than for, a reasonable assurance engagement. Consequently, the level of assurance obtained is substantially lower than the assurance that would have been obtained had a reasonable assurance engagement been performed.

Our responsibilities under ISAE 3000 (Revised) are further described in section ‘Independent Practitioner’s Responsibilities for the Assurance Engagement on the Responsibility Report’.

We are independent of the entity in accordance with the requirements of European law and German commercial and professional law, and we have fulfilled our other German professional responsibilities in accordance with these requirements. Our audit firm has applied the requirements of the IDW Quality Management Standards. We believe that the evidence we have obtained is sufficient and appropriate to provide a basis for our assurance conclusion.

Emphasis of Matter – Basis for Preparation of the Responsibility Report

Without modifying our conclusion, we draw attention to the details provided in the Responsibility Report, which describe the basis for preparation of the Responsibility Report. According to these principles, the Company has applied the European Sustainability Reporting Standards (ESRS) to the extent described in section ‘BP-1 General basis for preparation of sustainability statements’ in chapter ‘ESRS 2 – General Disclosures’ of the Responsibility Report.

Responsibilities of the Executive Directors for the Responsibility Report

The executive directors are responsible for the preparation of the Responsibility Report in accordance with the specifying criteria presented by the executive directors of the Company and for designing, implementing and maintaining such internal control as they have considered necessary to enable the preparation of a Responsibility Report in accordance with these requirements that is free from material misstatement, whether due to fraud (i.e. fraudulent reporting in the Responsibility Report) or error.

This responsibility of the executive directors includes establishing and maintaining the materiality assessment process, selecting and applying appropriate reporting policies for preparing the Responsibility Report as well as making assumptions and estimates and ascertaining forward-looking information for individual sustainability-related disclosures.

The Executive Directors are responsible for overseeing the process for the preparation of the Responsibility Report.

Inherent Limitations in Preparing the Responsibility Report

The specifying criteria contain wording and terms that are subject to considerable interpretation uncertainties and for which no authoritative comprehensive interpretations have yet been published. The executive directors have disclosed interpretations of such wording and terms in the Responsibility Report. The executive directors are responsible for the reasonableness of these interpretations. As such wording and terms may be interpreted differently by regulators or courts, the legality of measurements or evaluations of the sustainability matters based on these interpretations is uncertain. The quantification of non-financial performance indicators disclosed in the Responsibility Report is also subject to inherent uncertainties.

These inherent limitations also affect the assurance engagement on the Responsibility Report.

Independent Practitioner's Responsibilities for the Assurance Engagement on the Responsibility Report

Our objective is to express a limited assurance conclusion, based on the assurance engagement we have conducted, on whether any matters have come to our attention that cause us to believe that the Responsibility Report has not been prepared, in all material respects, in accordance with the specifying criteria presented by the executive directors of the Company and to issue an assurance report that includes our assurance conclusion on the Responsibility Report.

As part of a limited assurance engagement in accordance with ISAE 3000 (Revised), we exercise professional judgement and maintain professional scepticism. We also

- obtain an understanding of the process used to prepare the Responsibility Report, including the materiality assessment process carried out by the entity to identify the disclosures to be reported in the Responsibility Report.
- identify disclosures where a material misstatement due to fraud or error is likely to arise, design and perform procedures to address these disclosures and obtain limited assurance to support the assurance conclusion. The risk of not detecting a material misstatement resulting from fraud is higher than the risk of not detecting a material misstatement resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations or the override of internal control. In addition, the risk of not detecting a material misstatement in information obtained from sources not within the entity's control (value chain

information) is ordinarily higher than the risk of not detecting a material misstatement in information obtained from sources within the entity's control, as both the entity's executive directors and we as practitioners are ordinarily subject to restrictions on direct access to the sources of the value chain information.

- consider the forward-looking information, including the appropriateness of the underlying assumptions. There is a substantial unavoidable risk that future events will differ materially from the forward-looking information.

Summary of the Procedures Performed by the independent Practitioner

A limited assurance engagement involves the performance of procedures to obtain evidence about the sustainability information. The nature, timing and extent of the selected procedures are subject to our professional judgement.

In performing our limited assurance engagement, we

- evaluated the suitability of the criteria as a whole presented by the executive directors in the independent Practitioner.
- inquired of the executive directors and relevant employees involved in the preparation of the Responsibility Report about the preparation process, including the materiality assessment process carried out by the entity to identify the disclosures to be reported in the Responsibility Report, and about the internal controls related to this process.

- evaluated the reporting policies used by the executive directors to prepare the Responsibility Report.
- evaluated the reasonableness of the estimates and related information provided by the executive directors. If, in accordance with the ESRS, the executive directors estimate the value chain information to be reported for a case in which the executive directors are unable to obtain the information from the value chain despite making reasonable efforts, our assurance engagement is limited to evaluating whether the executive directors have undertaken these estimates in accordance with the ESRS and assessing the reasonableness of these estimates, but does not include identifying information in the value chain that the executive directors were unable to obtain.
- performed analytical procedures or tests of details and made inquiries in relation to selected information in the Responsibility Report.
- considered the presentation of the information in the Responsibility Report.

Restriction of Use

We issue this report as stipulated in the engagement letter agreed with the Company (including the 'General Engagement Terms for Wirtschaftsprüferinnen, Wirtschaftsprüfer und Wirtschaftsprüfungsgesellschaften (German Public Auditors and Public Audit Firms)' dated 1 January 2024 of the Institut der Wirtschaftsprüfer (IDW)). We draw attention to the fact that the assurance engagement was conducted for the Company's purposes and that the report is intended solely to inform the Company about the result of the assurance engagement. Consequently, it may not be suitable for any other than the aforementioned purpose. Accordingly, the report is not intended to be used by third parties as a basis for making (financial) decisions.

Our responsibility is to the Company alone. We do not accept any responsibility to third parties. Our assurance conclusion is not modified in this respect.


Köln/Germany, 7 Mai 2025

Deloitte GmbH

Wirtschaftsprüfungsgesellschaft

Sebastian Dingel


ppa. Arne Vilmar





Copyright

Photos are Copyright Grünenthal
if not otherwise stated.





IMPRINT

Contact

Hannah Engels

Global Compliance & Responsibility Officer

Tobias Schäfers

Head of Responsibility

E-Mail: esg@grunenthal.com

Publisher

Grünenthal Pharma GmbH & Co. KG

Zieglerstraße 6

52078 Aachen

Germany

Phone: +49 241 569 0

E-Mail: info@grunenthal.com

www.grunenthal.com

ESG consulting, concept, editing, communication & design

SILVESTER GROUP, Hamburg

www.silvestergroup.com



For more information, please visit
www.grunenthal.com

www.linkedin.com/company/gruenenthal
www.instagram.com/grunenthal